Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,28279893,apparent clearance (CL/F),"The typical population estimates of the apparent clearance (CL/F) and the volume of distribution (V/F) were 3.9L/h and 65.3L, respectively.",Population pharmacokinetics and dose-response relationship of levetiracetam in adult patients with epilepsy. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28279893/),[l] / [h],3.9,2616,DB01202,Levetiracetam
,28279893,volume of distribution (V/F),"The typical population estimates of the apparent clearance (CL/F) and the volume of distribution (V/F) were 3.9L/h and 65.3L, respectively.",Population pharmacokinetics and dose-response relationship of levetiracetam in adult patients with epilepsy. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28279893/),l,65.3,2617,DB01202,Levetiracetam
,17442002,half-life (t(1/2)),"The mean half-life (t(1/2)) of levetiracetam was 5.3 +/- 1.3 hours, and the apparent clearance was 1.46 +/- 0.42 mL/min/kg.",Pharmacokinetics of levetiracetam in infants and young children with epilepsy. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17442002/),h,5.3,5388,DB01202,Levetiracetam
,17442002,apparent clearance,"The mean half-life (t(1/2)) of levetiracetam was 5.3 +/- 1.3 hours, and the apparent clearance was 1.46 +/- 0.42 mL/min/kg.",Pharmacokinetics of levetiracetam in infants and young children with epilepsy. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17442002/),[ml] / [kg·min],1.46,5389,DB01202,Levetiracetam
,34051579,clearance (CL),Mean clearance (CL) was 3.55 L/h and volume of distribution (V) was 18.8 L.,Pharmacokinetics of levetiracetam in neurosurgical ICU patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34051579/),[l] / [h],3.55,6115,DB01202,Levetiracetam
,34051579,volume of distribution (V),Mean clearance (CL) was 3.55 L/h and volume of distribution (V) was 18.8 L.,Pharmacokinetics of levetiracetam in neurosurgical ICU patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34051579/),l,18.8,6116,DB01202,Levetiracetam
≥,34051579,trough at steady state,"Monte Carlo simulations showed a low probability of target attainment (PTA, trough at steady state of ≥6 mg/L) with a standard dose of 500 mg twice daily.",Pharmacokinetics of levetiracetam in neurosurgical ICU patients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34051579/),[mg] / [l],6,6117,DB01202,Levetiracetam
,9454787,half-life,"Levetiracetam had a relatively short half-life (about 2-3 hr) in rats, so that any lasting effects of the drug after chronic administration were certainly not due to drug accumulation.",Antiepileptogenic effects of the novel anticonvulsant levetiracetam (ucb L059) in the kindling model of temporal lobe epilepsy. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9454787/),h,2-3,9877,DB01202,Levetiracetam
,31015006,absolute bioavailability,"Similar plasma pharmacokinetic profiles were obtained and the intranasal absolute bioavailability was 107.44%, underscoring that a high drug fraction was systemically absorbed.",Nose-to-brain delivery of levetiracetam after intranasal administration to mice. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31015006/),%,107.44,12542,DB01202,Levetiracetam
,31015006,maximum drug concentrations,"In brain tissue, maximum drug concentrations were 4.48 and 4.02 μg/g (intranasal vs intravenous) and the mean cerebral concentrations were significantly higher after intranasal administration.",Nose-to-brain delivery of levetiracetam after intranasal administration to mice. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31015006/),[μg] / [g],4.48,12543,DB01202,Levetiracetam
,31015006,maximum drug concentrations,"In brain tissue, maximum drug concentrations were 4.48 and 4.02 μg/g (intranasal vs intravenous) and the mean cerebral concentrations were significantly higher after intranasal administration.",Nose-to-brain delivery of levetiracetam after intranasal administration to mice. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31015006/),[μg] / [g],4.02,12544,DB01202,Levetiracetam
,16878346,recovery,"The extraction procedure yielded extremely clean extracts with a recovery of 79.95% and 89.02% for levetiracetam and the internal standard (IS), respectively.",Determination of levetiracetam in human plasma by liquid chromatography/electrospray tandem mass spectrometry and its application to bioequivalence studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16878346/),%,79.95,14299,DB01202,Levetiracetam
,16878346,recovery,"The extraction procedure yielded extremely clean extracts with a recovery of 79.95% and 89.02% for levetiracetam and the internal standard (IS), respectively.",Determination of levetiracetam in human plasma by liquid chromatography/electrospray tandem mass spectrometry and its application to bioequivalence studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16878346/),%,89.02,14300,DB01202,Levetiracetam
,16878346,total instrumental run time,The method is rugged and fast with a total instrumental run time of 2 min.,Determination of levetiracetam in human plasma by liquid chromatography/electrospray tandem mass spectrometry and its application to bioequivalence studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16878346/),min,2,14301,DB01202,Levetiracetam
,16404803,Milk/maternal plasma concentration ratios,"Milk/maternal plasma concentration ratios close to 1 demonstrate extensive transfer to breast milk of many AEDs including ethosuximide, gabapentin, lamotrigine, levetiracetam, oxcarbazepine, topiramate, and zonisamide.",Gender aspects of pharmacokinetics of new and old AEDs: pregnancy and breast-feeding. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16404803/),,1,16688,DB01202,Levetiracetam
,26290357,Cmax,"Pharmacokinetic parameters for fasted versus fed animals, respectively, were (mean ± SEM): Cmax = 26.6 ± 2.38 and 30.7 ± 2.88 μ/mL, Tmax = 204.3 ± 18.9 and 393.8 ± 36.6 minutes, t1/2 = 4.95 ± 0.55 and 4.48 ± 0.48 hours, MRT = 9.8 ± 0.72 and 10 ± 0.64 hours, MAT = 4.7 ± 0.38 and 5.6 ± 0.67 hours, and F = 1.04 ± 0.04 and 1.26 ± 0.07%.",Disposition of Extended Release Levetiracetam in Normal Healthy Dogs After Single Oral Dosing. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26290357/),[μ] / [ml],26.6,18812,DB01202,Levetiracetam
,26290357,Cmax,"Pharmacokinetic parameters for fasted versus fed animals, respectively, were (mean ± SEM): Cmax = 26.6 ± 2.38 and 30.7 ± 2.88 μ/mL, Tmax = 204.3 ± 18.9 and 393.8 ± 36.6 minutes, t1/2 = 4.95 ± 0.55 and 4.48 ± 0.48 hours, MRT = 9.8 ± 0.72 and 10 ± 0.64 hours, MAT = 4.7 ± 0.38 and 5.6 ± 0.67 hours, and F = 1.04 ± 0.04 and 1.26 ± 0.07%.",Disposition of Extended Release Levetiracetam in Normal Healthy Dogs After Single Oral Dosing. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26290357/),[μ] / [ml],30.7,18813,DB01202,Levetiracetam
,26290357,Tmax,"Pharmacokinetic parameters for fasted versus fed animals, respectively, were (mean ± SEM): Cmax = 26.6 ± 2.38 and 30.7 ± 2.88 μ/mL, Tmax = 204.3 ± 18.9 and 393.8 ± 36.6 minutes, t1/2 = 4.95 ± 0.55 and 4.48 ± 0.48 hours, MRT = 9.8 ± 0.72 and 10 ± 0.64 hours, MAT = 4.7 ± 0.38 and 5.6 ± 0.67 hours, and F = 1.04 ± 0.04 and 1.26 ± 0.07%.",Disposition of Extended Release Levetiracetam in Normal Healthy Dogs After Single Oral Dosing. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26290357/),min,204.3,18814,DB01202,Levetiracetam
,26290357,Tmax,"Pharmacokinetic parameters for fasted versus fed animals, respectively, were (mean ± SEM): Cmax = 26.6 ± 2.38 and 30.7 ± 2.88 μ/mL, Tmax = 204.3 ± 18.9 and 393.8 ± 36.6 minutes, t1/2 = 4.95 ± 0.55 and 4.48 ± 0.48 hours, MRT = 9.8 ± 0.72 and 10 ± 0.64 hours, MAT = 4.7 ± 0.38 and 5.6 ± 0.67 hours, and F = 1.04 ± 0.04 and 1.26 ± 0.07%.",Disposition of Extended Release Levetiracetam in Normal Healthy Dogs After Single Oral Dosing. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26290357/),min,393.8,18815,DB01202,Levetiracetam
,26290357,t1/2,"Pharmacokinetic parameters for fasted versus fed animals, respectively, were (mean ± SEM): Cmax = 26.6 ± 2.38 and 30.7 ± 2.88 μ/mL, Tmax = 204.3 ± 18.9 and 393.8 ± 36.6 minutes, t1/2 = 4.95 ± 0.55 and 4.48 ± 0.48 hours, MRT = 9.8 ± 0.72 and 10 ± 0.64 hours, MAT = 4.7 ± 0.38 and 5.6 ± 0.67 hours, and F = 1.04 ± 0.04 and 1.26 ± 0.07%.",Disposition of Extended Release Levetiracetam in Normal Healthy Dogs After Single Oral Dosing. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26290357/),h,4.95,18816,DB01202,Levetiracetam
,26290357,t1/2,"Pharmacokinetic parameters for fasted versus fed animals, respectively, were (mean ± SEM): Cmax = 26.6 ± 2.38 and 30.7 ± 2.88 μ/mL, Tmax = 204.3 ± 18.9 and 393.8 ± 36.6 minutes, t1/2 = 4.95 ± 0.55 and 4.48 ± 0.48 hours, MRT = 9.8 ± 0.72 and 10 ± 0.64 hours, MAT = 4.7 ± 0.38 and 5.6 ± 0.67 hours, and F = 1.04 ± 0.04 and 1.26 ± 0.07%.",Disposition of Extended Release Levetiracetam in Normal Healthy Dogs After Single Oral Dosing. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26290357/),h,4.48,18817,DB01202,Levetiracetam
,26290357,MRT,"Pharmacokinetic parameters for fasted versus fed animals, respectively, were (mean ± SEM): Cmax = 26.6 ± 2.38 and 30.7 ± 2.88 μ/mL, Tmax = 204.3 ± 18.9 and 393.8 ± 36.6 minutes, t1/2 = 4.95 ± 0.55 and 4.48 ± 0.48 hours, MRT = 9.8 ± 0.72 and 10 ± 0.64 hours, MAT = 4.7 ± 0.38 and 5.6 ± 0.67 hours, and F = 1.04 ± 0.04 and 1.26 ± 0.07%.",Disposition of Extended Release Levetiracetam in Normal Healthy Dogs After Single Oral Dosing. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26290357/),h,9.8,18818,DB01202,Levetiracetam
,26290357,MRT,"Pharmacokinetic parameters for fasted versus fed animals, respectively, were (mean ± SEM): Cmax = 26.6 ± 2.38 and 30.7 ± 2.88 μ/mL, Tmax = 204.3 ± 18.9 and 393.8 ± 36.6 minutes, t1/2 = 4.95 ± 0.55 and 4.48 ± 0.48 hours, MRT = 9.8 ± 0.72 and 10 ± 0.64 hours, MAT = 4.7 ± 0.38 and 5.6 ± 0.67 hours, and F = 1.04 ± 0.04 and 1.26 ± 0.07%.",Disposition of Extended Release Levetiracetam in Normal Healthy Dogs After Single Oral Dosing. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26290357/),h,10,18819,DB01202,Levetiracetam
,26290357,MAT,"Pharmacokinetic parameters for fasted versus fed animals, respectively, were (mean ± SEM): Cmax = 26.6 ± 2.38 and 30.7 ± 2.88 μ/mL, Tmax = 204.3 ± 18.9 and 393.8 ± 36.6 minutes, t1/2 = 4.95 ± 0.55 and 4.48 ± 0.48 hours, MRT = 9.8 ± 0.72 and 10 ± 0.64 hours, MAT = 4.7 ± 0.38 and 5.6 ± 0.67 hours, and F = 1.04 ± 0.04 and 1.26 ± 0.07%.",Disposition of Extended Release Levetiracetam in Normal Healthy Dogs After Single Oral Dosing. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26290357/),h,4.7,18820,DB01202,Levetiracetam
,26290357,MAT,"Pharmacokinetic parameters for fasted versus fed animals, respectively, were (mean ± SEM): Cmax = 26.6 ± 2.38 and 30.7 ± 2.88 μ/mL, Tmax = 204.3 ± 18.9 and 393.8 ± 36.6 minutes, t1/2 = 4.95 ± 0.55 and 4.48 ± 0.48 hours, MRT = 9.8 ± 0.72 and 10 ± 0.64 hours, MAT = 4.7 ± 0.38 and 5.6 ± 0.67 hours, and F = 1.04 ± 0.04 and 1.26 ± 0.07%.",Disposition of Extended Release Levetiracetam in Normal Healthy Dogs After Single Oral Dosing. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26290357/),h,5.6,18821,DB01202,Levetiracetam
,26290357,F,"Pharmacokinetic parameters for fasted versus fed animals, respectively, were (mean ± SEM): Cmax = 26.6 ± 2.38 and 30.7 ± 2.88 μ/mL, Tmax = 204.3 ± 18.9 and 393.8 ± 36.6 minutes, t1/2 = 4.95 ± 0.55 and 4.48 ± 0.48 hours, MRT = 9.8 ± 0.72 and 10 ± 0.64 hours, MAT = 4.7 ± 0.38 and 5.6 ± 0.67 hours, and F = 1.04 ± 0.04 and 1.26 ± 0.07%.",Disposition of Extended Release Levetiracetam in Normal Healthy Dogs After Single Oral Dosing. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26290357/),%,1.04,18822,DB01202,Levetiracetam
,26290357,F,"Pharmacokinetic parameters for fasted versus fed animals, respectively, were (mean ± SEM): Cmax = 26.6 ± 2.38 and 30.7 ± 2.88 μ/mL, Tmax = 204.3 ± 18.9 and 393.8 ± 36.6 minutes, t1/2 = 4.95 ± 0.55 and 4.48 ± 0.48 hours, MRT = 9.8 ± 0.72 and 10 ± 0.64 hours, MAT = 4.7 ± 0.38 and 5.6 ± 0.67 hours, and F = 1.04 ± 0.04 and 1.26 ± 0.07%.",Disposition of Extended Release Levetiracetam in Normal Healthy Dogs After Single Oral Dosing. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26290357/),%,1.26,18823,DB01202,Levetiracetam
,29633294,Overall recovery,Overall recovery of levetiracetam from plasma was ~100%.,Development and validation of a HPLC-UV assay for quantification of levetiracetam concentrations in critically ill patients undergoing continuous renal replacement therapy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29633294/),%,100,24331,DB01202,Levetiracetam
,26913593,clearance,"The population mean clearance for an adult weighing 70 kg and with a normal renal function was 4.8 and 5.9 L/h for 500 mg bis in die (bid) and 1500 mg bid, respectively.",Population Pharmacokinetic Modeling of Levetiracetam in Pediatric and Adult Patients With Epilepsy by Using Routinely Monitored Data. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26913593/),[l] / [h],4.8,25575,DB01202,Levetiracetam
,26913593,clearance,"The population mean clearance for an adult weighing 70 kg and with a normal renal function was 4.8 and 5.9 L/h for 500 mg bis in die (bid) and 1500 mg bid, respectively.",Population Pharmacokinetic Modeling of Levetiracetam in Pediatric and Adult Patients With Epilepsy by Using Routinely Monitored Data. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26913593/),[l] / [h],5.9,25576,DB01202,Levetiracetam
,22669118,clearance (CL/F),"A regression equation of the basic model of levetiracetam was obtained, with clearance (CL/F)=0.988 L/h, volume of distribution (V/F)=12.3 L, and K(a)=1.95 h(-1).",Population pharmacokinetics modeling of levetiracetam in Chinese children with epilepsy. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22669118/),[l] / [h],0.988,32276,DB01202,Levetiracetam
,22669118,volume of distribution (V/F),"A regression equation of the basic model of levetiracetam was obtained, with clearance (CL/F)=0.988 L/h, volume of distribution (V/F)=12.3 L, and K(a)=1.95 h(-1).",Population pharmacokinetics modeling of levetiracetam in Chinese children with epilepsy. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22669118/),l,12.3,32277,DB01202,Levetiracetam
,22669118,K(a),"A regression equation of the basic model of levetiracetam was obtained, with clearance (CL/F)=0.988 L/h, volume of distribution (V/F)=12.3 L, and K(a)=1.95 h(-1).",Population pharmacokinetics modeling of levetiracetam in Chinese children with epilepsy. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22669118/),1/[h],1.95,32278,DB01202,Levetiracetam
,22669118,K(a),"The final model was as follows: K(a)=1.56 h(-1), V/F=12.1 (L), CL/F=1.04×(WEIG/25)(0.583) (L/h).",Population pharmacokinetics modeling of levetiracetam in Chinese children with epilepsy. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22669118/),1/[h],1.56,32279,DB01202,Levetiracetam
,22669118,V/F,"The final model was as follows: K(a)=1.56 h(-1), V/F=12.1 (L), CL/F=1.04×(WEIG/25)(0.583) (L/h).",Population pharmacokinetics modeling of levetiracetam in Chinese children with epilepsy. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22669118/),l,12.1,32280,DB01202,Levetiracetam
,22669118,CL/F,"The final model was as follows: K(a)=1.56 h(-1), V/F=12.1 (L), CL/F=1.04×(WEIG/25)(0.583) (L/h).",Population pharmacokinetics modeling of levetiracetam in Chinese children with epilepsy. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22669118/),[l] / [h],1.04×,32281,DB01202,Levetiracetam
,30241055,plasma concentrations,"There was no difference in median plasma concentrations (19.5 versus 21.5 mg/l; p = 0.71), median estimated LEV exposure (25.8 versus 37.0 mg/l; p = 0.61), peak (30.4 versus 41.5 mg/l; p = 0.36), or residual levels after loading dose (14.4 versus 20.5 mg/l; p = 0.07) between responders and nonresponders.",Levetiracetam circulating concentrations and response in status epilepticus. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30241055/),[mg] / [l],19.5,37788,DB01202,Levetiracetam
,30241055,plasma concentrations,"There was no difference in median plasma concentrations (19.5 versus 21.5 mg/l; p = 0.71), median estimated LEV exposure (25.8 versus 37.0 mg/l; p = 0.61), peak (30.4 versus 41.5 mg/l; p = 0.36), or residual levels after loading dose (14.4 versus 20.5 mg/l; p = 0.07) between responders and nonresponders.",Levetiracetam circulating concentrations and response in status epilepticus. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30241055/),[mg] / [l],21.5,37789,DB01202,Levetiracetam
,30241055,exposure,"There was no difference in median plasma concentrations (19.5 versus 21.5 mg/l; p = 0.71), median estimated LEV exposure (25.8 versus 37.0 mg/l; p = 0.61), peak (30.4 versus 41.5 mg/l; p = 0.36), or residual levels after loading dose (14.4 versus 20.5 mg/l; p = 0.07) between responders and nonresponders.",Levetiracetam circulating concentrations and response in status epilepticus. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30241055/),mg,25.8,37790,DB01202,Levetiracetam
,30241055,exposure,"There was no difference in median plasma concentrations (19.5 versus 21.5 mg/l; p = 0.71), median estimated LEV exposure (25.8 versus 37.0 mg/l; p = 0.61), peak (30.4 versus 41.5 mg/l; p = 0.36), or residual levels after loading dose (14.4 versus 20.5 mg/l; p = 0.07) between responders and nonresponders.",Levetiracetam circulating concentrations and response in status epilepticus. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30241055/),mg,37.0,37791,DB01202,Levetiracetam
,30241055,peak,"There was no difference in median plasma concentrations (19.5 versus 21.5 mg/l; p = 0.71), median estimated LEV exposure (25.8 versus 37.0 mg/l; p = 0.61), peak (30.4 versus 41.5 mg/l; p = 0.36), or residual levels after loading dose (14.4 versus 20.5 mg/l; p = 0.07) between responders and nonresponders.",Levetiracetam circulating concentrations and response in status epilepticus. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30241055/),[mg] / [l],30.4,37792,DB01202,Levetiracetam
,30241055,peak,"There was no difference in median plasma concentrations (19.5 versus 21.5 mg/l; p = 0.71), median estimated LEV exposure (25.8 versus 37.0 mg/l; p = 0.61), peak (30.4 versus 41.5 mg/l; p = 0.36), or residual levels after loading dose (14.4 versus 20.5 mg/l; p = 0.07) between responders and nonresponders.",Levetiracetam circulating concentrations and response in status epilepticus. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30241055/),[mg] / [l],41.5,37793,DB01202,Levetiracetam
,30241055,residual levels,"There was no difference in median plasma concentrations (19.5 versus 21.5 mg/l; p = 0.71), median estimated LEV exposure (25.8 versus 37.0 mg/l; p = 0.61), peak (30.4 versus 41.5 mg/l; p = 0.36), or residual levels after loading dose (14.4 versus 20.5 mg/l; p = 0.07) between responders and nonresponders.",Levetiracetam circulating concentrations and response in status epilepticus. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30241055/),[mg] / [l],14.4,37794,DB01202,Levetiracetam
,30241055,residual levels,"There was no difference in median plasma concentrations (19.5 versus 21.5 mg/l; p = 0.71), median estimated LEV exposure (25.8 versus 37.0 mg/l; p = 0.61), peak (30.4 versus 41.5 mg/l; p = 0.36), or residual levels after loading dose (14.4 versus 20.5 mg/l; p = 0.07) between responders and nonresponders.",Levetiracetam circulating concentrations and response in status epilepticus. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30241055/),[mg] / [l],20.5,37795,DB01202,Levetiracetam
,18781906,trough levels,"Mean imatinib trough levels in patients not receiving AEDs ( 1404 ng/ml, CV 64%) and on non-EIAEDs (1374 ng/ml, CV 46%) were comparable with mean imatinib trough levels of the historical control group of CML patients (1400 ng/ml, CV 50%).",Influence of enzyme-inducing antiepileptic drugs on trough level of imatinib in glioblastoma patients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18781906/),[ng] / [ml],1404,43042,DB01202,Levetiracetam
,18781906,trough levels,"Mean imatinib trough levels in patients not receiving AEDs ( 1404 ng/ml, CV 64%) and on non-EIAEDs (1374 ng/ml, CV 46%) were comparable with mean imatinib trough levels of the historical control group of CML patients (1400 ng/ml, CV 50%).",Influence of enzyme-inducing antiepileptic drugs on trough level of imatinib in glioblastoma patients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18781906/),[ng] / [ml],1374,43043,DB01202,Levetiracetam
,18781906,trough levels,"Mean imatinib trough levels in patients not receiving AEDs ( 1404 ng/ml, CV 64%) and on non-EIAEDs (1374 ng/ml, CV 46%) were comparable with mean imatinib trough levels of the historical control group of CML patients (1400 ng/ml, CV 50%).",Influence of enzyme-inducing antiepileptic drugs on trough level of imatinib in glioblastoma patients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18781906/),[ng] / [ml],1400,43044,DB01202,Levetiracetam
,18781906,trough levels,"Mean trough levels of imatinib were reduced up to 2.9-fold (477 ng/ml, CV 70%) in patients treated with EIAEDs.",Influence of enzyme-inducing antiepileptic drugs on trough level of imatinib in glioblastoma patients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18781906/),[ng] / [ml],477,43045,DB01202,Levetiracetam
,18781906,trough level,"Only slight, but although significant differences were observed in the mean trough level of the metabolite CGP74588 between EIAED-, non-EIAED and no-AED patients, 240 ng/ml (CV 57%), 351 ng/ml (CV 34%) and 356 ng/ml (CV 52%), respectively.",Influence of enzyme-inducing antiepileptic drugs on trough level of imatinib in glioblastoma patients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18781906/),[ng] / [ml],240,43046,DB01202,Levetiracetam
,18781906,trough level,"Only slight, but although significant differences were observed in the mean trough level of the metabolite CGP74588 between EIAED-, non-EIAED and no-AED patients, 240 ng/ml (CV 57%), 351 ng/ml (CV 34%) and 356 ng/ml (CV 52%), respectively.",Influence of enzyme-inducing antiepileptic drugs on trough level of imatinib in glioblastoma patients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18781906/),[ng] / [ml],351,43047,DB01202,Levetiracetam
,18781906,trough level,"Only slight, but although significant differences were observed in the mean trough level of the metabolite CGP74588 between EIAED-, non-EIAED and no-AED patients, 240 ng/ml (CV 57%), 351 ng/ml (CV 34%) and 356 ng/ml (CV 52%), respectively.",Influence of enzyme-inducing antiepileptic drugs on trough level of imatinib in glioblastoma patients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18781906/),[ng] / [ml],356,43048,DB01202,Levetiracetam
,31556719,serum maximum concentration (Cmax,"There were significant differences between the commercially available product and the compounded formulation for mean ± SD serum maximum concentration (Cmax; 126 ± 33 μg/mL and 169 ± 51 μg/mL, respectively), Cmax corrected for dose (0.83 ± 0.10 μg/mL/mg and 1.10 ± 0.28 μg/mL/mg, respectively), and time to Cmax (5.1 ± 1.6 hours and 3.1 ± 1.5 hours, respectively).",Pharmacokinetics of a commercially available product and a compounded formulation of extended-release levetiracetam after oral administration of a single dose in cats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31556719/),[μg] / [ml],126,43415,DB01202,Levetiracetam
,31556719,serum maximum concentration (Cmax,"There were significant differences between the commercially available product and the compounded formulation for mean ± SD serum maximum concentration (Cmax; 126 ± 33 μg/mL and 169 ± 51 μg/mL, respectively), Cmax corrected for dose (0.83 ± 0.10 μg/mL/mg and 1.10 ± 0.28 μg/mL/mg, respectively), and time to Cmax (5.1 ± 1.6 hours and 3.1 ± 1.5 hours, respectively).",Pharmacokinetics of a commercially available product and a compounded formulation of extended-release levetiracetam after oral administration of a single dose in cats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31556719/),[μg] / [ml],169,43416,DB01202,Levetiracetam
,31556719,Cmax,"There were significant differences between the commercially available product and the compounded formulation for mean ± SD serum maximum concentration (Cmax; 126 ± 33 μg/mL and 169 ± 51 μg/mL, respectively), Cmax corrected for dose (0.83 ± 0.10 μg/mL/mg and 1.10 ± 0.28 μg/mL/mg, respectively), and time to Cmax (5.1 ± 1.6 hours and 3.1 ± 1.5 hours, respectively).",Pharmacokinetics of a commercially available product and a compounded formulation of extended-release levetiracetam after oral administration of a single dose in cats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31556719/),[μg] / [mg·ml],0.83,43417,DB01202,Levetiracetam
,31556719,Cmax,"There were significant differences between the commercially available product and the compounded formulation for mean ± SD serum maximum concentration (Cmax; 126 ± 33 μg/mL and 169 ± 51 μg/mL, respectively), Cmax corrected for dose (0.83 ± 0.10 μg/mL/mg and 1.10 ± 0.28 μg/mL/mg, respectively), and time to Cmax (5.1 ± 1.6 hours and 3.1 ± 1.5 hours, respectively).",Pharmacokinetics of a commercially available product and a compounded formulation of extended-release levetiracetam after oral administration of a single dose in cats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31556719/),[μg] / [mg·ml],1.10,43418,DB01202,Levetiracetam
,31556719,time to Cmax,"There were significant differences between the commercially available product and the compounded formulation for mean ± SD serum maximum concentration (Cmax; 126 ± 33 μg/mL and 169 ± 51 μg/mL, respectively), Cmax corrected for dose (0.83 ± 0.10 μg/mL/mg and 1.10 ± 0.28 μg/mL/mg, respectively), and time to Cmax (5.1 ± 1.6 hours and 3.1 ± 1.5 hours, respectively).",Pharmacokinetics of a commercially available product and a compounded formulation of extended-release levetiracetam after oral administration of a single dose in cats. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31556719/),h,5.1,43419,DB01202,Levetiracetam
,31556719,time to Cmax,"There were significant differences between the commercially available product and the compounded formulation for mean ± SD serum maximum concentration (Cmax; 126 ± 33 μg/mL and 169 ± 51 μg/mL, respectively), Cmax corrected for dose (0.83 ± 0.10 μg/mL/mg and 1.10 ± 0.28 μg/mL/mg, respectively), and time to Cmax (5.1 ± 1.6 hours and 3.1 ± 1.5 hours, respectively).",Pharmacokinetics of a commercially available product and a compounded formulation of extended-release levetiracetam after oral administration of a single dose in cats. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31556719/),h,3.1,43420,DB01202,Levetiracetam
,31556719,Half-life,"Half-life for the commercially available product and compounded formulation of ER levetiracetam was 4.3 ± 2.0 hours and 5.0 ± 1.6 hours, respectively.",Pharmacokinetics of a commercially available product and a compounded formulation of extended-release levetiracetam after oral administration of a single dose in cats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31556719/),h,4.3,43421,DB01202,Levetiracetam
,31556719,Half-life,"Half-life for the commercially available product and compounded formulation of ER levetiracetam was 4.3 ± 2.0 hours and 5.0 ± 1.6 hours, respectively.",Pharmacokinetics of a commercially available product and a compounded formulation of extended-release levetiracetam after oral administration of a single dose in cats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31556719/),h,5.0,43422,DB01202,Levetiracetam
,33019727,Vd/F,"Male patients showed higher distribution volume (Vd/F) and oral clearance (CL/F) than female patients (median Vd/F: 52.40 L in males and 38.60 L in females, p = 0.011; median CL/F: 4.71 L/h in males and 3.91 L/h in females, p = 0.028).","Pharmacokinetic Monitoring of Levetiracetam in Portuguese Refractory Epileptic Patients: Effect of Gender, Weight and Concomitant Therapy. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33019727/),l,52.40,46556,DB01202,Levetiracetam
,33019727,Vd/F,"Male patients showed higher distribution volume (Vd/F) and oral clearance (CL/F) than female patients (median Vd/F: 52.40 L in males and 38.60 L in females, p = 0.011; median CL/F: 4.71 L/h in males and 3.91 L/h in females, p = 0.028).","Pharmacokinetic Monitoring of Levetiracetam in Portuguese Refractory Epileptic Patients: Effect of Gender, Weight and Concomitant Therapy. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33019727/),l,38.60,46557,DB01202,Levetiracetam
,33019727,CL/F,"Male patients showed higher distribution volume (Vd/F) and oral clearance (CL/F) than female patients (median Vd/F: 52.40 L in males and 38.60 L in females, p = 0.011; median CL/F: 4.71 L/h in males and 3.91 L/h in females, p = 0.028).","Pharmacokinetic Monitoring of Levetiracetam in Portuguese Refractory Epileptic Patients: Effect of Gender, Weight and Concomitant Therapy. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33019727/),[l] / [h],4.71,46558,DB01202,Levetiracetam
,33019727,CL/F,"Male patients showed higher distribution volume (Vd/F) and oral clearance (CL/F) than female patients (median Vd/F: 52.40 L in males and 38.60 L in females, p = 0.011; median CL/F: 4.71 L/h in males and 3.91 L/h in females, p = 0.028).","Pharmacokinetic Monitoring of Levetiracetam in Portuguese Refractory Epileptic Patients: Effect of Gender, Weight and Concomitant Therapy. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33019727/),[l] / [h],3.91,46559,DB01202,Levetiracetam
,33019727,Vd/F,"Carbamazepine was the co-administered antiepileptic drug that mostly affected the pharmacokinetics of levetiracetam, increasing both Vd/F (61.30 L with carbamazepine and 39.10 L without carbamazepine, p = 0.007) and CL/F (6.71 L/h with carbamazepine and 3.91 L/h without carbamazepine, p < 0.001).","Pharmacokinetic Monitoring of Levetiracetam in Portuguese Refractory Epileptic Patients: Effect of Gender, Weight and Concomitant Therapy. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33019727/),l,61.30,46560,DB01202,Levetiracetam
,33019727,Vd/F,"Carbamazepine was the co-administered antiepileptic drug that mostly affected the pharmacokinetics of levetiracetam, increasing both Vd/F (61.30 L with carbamazepine and 39.10 L without carbamazepine, p = 0.007) and CL/F (6.71 L/h with carbamazepine and 3.91 L/h without carbamazepine, p < 0.001).","Pharmacokinetic Monitoring of Levetiracetam in Portuguese Refractory Epileptic Patients: Effect of Gender, Weight and Concomitant Therapy. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33019727/),l,39.10,46561,DB01202,Levetiracetam
,33019727,CL/F,"Carbamazepine was the co-administered antiepileptic drug that mostly affected the pharmacokinetics of levetiracetam, increasing both Vd/F (61.30 L with carbamazepine and 39.10 L without carbamazepine, p = 0.007) and CL/F (6.71 L/h with carbamazepine and 3.91 L/h without carbamazepine, p < 0.001).","Pharmacokinetic Monitoring of Levetiracetam in Portuguese Refractory Epileptic Patients: Effect of Gender, Weight and Concomitant Therapy. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33019727/),[l] / [h],6.71,46562,DB01202,Levetiracetam
,33019727,CL/F,"Carbamazepine was the co-administered antiepileptic drug that mostly affected the pharmacokinetics of levetiracetam, increasing both Vd/F (61.30 L with carbamazepine and 39.10 L without carbamazepine, p = 0.007) and CL/F (6.71 L/h with carbamazepine and 3.91 L/h without carbamazepine, p < 0.001).","Pharmacokinetic Monitoring of Levetiracetam in Portuguese Refractory Epileptic Patients: Effect of Gender, Weight and Concomitant Therapy. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33019727/),[l] / [h],3.91,46563,DB01202,Levetiracetam
,29914474,minimum target concentration,"Plasma levetiracetam concentrations (measured at 0, 30, 60, 90, 120, 180, 240, 360, 720, and 1440 min after drug administration) reached the minimum target concentration (5 μg/ml) at 30 min in all but one patient.",Pharmacokinetics of rectal levetiracetam as add-on treatment in dogs affected by cluster seizures or status epilepticus. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29914474/),[μg] / [ml],5,47367,DB01202,Levetiracetam
,16822254,serum half-life,"Based on blood sampling in a formula-fed pair of twins, the estimated serum half-life of levetiracetam (LEV) at birth is 16-18 h.",Levetiracetam pharmacokinetics in neonates at birth. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16822254/),h,16-18,47546,DB01202,Levetiracetam
,18341442,maximum serum levetiracetam concentration,"Median maximum serum levetiracetam concentration was 25.5 microg/mL, median minimum serum levetiracetam concentration was 8.3 microg/mL, and median elimination half-life was 2.9 hours.",Levetiracetam as an adjunct to phenobarbital treatment in cats with suspected idiopathic epilepsy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18341442/),[μg] / [ml],25.5,48959,DB01202,Levetiracetam
,18341442,minimum serum levetiracetam concentration,"Median maximum serum levetiracetam concentration was 25.5 microg/mL, median minimum serum levetiracetam concentration was 8.3 microg/mL, and median elimination half-life was 2.9 hours.",Levetiracetam as an adjunct to phenobarbital treatment in cats with suspected idiopathic epilepsy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18341442/),[μg] / [ml],8.3,48960,DB01202,Levetiracetam
,18341442,elimination half-life,"Median maximum serum levetiracetam concentration was 25.5 microg/mL, median minimum serum levetiracetam concentration was 8.3 microg/mL, and median elimination half-life was 2.9 hours.",Levetiracetam as an adjunct to phenobarbital treatment in cats with suspected idiopathic epilepsy. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/18341442/),h,2.9,48961,DB01202,Levetiracetam
,21944894,weight-normalized CL/F,Median weight-normalized CL/F (mLmin(-1)kg(-1)) decreased from 1.23 (nonelderly) to 0.83 (elderly) and 0.59 (very elderly) (p<0.001).,Levetiracetam clinical pharmacokinetics in elderly and very elderly patients with epilepsy. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21944894/),1/[mlmin],1.23,51130,DB01202,Levetiracetam
,21944894,weight-normalized CL/F,Median weight-normalized CL/F (mLmin(-1)kg(-1)) decreased from 1.23 (nonelderly) to 0.83 (elderly) and 0.59 (very elderly) (p<0.001).,Levetiracetam clinical pharmacokinetics in elderly and very elderly patients with epilepsy. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21944894/),1/[mlmin],0.83,51131,DB01202,Levetiracetam
,21944894,weight-normalized CL/F,Median weight-normalized CL/F (mLmin(-1)kg(-1)) decreased from 1.23 (nonelderly) to 0.83 (elderly) and 0.59 (very elderly) (p<0.001).,Levetiracetam clinical pharmacokinetics in elderly and very elderly patients with epilepsy. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21944894/),1/[mlmin],0.59,51132,DB01202,Levetiracetam
,33336359,total plasma concentrations,"The total plasma concentrations ranged from 69 to 151.3 μg/mL for LEV, 11.3 to 26.7 μg/mL for PHT and 126 to 223 μg/mL for VPA.","Early Exposure of Fosphenytoin, Levetiracetam, and Valproic Acid After High-Dose Intravenous Administration in Young Children With Benzodiazepine-Refractory Status Epilepticus. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33336359/),[μg] / [ml],69 to 151.3,52778,DB01202,Levetiracetam
,33336359,total plasma concentrations,"The total plasma concentrations ranged from 69 to 151.3 μg/mL for LEV, 11.3 to 26.7 μg/mL for PHT and 126 to 223 μg/mL for VPA.","Early Exposure of Fosphenytoin, Levetiracetam, and Valproic Acid After High-Dose Intravenous Administration in Young Children With Benzodiazepine-Refractory Status Epilepticus. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33336359/),[μg] / [ml],11.3 to 26.7,52779,DB01202,Levetiracetam
,33336359,total plasma concentrations,"The total plasma concentrations ranged from 69 to 151.3 μg/mL for LEV, 11.3 to 26.7 μg/mL for PHT and 126 to 223 μg/mL for VPA.","Early Exposure of Fosphenytoin, Levetiracetam, and Valproic Acid After High-Dose Intravenous Administration in Young Children With Benzodiazepine-Refractory Status Epilepticus. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33336359/),[μg] / [ml],126 to 223,52780,DB01202,Levetiracetam
,33336359,Free fraction,Free fraction ranged from 4% to 19% for PHT and 17% to 51% for VPA.,"Early Exposure of Fosphenytoin, Levetiracetam, and Valproic Acid After High-Dose Intravenous Administration in Young Children With Benzodiazepine-Refractory Status Epilepticus. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33336359/),%,4,52781,DB01202,Levetiracetam
,33336359,Free fraction,Free fraction ranged from 4% to 19% for PHT and 17% to 51% for VPA.,"Early Exposure of Fosphenytoin, Levetiracetam, and Valproic Acid After High-Dose Intravenous Administration in Young Children With Benzodiazepine-Refractory Status Epilepticus. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33336359/),%,19,52782,DB01202,Levetiracetam
,33336359,Free fraction,Free fraction ranged from 4% to 19% for PHT and 17% to 51% for VPA.,"Early Exposure of Fosphenytoin, Levetiracetam, and Valproic Acid After High-Dose Intravenous Administration in Young Children With Benzodiazepine-Refractory Status Epilepticus. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33336359/),%,17,52783,DB01202,Levetiracetam
,33336359,Free fraction,Free fraction ranged from 4% to 19% for PHT and 17% to 51% for VPA.,"Early Exposure of Fosphenytoin, Levetiracetam, and Valproic Acid After High-Dose Intravenous Administration in Young Children With Benzodiazepine-Refractory Status Epilepticus. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33336359/),%,51,52784,DB01202,Levetiracetam
,22171585,CL/F,"Eslicarbazepine CL/F was affected by bodyweight, dose of carbamazepine (D(CAR)) and co-administration of barbiturates or phenytoin (AED(PB)), as predicted by the equation CL/F = (2.36 + 0.00149 • D(CAR) + 1.41 • AED(PB)) • (weight/70)0.75, which means that CL/F is 2.36 L/h for a subject with a bodyweight of 70 kg and without concomitant carbamazepine and barbiturates/phenytoin.","Pharmacokinetics, drug interactions and exposure-response relationship of eslicarbazepine acetate in adult patients with partial-onset seizures: population pharmacokinetic and pharmacokinetic/pharmacodynamic analyses. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22171585/),[l] / [h],2.36,53544,DB01202,Levetiracetam
,29671898,trough,"Median (range) trough, 4, 6, and 8 hour serum levetiracetam concentrations were 7.0 (2.3-14.1), 82.6 (7.8-125.3), 92.3 (13.3-97.3), and 72 (22.8-96.4) μg/mL, respectively.",Serum levetiracetam concentrations and adverse events after multiple dose extended release levetiracetam administration to healthy cats. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29671898/),[μg] / [ml],7.0,56471,DB01202,Levetiracetam
,29671898,serum levetiracetam concentrations,"Median (range) trough, 4, 6, and 8 hour serum levetiracetam concentrations were 7.0 (2.3-14.1), 82.6 (7.8-125.3), 92.3 (13.3-97.3), and 72 (22.8-96.4) μg/mL, respectively.",Serum levetiracetam concentrations and adverse events after multiple dose extended release levetiracetam administration to healthy cats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29671898/),[μg] / [ml],7.0,56472,DB01202,Levetiracetam
,29671898,serum levetiracetam concentrations,"Median (range) trough, 4, 6, and 8 hour serum levetiracetam concentrations were 7.0 (2.3-14.1), 82.6 (7.8-125.3), 92.3 (13.3-97.3), and 72 (22.8-96.4) μg/mL, respectively.",Serum levetiracetam concentrations and adverse events after multiple dose extended release levetiracetam administration to healthy cats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29671898/),[μg] / [ml],82.6,56473,DB01202,Levetiracetam
,29671898,serum levetiracetam concentrations,"Median (range) trough, 4, 6, and 8 hour serum levetiracetam concentrations were 7.0 (2.3-14.1), 82.6 (7.8-125.3), 92.3 (13.3-97.3), and 72 (22.8-96.4) μg/mL, respectively.",Serum levetiracetam concentrations and adverse events after multiple dose extended release levetiracetam administration to healthy cats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29671898/),[μg] / [ml],92.3,56474,DB01202,Levetiracetam
,29671898,serum levetiracetam concentrations,"Median (range) trough, 4, 6, and 8 hour serum levetiracetam concentrations were 7.0 (2.3-14.1), 82.6 (7.8-125.3), 92.3 (13.3-97.3), and 72 (22.8-96.4) μg/mL, respectively.",Serum levetiracetam concentrations and adverse events after multiple dose extended release levetiracetam administration to healthy cats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29671898/),[μg] / [ml],72,56475,DB01202,Levetiracetam
,29671898,time of maximal concentration (Tmax ),Median time of maximal concentration (Tmax ) for the remaining 5 cats 5.2 (range 4-6) hours.,Serum levetiracetam concentrations and adverse events after multiple dose extended release levetiracetam administration to healthy cats. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29671898/),h,5.2,56476,DB01202,Levetiracetam
≥,29671898,trough serum levetiracetam concentrations,"Mean trough serum levetiracetam concentrations were ≥5 μg/mL and adverse effects were minimal throughout dosing period, indicating that the drug was well tolerated.",Serum levetiracetam concentrations and adverse events after multiple dose extended release levetiracetam administration to healthy cats. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29671898/),[μg] / [ml],5,56477,DB01202,Levetiracetam
,33428169,bioavailability (F),"The mean ± standard deviation parameter estimates were bioavailability (F) of 0.8 ± 0.2, absorption rate constant of 2.4 ± 2 h-1, clearance 2.5 ± 1.1 L/h, central volume of distribution 8.9 ± 3.0 L/h, and transfer rate constraints of 1.8 ± 1.1 h-1 from central to peripheral compartments and 0.7 ± 0.3 h-1 from peripheral to central compartments.",Population Pharmacokinetics of Levetiracetam in Patients with Traumatic Brain Injury and Subarachnoid Hemorrhage Exhibiting Augmented Renal Clearance. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33428169/),,0.8,58854,DB01202,Levetiracetam
,33428169,absorption rate constant,"The mean ± standard deviation parameter estimates were bioavailability (F) of 0.8 ± 0.2, absorption rate constant of 2.4 ± 2 h-1, clearance 2.5 ± 1.1 L/h, central volume of distribution 8.9 ± 3.0 L/h, and transfer rate constraints of 1.8 ± 1.1 h-1 from central to peripheral compartments and 0.7 ± 0.3 h-1 from peripheral to central compartments.",Population Pharmacokinetics of Levetiracetam in Patients with Traumatic Brain Injury and Subarachnoid Hemorrhage Exhibiting Augmented Renal Clearance. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33428169/),1/[h],2.4,58855,DB01202,Levetiracetam
,33428169,clearance,"The mean ± standard deviation parameter estimates were bioavailability (F) of 0.8 ± 0.2, absorption rate constant of 2.4 ± 2 h-1, clearance 2.5 ± 1.1 L/h, central volume of distribution 8.9 ± 3.0 L/h, and transfer rate constraints of 1.8 ± 1.1 h-1 from central to peripheral compartments and 0.7 ± 0.3 h-1 from peripheral to central compartments.",Population Pharmacokinetics of Levetiracetam in Patients with Traumatic Brain Injury and Subarachnoid Hemorrhage Exhibiting Augmented Renal Clearance. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33428169/),[l] / [h],2.5,58856,DB01202,Levetiracetam
,33428169,central volume of distribution,"The mean ± standard deviation parameter estimates were bioavailability (F) of 0.8 ± 0.2, absorption rate constant of 2.4 ± 2 h-1, clearance 2.5 ± 1.1 L/h, central volume of distribution 8.9 ± 3.0 L/h, and transfer rate constraints of 1.8 ± 1.1 h-1 from central to peripheral compartments and 0.7 ± 0.3 h-1 from peripheral to central compartments.",Population Pharmacokinetics of Levetiracetam in Patients with Traumatic Brain Injury and Subarachnoid Hemorrhage Exhibiting Augmented Renal Clearance. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33428169/),[l] / [h],8.9,58857,DB01202,Levetiracetam
,33428169,transfer rate constraints,"The mean ± standard deviation parameter estimates were bioavailability (F) of 0.8 ± 0.2, absorption rate constant of 2.4 ± 2 h-1, clearance 2.5 ± 1.1 L/h, central volume of distribution 8.9 ± 3.0 L/h, and transfer rate constraints of 1.8 ± 1.1 h-1 from central to peripheral compartments and 0.7 ± 0.3 h-1 from peripheral to central compartments.",Population Pharmacokinetics of Levetiracetam in Patients with Traumatic Brain Injury and Subarachnoid Hemorrhage Exhibiting Augmented Renal Clearance. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33428169/),1/[h],1.8,58858,DB01202,Levetiracetam
,33428169,transfer rate constraints,"The mean ± standard deviation parameter estimates were bioavailability (F) of 0.8 ± 0.2, absorption rate constant of 2.4 ± 2 h-1, clearance 2.5 ± 1.1 L/h, central volume of distribution 8.9 ± 3.0 L/h, and transfer rate constraints of 1.8 ± 1.1 h-1 from central to peripheral compartments and 0.7 ± 0.3 h-1 from peripheral to central compartments.",Population Pharmacokinetics of Levetiracetam in Patients with Traumatic Brain Injury and Subarachnoid Hemorrhage Exhibiting Augmented Renal Clearance. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33428169/),1/[h],0.7,58859,DB01202,Levetiracetam
,12576167,concentration at 1h (C(1h)),"Estimated pharmacokinetic values, normalized to a dose of 1 mgkg(-1) b.i.d., were: concentration at 1h (C(1h)) 2.1 microgram ml(-1), concentration at 12h (C(12h)) 0.8 microgram ml(-1), area under the curve from 0 to 12h (AUC(0-12h)) 17.1 microgram ml(-1)h, half-life (t(1/2)) 8.1h, and apparent oral clearance (CL/F) 0.97 mlmin(-1)kg(-1).",Effects of antiepileptic comedication on levetiracetam pharmacokinetics: a pooled analysis of data from randomized adjunctive therapy trials. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12576167/),[μg] / [ml],2.1,63306,DB01202,Levetiracetam
,12576167,concentration at 12h (C(12h)),"Estimated pharmacokinetic values, normalized to a dose of 1 mgkg(-1) b.i.d., were: concentration at 1h (C(1h)) 2.1 microgram ml(-1), concentration at 12h (C(12h)) 0.8 microgram ml(-1), area under the curve from 0 to 12h (AUC(0-12h)) 17.1 microgram ml(-1)h, half-life (t(1/2)) 8.1h, and apparent oral clearance (CL/F) 0.97 mlmin(-1)kg(-1).",Effects of antiepileptic comedication on levetiracetam pharmacokinetics: a pooled analysis of data from randomized adjunctive therapy trials. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12576167/),[μg] / [ml],0.8,63307,DB01202,Levetiracetam
,12576167,area under the curve from 0 to 12h (AUC(0-12h)),"Estimated pharmacokinetic values, normalized to a dose of 1 mgkg(-1) b.i.d., were: concentration at 1h (C(1h)) 2.1 microgram ml(-1), concentration at 12h (C(12h)) 0.8 microgram ml(-1), area under the curve from 0 to 12h (AUC(0-12h)) 17.1 microgram ml(-1)h, half-life (t(1/2)) 8.1h, and apparent oral clearance (CL/F) 0.97 mlmin(-1)kg(-1).",Effects of antiepileptic comedication on levetiracetam pharmacokinetics: a pooled analysis of data from randomized adjunctive therapy trials. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12576167/),[μg] / [ml],17.1,63308,DB01202,Levetiracetam
,12576167,half-life (t(1/2)),"Estimated pharmacokinetic values, normalized to a dose of 1 mgkg(-1) b.i.d., were: concentration at 1h (C(1h)) 2.1 microgram ml(-1), concentration at 12h (C(12h)) 0.8 microgram ml(-1), area under the curve from 0 to 12h (AUC(0-12h)) 17.1 microgram ml(-1)h, half-life (t(1/2)) 8.1h, and apparent oral clearance (CL/F) 0.97 mlmin(-1)kg(-1).",Effects of antiepileptic comedication on levetiracetam pharmacokinetics: a pooled analysis of data from randomized adjunctive therapy trials. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12576167/),h,8.1,63309,DB01202,Levetiracetam
,12576167,apparent oral clearance (CL/F),"Estimated pharmacokinetic values, normalized to a dose of 1 mgkg(-1) b.i.d., were: concentration at 1h (C(1h)) 2.1 microgram ml(-1), concentration at 12h (C(12h)) 0.8 microgram ml(-1), area under the curve from 0 to 12h (AUC(0-12h)) 17.1 microgram ml(-1)h, half-life (t(1/2)) 8.1h, and apparent oral clearance (CL/F) 0.97 mlmin(-1)kg(-1).",Effects of antiepileptic comedication on levetiracetam pharmacokinetics: a pooled analysis of data from randomized adjunctive therapy trials. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12576167/),1/[mlmin],0.97,63310,DB01202,Levetiracetam
,32223067,sieving coefficient (SC),"The average sieving coefficient (SC) for levetiracetam was 0.89 ± 0.1, indicating high filter efficiency.","A Practice-Based, Clinical Pharmacokinetic Study to Inform Levetiracetam Dosing in Critically Ill Patients Undergoing Continuous Venovenous Hemofiltration (PADRE-01). ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32223067/),,0.89,64474,DB01202,Levetiracetam
,32223067,volume of distribution,The average volume of distribution was 0.73 L/kg.,"A Practice-Based, Clinical Pharmacokinetic Study to Inform Levetiracetam Dosing in Critically Ill Patients Undergoing Continuous Venovenous Hemofiltration (PADRE-01). ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32223067/),[l] / [kg],0.73,64475,DB01202,Levetiracetam
,17256450,saliva to plasma concentration ratio,"The saliva to plasma concentration ratio was 1.11 (95% confidence interval: 0.99 - 1.22) following tablet intake, and 1.55 (95% CI: 1.34 1.77) following oral solution (> or = 4 hours post dose).",Comparison of plasma and saliva concentrations of levetiracetam following administration orally as a tablet and as a solution in healthy adult volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17256450/),,1,64882,DB01202,Levetiracetam
,21194605,AUC(0-last),"The geometric mean (%CV) AUC(0-last) values of levetiracetam delivered in the proximal small bowel, distal small bowel, ascending colon, and stomach (oral tablet) were 58.2 (9.3%), 59.6 (8.9%), 51.5 (12.0%), and 59.0 (7.4%) μg · h/mL, respectively.","Assessment of levetiracetam bioavailability from targeted sites in the human intestine using remotely activated capsules and gamma scintigraphy: Open-label, single-dose, randomized, four-way crossover study in healthy male volunteers. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21194605/),[h·μg] / [ml],58.2,72981,DB01202,Levetiracetam
,21194605,AUC(0-last),"The geometric mean (%CV) AUC(0-last) values of levetiracetam delivered in the proximal small bowel, distal small bowel, ascending colon, and stomach (oral tablet) were 58.2 (9.3%), 59.6 (8.9%), 51.5 (12.0%), and 59.0 (7.4%) μg · h/mL, respectively.","Assessment of levetiracetam bioavailability from targeted sites in the human intestine using remotely activated capsules and gamma scintigraphy: Open-label, single-dose, randomized, four-way crossover study in healthy male volunteers. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21194605/),[h·μg] / [ml],59.6,72982,DB01202,Levetiracetam
,21194605,AUC(0-last),"The geometric mean (%CV) AUC(0-last) values of levetiracetam delivered in the proximal small bowel, distal small bowel, ascending colon, and stomach (oral tablet) were 58.2 (9.3%), 59.6 (8.9%), 51.5 (12.0%), and 59.0 (7.4%) μg · h/mL, respectively.","Assessment of levetiracetam bioavailability from targeted sites in the human intestine using remotely activated capsules and gamma scintigraphy: Open-label, single-dose, randomized, four-way crossover study in healthy male volunteers. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21194605/),[h·μg] / [ml],51.5,72983,DB01202,Levetiracetam
,21194605,AUC(0-last),"The geometric mean (%CV) AUC(0-last) values of levetiracetam delivered in the proximal small bowel, distal small bowel, ascending colon, and stomach (oral tablet) were 58.2 (9.3%), 59.6 (8.9%), 51.5 (12.0%), and 59.0 (7.4%) μg · h/mL, respectively.","Assessment of levetiracetam bioavailability from targeted sites in the human intestine using remotely activated capsules and gamma scintigraphy: Open-label, single-dose, randomized, four-way crossover study in healthy male volunteers. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21194605/),[h·μg] / [ml],59.0,72984,DB01202,Levetiracetam
,21194605,bioavailability,"Values for bioavailability in the proximal small bowel, distal small bowel, and ascending colon relative to the tablet were 98.5% (95% CI, 89.7%-108.2%), 100.8% (95% CI, 91.4%-111.1%), and 87.1% (95% CI, 77.9%-97.5%).","Assessment of levetiracetam bioavailability from targeted sites in the human intestine using remotely activated capsules and gamma scintigraphy: Open-label, single-dose, randomized, four-way crossover study in healthy male volunteers. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21194605/),%,98.5,72985,DB01202,Levetiracetam
,21194605,bioavailability,"Values for bioavailability in the proximal small bowel, distal small bowel, and ascending colon relative to the tablet were 98.5% (95% CI, 89.7%-108.2%), 100.8% (95% CI, 91.4%-111.1%), and 87.1% (95% CI, 77.9%-97.5%).","Assessment of levetiracetam bioavailability from targeted sites in the human intestine using remotely activated capsules and gamma scintigraphy: Open-label, single-dose, randomized, four-way crossover study in healthy male volunteers. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21194605/),%,100.8,72986,DB01202,Levetiracetam
,21194605,bioavailability,"Values for bioavailability in the proximal small bowel, distal small bowel, and ascending colon relative to the tablet were 98.5% (95% CI, 89.7%-108.2%), 100.8% (95% CI, 91.4%-111.1%), and 87.1% (95% CI, 77.9%-97.5%).","Assessment of levetiracetam bioavailability from targeted sites in the human intestine using remotely activated capsules and gamma scintigraphy: Open-label, single-dose, randomized, four-way crossover study in healthy male volunteers. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21194605/),%,87.1,72987,DB01202,Levetiracetam
,32208795,V/F,Plasma concentrations of levetiracetam were best described by a one-compartment pharmacokinetic model (V/F = 34.7 L) with first-order absorption (ka = 0.616 h-1) and clearance (CL/F = 3.26 L/h).,Pharmacokinetic and pharmacodynamic modeling of levetiracetam: investigation of factors affecting the clinical outcome. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32208795/),l,34.7,73291,DB01202,Levetiracetam
,32208795,first-order absorption (ka,Plasma concentrations of levetiracetam were best described by a one-compartment pharmacokinetic model (V/F = 34.7 L) with first-order absorption (ka = 0.616 h-1) and clearance (CL/F = 3.26 L/h).,Pharmacokinetic and pharmacodynamic modeling of levetiracetam: investigation of factors affecting the clinical outcome. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32208795/),1/[h],0.616,73292,DB01202,Levetiracetam
,32208795,clearance (CL/F,Plasma concentrations of levetiracetam were best described by a one-compartment pharmacokinetic model (V/F = 34.7 L) with first-order absorption (ka = 0.616 h-1) and clearance (CL/F = 3.26 L/h).,Pharmacokinetic and pharmacodynamic modeling of levetiracetam: investigation of factors affecting the clinical outcome. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32208795/),[l] / [h],3.26,73293,DB01202,Levetiracetam
,32208795,time to seizure occurrence,Time to seizure occurrence followed an exponential distribution and the mean time to seizure occurrence was estimated Te = 22.08 days.,Pharmacokinetic and pharmacodynamic modeling of levetiracetam: investigation of factors affecting the clinical outcome. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32208795/),d,22.08,73294,DB01202,Levetiracetam
,32208795,Te,Time to seizure occurrence followed an exponential distribution and the mean time to seizure occurrence was estimated Te = 22.08 days.,Pharmacokinetic and pharmacodynamic modeling of levetiracetam: investigation of factors affecting the clinical outcome. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32208795/),d,22.08,73295,DB01202,Levetiracetam
,14639055,LDR,"The median LDR of LEV was 0.32 for LEV + phenytoin, 0.32 for LEV + carbamazepine, 0.34 LEV + oxcarbazepine, 0.45 for LEV + lamotrigine, 0.46 for LEV + phenobarital, 0.52 for LEV monotherapy, 0.53 for LEV + valproic acid, and 0.54 LEV + valproic acid + lamotrigine.",Serum concentrations of Levetiracetam in epileptic patients: the influence of dose and co-medication. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14639055/),,0.32,73970,DB01202,Levetiracetam
,14639055,LDR,"The median LDR of LEV was 0.32 for LEV + phenytoin, 0.32 for LEV + carbamazepine, 0.34 LEV + oxcarbazepine, 0.45 for LEV + lamotrigine, 0.46 for LEV + phenobarital, 0.52 for LEV monotherapy, 0.53 for LEV + valproic acid, and 0.54 LEV + valproic acid + lamotrigine.",Serum concentrations of Levetiracetam in epileptic patients: the influence of dose and co-medication. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14639055/),,0.34,73971,DB01202,Levetiracetam
,14639055,LDR,"The median LDR of LEV was 0.32 for LEV + phenytoin, 0.32 for LEV + carbamazepine, 0.34 LEV + oxcarbazepine, 0.45 for LEV + lamotrigine, 0.46 for LEV + phenobarital, 0.52 for LEV monotherapy, 0.53 for LEV + valproic acid, and 0.54 LEV + valproic acid + lamotrigine.",Serum concentrations of Levetiracetam in epileptic patients: the influence of dose and co-medication. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14639055/),,0.45,73972,DB01202,Levetiracetam
,14639055,LDR,"The median LDR of LEV was 0.32 for LEV + phenytoin, 0.32 for LEV + carbamazepine, 0.34 LEV + oxcarbazepine, 0.45 for LEV + lamotrigine, 0.46 for LEV + phenobarital, 0.52 for LEV monotherapy, 0.53 for LEV + valproic acid, and 0.54 LEV + valproic acid + lamotrigine.",Serum concentrations of Levetiracetam in epileptic patients: the influence of dose and co-medication. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14639055/),,0.46,73973,DB01202,Levetiracetam
,14639055,LDR,"The median LDR of LEV was 0.32 for LEV + phenytoin, 0.32 for LEV + carbamazepine, 0.34 LEV + oxcarbazepine, 0.45 for LEV + lamotrigine, 0.46 for LEV + phenobarital, 0.52 for LEV monotherapy, 0.53 for LEV + valproic acid, and 0.54 LEV + valproic acid + lamotrigine.",Serum concentrations of Levetiracetam in epileptic patients: the influence of dose and co-medication. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14639055/),,0.52,73974,DB01202,Levetiracetam
,14639055,LDR,"The median LDR of LEV was 0.32 for LEV + phenytoin, 0.32 for LEV + carbamazepine, 0.34 LEV + oxcarbazepine, 0.45 for LEV + lamotrigine, 0.46 for LEV + phenobarital, 0.52 for LEV monotherapy, 0.53 for LEV + valproic acid, and 0.54 LEV + valproic acid + lamotrigine.",Serum concentrations of Levetiracetam in epileptic patients: the influence of dose and co-medication. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14639055/),,0.53,73975,DB01202,Levetiracetam
,14639055,LDR,"The median LDR of LEV was 0.32 for LEV + phenytoin, 0.32 for LEV + carbamazepine, 0.34 LEV + oxcarbazepine, 0.45 for LEV + lamotrigine, 0.46 for LEV + phenobarital, 0.52 for LEV monotherapy, 0.53 for LEV + valproic acid, and 0.54 LEV + valproic acid + lamotrigine.",Serum concentrations of Levetiracetam in epileptic patients: the influence of dose and co-medication. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14639055/),,0.54,73976,DB01202,Levetiracetam
,26908152,CL/F,"For a typical patient with CLcr of 90 mL/min and DOSE of 100mg, co-medication with PHT, CBZ, OXC, and PB increased the CL/F to 2.52 (1.16+1.36)L/h, 2.17 (1.16+1.01)L/h, 1.803 (1.16+0.643)L/h, and 1.636 (1.16+0.476)L/h, respectively, which was 117, 87, 55, and 41% higher, respectively, than in patients without co-medication.",Factors influencing topiramate clearance in adult patients with epilepsy: A population pharmacokinetic analysis. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26908152/),[l] / [h],2.52,74496,DB01202,Levetiracetam
,26908152,CL/F,"For a typical patient with CLcr of 90 mL/min and DOSE of 100mg, co-medication with PHT, CBZ, OXC, and PB increased the CL/F to 2.52 (1.16+1.36)L/h, 2.17 (1.16+1.01)L/h, 1.803 (1.16+0.643)L/h, and 1.636 (1.16+0.476)L/h, respectively, which was 117, 87, 55, and 41% higher, respectively, than in patients without co-medication.",Factors influencing topiramate clearance in adult patients with epilepsy: A population pharmacokinetic analysis. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26908152/),[l] / [h],2.17,74497,DB01202,Levetiracetam
,26908152,CL/F,"For a typical patient with CLcr of 90 mL/min and DOSE of 100mg, co-medication with PHT, CBZ, OXC, and PB increased the CL/F to 2.52 (1.16+1.36)L/h, 2.17 (1.16+1.01)L/h, 1.803 (1.16+0.643)L/h, and 1.636 (1.16+0.476)L/h, respectively, which was 117, 87, 55, and 41% higher, respectively, than in patients without co-medication.",Factors influencing topiramate clearance in adult patients with epilepsy: A population pharmacokinetic analysis. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26908152/),[l] / [h],1.803,74498,DB01202,Levetiracetam
,26908152,CL/F,"For a typical patient with CLcr of 90 mL/min and DOSE of 100mg, co-medication with PHT, CBZ, OXC, and PB increased the CL/F to 2.52 (1.16+1.36)L/h, 2.17 (1.16+1.01)L/h, 1.803 (1.16+0.643)L/h, and 1.636 (1.16+0.476)L/h, respectively, which was 117, 87, 55, and 41% higher, respectively, than in patients without co-medication.",Factors influencing topiramate clearance in adult patients with epilepsy: A population pharmacokinetic analysis. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26908152/),[l] / [h],1.636,74499,DB01202,Levetiracetam
,22495532,clearance (CL),LEV clearance (CL) increased from a mean of 0.7 ml/min/kg (SD 0.27 ml/min/kg) on day 1 to 1.33 ml/min/kg (SD 0.35 ml/min/kg) by day 7.,A seven-day study of the pharmacokinetics of intravenous levetiracetam in neonates: marked changes in pharmacokinetics occur during the first week of life. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22495532/),[ml] / [kg·min],0.7,76048,DB01202,Levetiracetam
,22495532,clearance (CL),LEV clearance (CL) increased from a mean of 0.7 ml/min/kg (SD 0.27 ml/min/kg) on day 1 to 1.33 ml/min/kg (SD 0.35 ml/min/kg) by day 7.,A seven-day study of the pharmacokinetics of intravenous levetiracetam in neonates: marked changes in pharmacokinetics occur during the first week of life. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22495532/),[ml] / [kg·min],1.33,76049,DB01202,Levetiracetam
,22495532,half-life,Mean half-life was 18.5 h (SD 7.1 h) on day 1 of the study and decreased to 9.1 h (SD 2.0 h) by day 7.,A seven-day study of the pharmacokinetics of intravenous levetiracetam in neonates: marked changes in pharmacokinetics occur during the first week of life. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22495532/),h,18.5,76050,DB01202,Levetiracetam
,22495532,half-life,Mean half-life was 18.5 h (SD 7.1 h) on day 1 of the study and decreased to 9.1 h (SD 2.0 h) by day 7.,A seven-day study of the pharmacokinetics of intravenous levetiracetam in neonates: marked changes in pharmacokinetics occur during the first week of life. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22495532/),h,9.1,76051,DB01202,Levetiracetam
,22495532,volume of distribution,The mean volume of distribution was 1.01 l/kg (SD 0.13 l/kg).,A seven-day study of the pharmacokinetics of intravenous levetiracetam in neonates: marked changes in pharmacokinetics occur during the first week of life. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22495532/),[l] / [kg],1.01,76052,DB01202,Levetiracetam
,26242293,volume of distribution,"The volume of distribution was 0.65 L/kg, and clearance was measured with peak (ranging from 26.5-39.8 μg/ml) and trough (ranging from 13.9-18.2 μg/ml) concentrations.",Levetiracetam Pharmacokinetics in a Patient Receiving Continuous Venovenous Hemofiltration and Venoarterial Extracorporeal Membrane Oxygenation. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26242293/),[l] / [kg],0.65,80147,DB01202,Levetiracetam
,26242293,peak,"The volume of distribution was 0.65 L/kg, and clearance was measured with peak (ranging from 26.5-39.8 μg/ml) and trough (ranging from 13.9-18.2 μg/ml) concentrations.",Levetiracetam Pharmacokinetics in a Patient Receiving Continuous Venovenous Hemofiltration and Venoarterial Extracorporeal Membrane Oxygenation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26242293/),[μg] / [ml],26.5-39.8,80148,DB01202,Levetiracetam
,26242293,trough,"The volume of distribution was 0.65 L/kg, and clearance was measured with peak (ranging from 26.5-39.8 μg/ml) and trough (ranging from 13.9-18.2 μg/ml) concentrations.",Levetiracetam Pharmacokinetics in a Patient Receiving Continuous Venovenous Hemofiltration and Venoarterial Extracorporeal Membrane Oxygenation. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26242293/),[μg] / [ml],13.9-18.2,80149,DB01202,Levetiracetam
,26242293,Elimination half-life,Elimination half-life ranged from 8.7-10.1 hours.,Levetiracetam Pharmacokinetics in a Patient Receiving Continuous Venovenous Hemofiltration and Venoarterial Extracorporeal Membrane Oxygenation. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/26242293/),h,8.7-10.1,80150,DB01202,Levetiracetam
,25220641,Ka,"The population values of pharmacokinetic parameters estimated in the final model were as follows: Ka=0.83 h-1, Vd=0.67 L/kg, and CL=0.035 L·kg(-1)·h(-1).",Population pharmacokinetics modeling of oxcarbazepine to characterize drug interactions in Chinese children with epilepsy. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25220641/),1/[h],0.83,82170,DB01202,Levetiracetam
,25220641,Vd,"The population values of pharmacokinetic parameters estimated in the final model were as follows: Ka=0.83 h-1, Vd=0.67 L/kg, and CL=0.035 L·kg(-1)·h(-1).",Population pharmacokinetics modeling of oxcarbazepine to characterize drug interactions in Chinese children with epilepsy. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25220641/),[l] / [kg],0.67,82171,DB01202,Levetiracetam
,25220641,CL,"The population values of pharmacokinetic parameters estimated in the final model were as follows: Ka=0.83 h-1, Vd=0.67 L/kg, and CL=0.035 L·kg(-1)·h(-1).",Population pharmacokinetics modeling of oxcarbazepine to characterize drug interactions in Chinese children with epilepsy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25220641/),[l] / [h·kg],0.035,82172,DB01202,Levetiracetam
,25220641,MP,"For the final model, the evaluation results (95% CI) were MPE=0.01 (-0.07-0.10) mg/L, MAE=0.46 (0.40-0.51) mg/L, MSE=0.39 (0.27-0.51) (mg/L)(2).",Population pharmacokinetics modeling of oxcarbazepine to characterize drug interactions in Chinese children with epilepsy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25220641/),[mg] / [l],0.01,82173,DB01202,Levetiracetam
,25220641,MAE,"For the final model, the evaluation results (95% CI) were MPE=0.01 (-0.07-0.10) mg/L, MAE=0.46 (0.40-0.51) mg/L, MSE=0.39 (0.27-0.51) (mg/L)(2).",Population pharmacokinetics modeling of oxcarbazepine to characterize drug interactions in Chinese children with epilepsy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25220641/),[mg] / [l],0.46,82174,DB01202,Levetiracetam
,25220641,MSE,"For the final model, the evaluation results (95% CI) were MPE=0.01 (-0.07-0.10) mg/L, MAE=0.46 (0.40-0.51) mg/L, MSE=0.39 (0.27-0.51) (mg/L)(2).",Population pharmacokinetics modeling of oxcarbazepine to characterize drug interactions in Chinese children with epilepsy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25220641/),,0.39,82175,DB01202,Levetiracetam
,17270398,t(max),"Levetiracetam was rapidly absorbed following oral dosing, with median t(max) of 0.5 h.",Prospective assessment of levetiracetam pharmacokinetics during dose escalation in 4- to 12-year-old children with partial-onset seizures on concomitant carbamazepine or valproate. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17270398/),h,0.5,91035,DB01202,Levetiracetam
,17270398,t(1/2),Dose proportional increases were observed for C(max) and AUC((0-12)) over the dose range; t(1/2) was 4.9 h.,Prospective assessment of levetiracetam pharmacokinetics during dose escalation in 4- to 12-year-old children with partial-onset seizures on concomitant carbamazepine or valproate. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17270398/),h,4.9,91036,DB01202,Levetiracetam
,20187836,absorption half-life,"Peak concentration occurred 0.6 hours after administration of the first dose, with an absorption half-life of 0.06 hours.",Levetiracetam pharmacokinetics in healthy dogs following oral administration of single and multiple doses. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/20187836/),h,0.06,92245,DB01202,Levetiracetam
,20187836,total area under the concentration-versus-time curve,"Minimal accumulation occurred over the 7 days, with only a slight increase in total area under the concentration-versus-time curve from 268.52 +/- 56.33 h x microg/mL (mean +/- SD) to 289.31 +/- 51.68 h x microg/mL after 7 days.",Levetiracetam pharmacokinetics in healthy dogs following oral administration of single and multiple doses. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20187836/),[h·μg] / [ml],268.52,92246,DB01202,Levetiracetam
,20187836,total area under the concentration-versus-time curve,"Minimal accumulation occurred over the 7 days, with only a slight increase in total area under the concentration-versus-time curve from 268.52 +/- 56.33 h x microg/mL (mean +/- SD) to 289.31 +/- 51.68 h x microg/mL after 7 days.",Levetiracetam pharmacokinetics in healthy dogs following oral administration of single and multiple doses. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20187836/),[h·μg] / [ml],289.31,92247,DB01202,Levetiracetam
,20187836,Terminal half-life,Terminal half-life was 2.87 +/- 0.21 hours after the first dose and 3.59 +/- 0.82 hours after the last dose on day 7.,Levetiracetam pharmacokinetics in healthy dogs following oral administration of single and multiple doses. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/20187836/),h,2.87,92248,DB01202,Levetiracetam
,20187836,Terminal half-life,Terminal half-life was 2.87 +/- 0.21 hours after the first dose and 3.59 +/- 0.82 hours after the last dose on day 7.,Levetiracetam pharmacokinetics in healthy dogs following oral administration of single and multiple doses. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/20187836/),h,3.59,92249,DB01202,Levetiracetam
,20187836,morning,"Trough plasma concentrations were variable, depending on the time of day they were measured (morning trough concentration, 18.42 +/- 5.16 microg/mL; midday trough concentration, 12.57 +/- 4.34 microg/mL), suggesting a diurnal variation in drug excretion.",Levetiracetam pharmacokinetics in healthy dogs following oral administration of single and multiple doses. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20187836/),[μg] / [ml],18.42,92250,DB01202,Levetiracetam
,20187836,trough concentration,"Trough plasma concentrations were variable, depending on the time of day they were measured (morning trough concentration, 18.42 +/- 5.16 microg/mL; midday trough concentration, 12.57 +/- 4.34 microg/mL), suggesting a diurnal variation in drug excretion.",Levetiracetam pharmacokinetics in healthy dogs following oral administration of single and multiple doses. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20187836/),[μg] / [ml],18.42,92251,DB01202,Levetiracetam
,20187836,trough concentration,"Trough plasma concentrations were variable, depending on the time of day they were measured (morning trough concentration, 18.42 +/- 5.16 microg/mL; midday trough concentration, 12.57 +/- 4.34 microg/mL), suggesting a diurnal variation in drug excretion.",Levetiracetam pharmacokinetics in healthy dogs following oral administration of single and multiple doses. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20187836/),[μg] / [ml],12.57,92252,DB01202,Levetiracetam
,14530892,apparent volume of distribution,The apparent volume of distribution of the compound was close (0.55-0.62 l/kg) to the volume of total body water.,"Pharmacokinetics and metabolism of 14C-levetiracetam, a new antiepileptic agent, in healthy volunteers. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14530892/),[l] / [kg],0.55-0.62,93232,DB01202,Levetiracetam
,14530892,Total body clearance,Total body clearance (0.80-0.97 ml/min/kg) was much lower than the nominal hepatic blood flow.,"Pharmacokinetics and metabolism of 14C-levetiracetam, a new antiepileptic agent, in healthy volunteers. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14530892/),[ml] / [kg·min],0.80-0.97,93233,DB01202,Levetiracetam
,14530892,plasma elimination half-life,The plasma elimination half-life of the unchanged drug varied between 7.4 h and 7.9 h.,"Pharmacokinetics and metabolism of 14C-levetiracetam, a new antiepileptic agent, in healthy volunteers. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/14530892/),h,7.4,93234,DB01202,Levetiracetam
,14530892,plasma elimination half-life,The plasma elimination half-life of the unchanged drug varied between 7.4 h and 7.9 h.,"Pharmacokinetics and metabolism of 14C-levetiracetam, a new antiepileptic agent, in healthy volunteers. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/14530892/),h,7.9,93235,DB01202,Levetiracetam
,14530892,Plasma to blood ratio of total radioactivity concentrations,"Plasma to blood ratio of total radioactivity concentrations was 1.1-1.3, showing that radioactivity concentrations were similar in blood cells and plasma.","Pharmacokinetics and metabolism of 14C-levetiracetam, a new antiepileptic agent, in healthy volunteers. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14530892/),,1.1-1.3,93236,DB01202,Levetiracetam
,14530892,Km,"Hydrolysis of levetiracetam in human blood followed Michaelis-Menten kinetics with Km and V(max) values of 435 microM and 129 pmol/min/ml blood, respectively.","Pharmacokinetics and metabolism of 14C-levetiracetam, a new antiepileptic agent, in healthy volunteers. ",Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14530892/),μM,435,93237,DB01202,Levetiracetam
,14530892,V(max),"Hydrolysis of levetiracetam in human blood followed Michaelis-Menten kinetics with Km and V(max) values of 435 microM and 129 pmol/min/ml blood, respectively.","Pharmacokinetics and metabolism of 14C-levetiracetam, a new antiepileptic agent, in healthy volunteers. ",Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14530892/),[pM] / [min·ml],129,93238,DB01202,Levetiracetam
>,15301575,bioavailability,"After oral ingestion, levetiracetam is rapidly absorbed, with peak concentration occurring after 1.3 hours, and its bioavailability is >95%.",Clinical pharmacokinetics of levetiracetam. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15301575/),%,95,93302,DB01202,Levetiracetam
,15301575,volume of distribution,Levetiracetam is not bound to plasma proteins and has a volume of distribution of 0.5-0.7 L/kg.,Clinical pharmacokinetics of levetiracetam. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15301575/),[l] / [kg],0.5-0.7,93303,DB01202,Levetiracetam
,15301575,elimination half-life,"The elimination half-life in adult volunteers, adults with epilepsy, children with epilepsy and elderly volunteers is 6-8, 6-8, 5-7 and 10-11 hours, respectively.",Clinical pharmacokinetics of levetiracetam. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15301575/),h,6-8,93304,DB01202,Levetiracetam
,15301575,elimination half-life,"The elimination half-life in adult volunteers, adults with epilepsy, children with epilepsy and elderly volunteers is 6-8, 6-8, 5-7 and 10-11 hours, respectively.",Clinical pharmacokinetics of levetiracetam. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15301575/),h,5-7,93305,DB01202,Levetiracetam
,15301575,elimination half-life,"The elimination half-life in adult volunteers, adults with epilepsy, children with epilepsy and elderly volunteers is 6-8, 6-8, 5-7 and 10-11 hours, respectively.",Clinical pharmacokinetics of levetiracetam. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15301575/),h,10-11,93306,DB01202,Levetiracetam
,31729053,time to methotrexate clearance,"The mean time to methotrexate clearance was 82.5 hours (SD, 51.2; 95% confidence interval, 69.4-95.7) in the concomitant levetiracetam group and 72.4 hours (SD, 31.2; 95% confidence interval, 61.7-83.0) in the nonlevetiracetam group, which was not significantly different (P > .05), even in the subgroup receiving methotrexate doses >3500 mg/m2 .",Effect of Levetiracetam on Time to High-Dose Methotrexate Clearance in Patients With Hematologic Malignancies. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31729053/),h,82.5,95819,DB01202,Levetiracetam
,31729053,time to methotrexate clearance,"The mean time to methotrexate clearance was 82.5 hours (SD, 51.2; 95% confidence interval, 69.4-95.7) in the concomitant levetiracetam group and 72.4 hours (SD, 31.2; 95% confidence interval, 61.7-83.0) in the nonlevetiracetam group, which was not significantly different (P > .05), even in the subgroup receiving methotrexate doses >3500 mg/m2 .",Effect of Levetiracetam on Time to High-Dose Methotrexate Clearance in Patients With Hematologic Malignancies. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31729053/),h,72.4,95820,DB01202,Levetiracetam
,11488879,clearance,LEV and REV had similar mean +/- SD values for clearance; 1.5 +/- 0.3 ml/min/kg and volume of distribution; 0.5 +/- 0.1 L/kg.,Pharmacokinetics of levetiracetam and its enantiomer (R)-alpha-ethyl-2-oxo-pyrrolidine acetamide in dogs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11488879/),[ml] / [kg·min],1.5,96198,DB01202,Levetiracetam
,11488879,volume of distribution,LEV and REV had similar mean +/- SD values for clearance; 1.5 +/- 0.3 ml/min/kg and volume of distribution; 0.5 +/- 0.1 L/kg.,Pharmacokinetics of levetiracetam and its enantiomer (R)-alpha-ethyl-2-oxo-pyrrolidine acetamide in dogs. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11488879/),[l] / [kg],0.5,96199,DB01202,Levetiracetam
,11488879,t1/2,"The half-life (t1/2) and mean residence time (MRT) of REV (t1/2, 4.3 +/- 0.8 h, and MRT, 6.0 +/- 1.1 h) were, however, significantly longer than those of LEV (t1/2, 3.6 +/- 0.8 h, and MRT, 5.0 +/- 1.2 h).",Pharmacokinetics of levetiracetam and its enantiomer (R)-alpha-ethyl-2-oxo-pyrrolidine acetamide in dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11488879/),h,4.3,96200,DB01202,Levetiracetam
,11488879,MRT,"The half-life (t1/2) and mean residence time (MRT) of REV (t1/2, 4.3 +/- 0.8 h, and MRT, 6.0 +/- 1.1 h) were, however, significantly longer than those of LEV (t1/2, 3.6 +/- 0.8 h, and MRT, 5.0 +/- 1.2 h).",Pharmacokinetics of levetiracetam and its enantiomer (R)-alpha-ethyl-2-oxo-pyrrolidine acetamide in dogs. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11488879/),h,6.0,96201,DB01202,Levetiracetam
,11488879,t1/2,"The half-life (t1/2) and mean residence time (MRT) of REV (t1/2, 4.3 +/- 0.8 h, and MRT, 6.0 +/- 1.1 h) were, however, significantly longer than those of LEV (t1/2, 3.6 +/- 0.8 h, and MRT, 5.0 +/- 1.2 h).",Pharmacokinetics of levetiracetam and its enantiomer (R)-alpha-ethyl-2-oxo-pyrrolidine acetamide in dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11488879/),h,3.6,96202,DB01202,Levetiracetam
,11488879,MRT,"The half-life (t1/2) and mean residence time (MRT) of REV (t1/2, 4.3 +/- 0.8 h, and MRT, 6.0 +/- 1.1 h) were, however, significantly longer than those of LEV (t1/2, 3.6 +/- 0.8 h, and MRT, 5.0 +/- 1.2 h).",Pharmacokinetics of levetiracetam and its enantiomer (R)-alpha-ethyl-2-oxo-pyrrolidine acetamide in dogs. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11488879/),h,5.0,96203,DB01202,Levetiracetam
,24259740,clearance,Phenytoin clearance by CVVH ranged from 11 to 13 mL/min in these patients.,Phenytoin removal by continuous venovenous hemofiltration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24259740/),[ml] / [min],11 to 13,101362,DB01202,Levetiracetam
,26135593,area under the plasma concentration-time curve (AUC) from time 0 to infinity (AUC(∞)),"Bioequivalence was demonstrated between the 45-min intravenous infusion and oral tablets, with geometric mean area under the plasma concentration-time curve (AUC) from time 0 to infinity (AUC(∞)) 492.3 and 506.8 μg·h/mL, and geometric mean maximum concentration (Cmax) 65.12 and 55.93 μg/mL for intravenous infusion and oral dosing, respectively.","Pharmacokinetics, Safety and Bioequivalence of Levetiracetam Intravenous Infusion and Oral Tablets in Healthy Chinese Subjects. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26135593/),[h·μg] / [ml],492.3,105539,DB01202,Levetiracetam
,26135593,area under the plasma concentration-time curve (AUC) from time 0 to infinity (AUC(∞)),"Bioequivalence was demonstrated between the 45-min intravenous infusion and oral tablets, with geometric mean area under the plasma concentration-time curve (AUC) from time 0 to infinity (AUC(∞)) 492.3 and 506.8 μg·h/mL, and geometric mean maximum concentration (Cmax) 65.12 and 55.93 μg/mL for intravenous infusion and oral dosing, respectively.","Pharmacokinetics, Safety and Bioequivalence of Levetiracetam Intravenous Infusion and Oral Tablets in Healthy Chinese Subjects. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26135593/),[h·μg] / [ml],506.8,105540,DB01202,Levetiracetam
,26135593,maximum concentration (Cmax),"Bioequivalence was demonstrated between the 45-min intravenous infusion and oral tablets, with geometric mean area under the plasma concentration-time curve (AUC) from time 0 to infinity (AUC(∞)) 492.3 and 506.8 μg·h/mL, and geometric mean maximum concentration (Cmax) 65.12 and 55.93 μg/mL for intravenous infusion and oral dosing, respectively.","Pharmacokinetics, Safety and Bioequivalence of Levetiracetam Intravenous Infusion and Oral Tablets in Healthy Chinese Subjects. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26135593/),[μg] / [ml],65.12,105541,DB01202,Levetiracetam
,26135593,maximum concentration (Cmax),"Bioequivalence was demonstrated between the 45-min intravenous infusion and oral tablets, with geometric mean area under the plasma concentration-time curve (AUC) from time 0 to infinity (AUC(∞)) 492.3 and 506.8 μg·h/mL, and geometric mean maximum concentration (Cmax) 65.12 and 55.93 μg/mL for intravenous infusion and oral dosing, respectively.","Pharmacokinetics, Safety and Bioequivalence of Levetiracetam Intravenous Infusion and Oral Tablets in Healthy Chinese Subjects. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26135593/),[μg] / [ml],55.93,105542,DB01202,Levetiracetam
,26135593,"AUC during the dosing interval τ at steady state (AUC(τ,ss))","Linear pharmacokinetics were demonstrated (geometric least-squares mean AUC during the dosing interval τ at steady state (AUC(τ,ss)) 475.6 μg·h/mL; geometric least-squares mean AUC(∞) after single dose 501.7 μg·h/mL; linearity factor = 0.948).","Pharmacokinetics, Safety and Bioequivalence of Levetiracetam Intravenous Infusion and Oral Tablets in Healthy Chinese Subjects. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26135593/),[h·μg] / [ml],475.6,105543,DB01202,Levetiracetam
,26135593,AUC(∞),"Linear pharmacokinetics were demonstrated (geometric least-squares mean AUC during the dosing interval τ at steady state (AUC(τ,ss)) 475.6 μg·h/mL; geometric least-squares mean AUC(∞) after single dose 501.7 μg·h/mL; linearity factor = 0.948).","Pharmacokinetics, Safety and Bioequivalence of Levetiracetam Intravenous Infusion and Oral Tablets in Healthy Chinese Subjects. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26135593/),[h·μg] / [ml],501.7,105544,DB01202,Levetiracetam
,26135593,Cmax,"Geometric mean Cmax (77.44 μg/mL) and AUC(τ,ss) (475.6 μg·h/mL) of intravenous infusion levetiracetam 1500 mg after multiple doses were within the expected range, based on their respective single-dose values and the terminal half-life of levetiracetam after a single dose (7.13 h).","Pharmacokinetics, Safety and Bioequivalence of Levetiracetam Intravenous Infusion and Oral Tablets in Healthy Chinese Subjects. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26135593/),[μg] / [ml],77.44,105545,DB01202,Levetiracetam
,26135593,"AUC(τ,ss)","Geometric mean Cmax (77.44 μg/mL) and AUC(τ,ss) (475.6 μg·h/mL) of intravenous infusion levetiracetam 1500 mg after multiple doses were within the expected range, based on their respective single-dose values and the terminal half-life of levetiracetam after a single dose (7.13 h).","Pharmacokinetics, Safety and Bioequivalence of Levetiracetam Intravenous Infusion and Oral Tablets in Healthy Chinese Subjects. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26135593/),[h·μg] / [ml],475.6,105546,DB01202,Levetiracetam
,26135593,terminal half-life,"Geometric mean Cmax (77.44 μg/mL) and AUC(τ,ss) (475.6 μg·h/mL) of intravenous infusion levetiracetam 1500 mg after multiple doses were within the expected range, based on their respective single-dose values and the terminal half-life of levetiracetam after a single dose (7.13 h).","Pharmacokinetics, Safety and Bioequivalence of Levetiracetam Intravenous Infusion and Oral Tablets in Healthy Chinese Subjects. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/26135593/),h,7.13,105547,DB01202,Levetiracetam
,25375249,run time,"Detection was performed using an AB Sciex API 3000 triple quadrupole mass spectrometer, equipped with a Turbo Ion Spray source, operating in a positive mode: LEV at transition 171.1>154.1, UCB L057 at 172.5>126.1, and IS at 256.3>167.3; with an assay run time of 2 minutes.",Rapid and simultaneous quantification of levetiracetam and its carboxylic metabolite in human plasma by liquid chromatography tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25375249/),min,2,105617,DB01202,Levetiracetam
,25375249,recoveries,Matrix effects were consistent between sources of plasma and the recoveries of all compounds were between 100% and 110%.,Rapid and simultaneous quantification of levetiracetam and its carboxylic metabolite in human plasma by liquid chromatography tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25375249/),%,100,105618,DB01202,Levetiracetam
,25375249,recoveries,Matrix effects were consistent between sources of plasma and the recoveries of all compounds were between 100% and 110%.,Rapid and simultaneous quantification of levetiracetam and its carboxylic metabolite in human plasma by liquid chromatography tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25375249/),%,110,105619,DB01202,Levetiracetam
,21549563,clearance (plasma concentration,The estimated clearance (plasma concentration/daily dose) was 39 nmol/L/mg (range 14-88 nmol/L/mg) among women who did not use OC (n=30) and 38 nmol/L/mg (range 18-103 nmol/L/mg) among OC users (n=23) (p=0.8).,No effect of oral contraceptives on the metabolism of levetiracetam. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21549563/),[nM] / [l·mg],39,107158,DB01202,Levetiracetam
,21549563,clearance (plasma concentration,The estimated clearance (plasma concentration/daily dose) was 39 nmol/L/mg (range 14-88 nmol/L/mg) among women who did not use OC (n=30) and 38 nmol/L/mg (range 18-103 nmol/L/mg) among OC users (n=23) (p=0.8).,No effect of oral contraceptives on the metabolism of levetiracetam. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21549563/),[nM] / [l·mg],38,107159,DB01202,Levetiracetam
,15978308,AUC,"Mean AUC values were 191.9 (50.2), 165.7 (43.4), and 168.3 (43.9) microg/mL . h for treatments A, B, and C, respectively.",Oral absorption kinetics of levetiracetam: the effect of mixing with food or enteral nutrition formulas. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15978308/),[μg] / [h·ml],191.9,108344,DB01202,Levetiracetam
,15978308,AUC,"Mean AUC values were 191.9 (50.2), 165.7 (43.4), and 168.3 (43.9) microg/mL . h for treatments A, B, and C, respectively.",Oral absorption kinetics of levetiracetam: the effect of mixing with food or enteral nutrition formulas. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15978308/),[μg] / [h·ml],165.7,108345,DB01202,Levetiracetam
,15978308,AUC,"Mean AUC values were 191.9 (50.2), 165.7 (43.4), and 168.3 (43.9) microg/mL . h for treatments A, B, and C, respectively.",Oral absorption kinetics of levetiracetam: the effect of mixing with food or enteral nutrition formulas. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15978308/),[μg] / [h·ml],168.3,108346,DB01202,Levetiracetam
,15978308,T(max),"Mean T(max) values were 1.08 (0.65), 1.32 (0.75), and 1.62 (0.73) hours, respectively.",Oral absorption kinetics of levetiracetam: the effect of mixing with food or enteral nutrition formulas. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15978308/),h,1.08,108347,DB01202,Levetiracetam
,15978308,T(max),"Mean T(max) values were 1.08 (0.65), 1.32 (0.75), and 1.62 (0.73) hours, respectively.",Oral absorption kinetics of levetiracetam: the effect of mixing with food or enteral nutrition formulas. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15978308/),h,1.32,108348,DB01202,Levetiracetam
,15978308,T(max),"Mean T(max) values were 1.08 (0.65), 1.32 (0.75), and 1.62 (0.73) hours, respectively.",Oral absorption kinetics of levetiracetam: the effect of mixing with food or enteral nutrition formulas. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15978308/),h,1.62,108349,DB01202,Levetiracetam
,15978308,C(max),"Mean C(max) values were 14.8 (5.6), 12.1 (2.8), and 10.8 (2.0) microg/mL for the respective treatments.",Oral absorption kinetics of levetiracetam: the effect of mixing with food or enteral nutrition formulas. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15978308/),[μg] / [ml],14.8,108350,DB01202,Levetiracetam
,15978308,C(max),"Mean C(max) values were 14.8 (5.6), 12.1 (2.8), and 10.8 (2.0) microg/mL for the respective treatments.",Oral absorption kinetics of levetiracetam: the effect of mixing with food or enteral nutrition formulas. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15978308/),[μg] / [ml],12.1,108351,DB01202,Levetiracetam
,15978308,C(max),"Mean C(max) values were 14.8 (5.6), 12.1 (2.8), and 10.8 (2.0) microg/mL for the respective treatments.",Oral absorption kinetics of levetiracetam: the effect of mixing with food or enteral nutrition formulas. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15978308/),[μg] / [ml],10.8,108352,DB01202,Levetiracetam
,15978308,serum concentrations,"Mean LEV serum concentrations at 12 hours after dosing were similar for all study treatments (3.9, 4.1, and 4.0 microg/mL).",Oral absorption kinetics of levetiracetam: the effect of mixing with food or enteral nutrition formulas. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15978308/),[μg] / [ml],3.9,108353,DB01202,Levetiracetam
,15978308,serum concentrations,"Mean LEV serum concentrations at 12 hours after dosing were similar for all study treatments (3.9, 4.1, and 4.0 microg/mL).",Oral absorption kinetics of levetiracetam: the effect of mixing with food or enteral nutrition formulas. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15978308/),[μg] / [ml],4.1,108354,DB01202,Levetiracetam
,15978308,serum concentrations,"Mean LEV serum concentrations at 12 hours after dosing were similar for all study treatments (3.9, 4.1, and 4.0 microg/mL).",Oral absorption kinetics of levetiracetam: the effect of mixing with food or enteral nutrition formulas. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15978308/),[μg] / [ml],4.0,108355,DB01202,Levetiracetam
,29393846,volume of distribution (V),"Typical parameter estimates of the final PK model obtained, evaluated at covariate medians, were 1.08 L/kg for volume of distribution (V) and 0.073 L/h/kg (= 1.23 mL/min/kg) for CL, illustrating that V in Korean neonates is a little larger than in Western population while CL is similar.",Population pharmacokinetic model of levetiracetam in Korean neonates with seizures . ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29393846/),[l] / [kg],1.08,108838,DB01202,Levetiracetam
,29393846,CL,"Typical parameter estimates of the final PK model obtained, evaluated at covariate medians, were 1.08 L/kg for volume of distribution (V) and 0.073 L/h/kg (= 1.23 mL/min/kg) for CL, illustrating that V in Korean neonates is a little larger than in Western population while CL is similar.",Population pharmacokinetic model of levetiracetam in Korean neonates with seizures . ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29393846/),[l] / [h·kg],0.073,108839,DB01202,Levetiracetam
,29393846,CL,"Typical parameter estimates of the final PK model obtained, evaluated at covariate medians, were 1.08 L/kg for volume of distribution (V) and 0.073 L/h/kg (= 1.23 mL/min/kg) for CL, illustrating that V in Korean neonates is a little larger than in Western population while CL is similar.",Population pharmacokinetic model of levetiracetam in Korean neonates with seizures . ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29393846/),[ml] / [kg·min],1.23,108840,DB01202,Levetiracetam
,17573925,CL,Mean LEV CL differed significantly between older (46.5 ml/h/kg) and younger adults (78.3 ml/h/kg).,Effect of age and comedication on levetiracetam pharmacokinetics and tolerability. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17573925/),[ml] / [h·kg],46.5,113565,DB01202,Levetiracetam
,17573925,CL,Mean LEV CL differed significantly between older (46.5 ml/h/kg) and younger adults (78.3 ml/h/kg).,Effect of age and comedication on levetiracetam pharmacokinetics and tolerability. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17573925/),[ml] / [h·kg],78.3,113566,DB01202,Levetiracetam
,23891703,Volume of distribution,Volume of distribution of TPM was estimated at 0.575 l/kg.,Population pharmacokinetics of topiramate in adult patients with epilepsy using nonlinear mixed effects modelling. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23891703/),[l] / [kg],0.575,116785,DB01202,Levetiracetam
,23891703,CL/F,"Mean TPM CL/F during CBZ co-therapy was 2.46 l/h, which is higher for 60.8% than in patients not co-treated with CBZ.",Population pharmacokinetics of topiramate in adult patients with epilepsy using nonlinear mixed effects modelling. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23891703/),[l] / [h],2.46,116786,DB01202,Levetiracetam
,12507057,elimination half-life,The elimination half-life was calculated to be 5.14 hours.,A case of levetiracetam (Keppra) poisoning with clinical and toxicokinetic data. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12507057/),h,5.14,117772,DB01202,Levetiracetam
,18471147,half-life,Intravenous LEV half-life was 180 +/- 18 min.,"Intramuscular, intravenous and oral levetiracetam in dogs: safety and pharmacokinetics. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18471147/),min,180,122658,DB01202,Levetiracetam
,18471147,Bioavailability,Bioavailability of IM LEV was 100%.,"Intramuscular, intravenous and oral levetiracetam in dogs: safety and pharmacokinetics. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18471147/),%,100,122659,DB01202,Levetiracetam
,18471147,time to T(max),Mean time to T(max) after IM was 40 +/- 16 min.,"Intramuscular, intravenous and oral levetiracetam in dogs: safety and pharmacokinetics. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18471147/),min,40,122660,DB01202,Levetiracetam
,18471147,C(max),The mean C(max) IM was 30.3 +/- 3 mug/mL compared to the C(0) of 37 +/- 5 mug/mL for IV.,"Intramuscular, intravenous and oral levetiracetam in dogs: safety and pharmacokinetics. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18471147/),[μg] / [ml],30.3,122661,DB01202,Levetiracetam
,18471147,C(0),The mean C(max) IM was 30.3 +/- 3 mug/mL compared to the C(0) of 37 +/- 5 mug/mL for IV.,"Intramuscular, intravenous and oral levetiracetam in dogs: safety and pharmacokinetics. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18471147/),[μg] / [ml],37,122662,DB01202,Levetiracetam
,18471147,inflammation score,Mean inflammation score (0-4 scale) for IM LEV was 0.28 and for saline 0.62.,"Intramuscular, intravenous and oral levetiracetam in dogs: safety and pharmacokinetics. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18471147/),,0.28,122663,DB01202,Levetiracetam
,18471147,inflammation score,Mean inflammation score (0-4 scale) for IM LEV was 0.28 and for saline 0.62.,"Intramuscular, intravenous and oral levetiracetam in dogs: safety and pharmacokinetics. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18471147/),,0.62,122664,DB01202,Levetiracetam
,19054418,time,The median time from hospital admission to ivLEV was 36 min.,Safety and pharmacokinetics of intravenous levetiracetam infusion as add-on in status epilepticus. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19054418/),min,36,126739,DB01202,Levetiracetam
,19054418,volume of distribution of central compartment,"Mean (standard deviation, SD) population parameters included volume of distribution of central compartment: 0.45 (0.084) L/kg; total body clearance: 0.0476 (0.0147) L/h/kg; distribution rate constants, central to peripheral compartment (k(12)): 0.24 (0.12)/h, and peripheral to central (k(21)): 0.70 (0.22)/h.",Safety and pharmacokinetics of intravenous levetiracetam infusion as add-on in status epilepticus. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19054418/),[l] / [kg],0.45,126740,DB01202,Levetiracetam
,19054418,total body clearance,"Mean (standard deviation, SD) population parameters included volume of distribution of central compartment: 0.45 (0.084) L/kg; total body clearance: 0.0476 (0.0147) L/h/kg; distribution rate constants, central to peripheral compartment (k(12)): 0.24 (0.12)/h, and peripheral to central (k(21)): 0.70 (0.22)/h.",Safety and pharmacokinetics of intravenous levetiracetam infusion as add-on in status epilepticus. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19054418/),[l] / [h·kg],0.0476,126741,DB01202,Levetiracetam
,19054418,"distribution rate constants, central to peripheral compartment (k(12))","Mean (standard deviation, SD) population parameters included volume of distribution of central compartment: 0.45 (0.084) L/kg; total body clearance: 0.0476 (0.0147) L/h/kg; distribution rate constants, central to peripheral compartment (k(12)): 0.24 (0.12)/h, and peripheral to central (k(21)): 0.70 (0.22)/h.",Safety and pharmacokinetics of intravenous levetiracetam infusion as add-on in status epilepticus. ,"K12, K21-Q48",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19054418/),1/[h],0.24,126742,DB01202,Levetiracetam
,19054418,peripheral to central (k(21)),"Mean (standard deviation, SD) population parameters included volume of distribution of central compartment: 0.45 (0.084) L/kg; total body clearance: 0.0476 (0.0147) L/h/kg; distribution rate constants, central to peripheral compartment (k(12)): 0.24 (0.12)/h, and peripheral to central (k(21)): 0.70 (0.22)/h.",Safety and pharmacokinetics of intravenous levetiracetam infusion as add-on in status epilepticus. ,"K12, K21-Q48",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19054418/),1/[h],0.70,126743,DB01202,Levetiracetam
,19054418,maximal plasma concentration,Mean maximal plasma concentration was 85 (19) mg/L.,Safety and pharmacokinetics of intravenous levetiracetam infusion as add-on in status epilepticus. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19054418/),[mg] / [l],85,126744,DB01202,Levetiracetam
,25843318,maximum plasma concentrations,"The concentration-time profiles resembled characteristic absorption, with maximum plasma concentrations of 61.0 μg/mL and 95.1 μg/mL at 60 minutes; terminal half-lives at 2.38 and 2.37 hours; volumes of distribution of 0.807 and 0.773 L/kg, with an area under the curve at 14 100 and 28 820 mg × min/L; and clearance rates of 3.65 and 3.60 mL/min per kg, respectively.",Pharmacokinetics of Levetiracetam in Healthy Hispaniolan Amazon Parrots ( Amazona ventralis ) After Oral Administration of a Single Dose. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25843318/),[μg] / [ml],61.0,128759,DB01202,Levetiracetam
,25843318,maximum plasma concentrations,"The concentration-time profiles resembled characteristic absorption, with maximum plasma concentrations of 61.0 μg/mL and 95.1 μg/mL at 60 minutes; terminal half-lives at 2.38 and 2.37 hours; volumes of distribution of 0.807 and 0.773 L/kg, with an area under the curve at 14 100 and 28 820 mg × min/L; and clearance rates of 3.65 and 3.60 mL/min per kg, respectively.",Pharmacokinetics of Levetiracetam in Healthy Hispaniolan Amazon Parrots ( Amazona ventralis ) After Oral Administration of a Single Dose. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25843318/),[μg] / [ml],95.1,128760,DB01202,Levetiracetam
,25843318,terminal half-lives,"The concentration-time profiles resembled characteristic absorption, with maximum plasma concentrations of 61.0 μg/mL and 95.1 μg/mL at 60 minutes; terminal half-lives at 2.38 and 2.37 hours; volumes of distribution of 0.807 and 0.773 L/kg, with an area under the curve at 14 100 and 28 820 mg × min/L; and clearance rates of 3.65 and 3.60 mL/min per kg, respectively.",Pharmacokinetics of Levetiracetam in Healthy Hispaniolan Amazon Parrots ( Amazona ventralis ) After Oral Administration of a Single Dose. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/25843318/),h,2.38,128761,DB01202,Levetiracetam
,25843318,terminal half-lives,"The concentration-time profiles resembled characteristic absorption, with maximum plasma concentrations of 61.0 μg/mL and 95.1 μg/mL at 60 minutes; terminal half-lives at 2.38 and 2.37 hours; volumes of distribution of 0.807 and 0.773 L/kg, with an area under the curve at 14 100 and 28 820 mg × min/L; and clearance rates of 3.65 and 3.60 mL/min per kg, respectively.",Pharmacokinetics of Levetiracetam in Healthy Hispaniolan Amazon Parrots ( Amazona ventralis ) After Oral Administration of a Single Dose. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/25843318/),h,2.37,128762,DB01202,Levetiracetam
,25843318,volumes of distribution,"The concentration-time profiles resembled characteristic absorption, with maximum plasma concentrations of 61.0 μg/mL and 95.1 μg/mL at 60 minutes; terminal half-lives at 2.38 and 2.37 hours; volumes of distribution of 0.807 and 0.773 L/kg, with an area under the curve at 14 100 and 28 820 mg × min/L; and clearance rates of 3.65 and 3.60 mL/min per kg, respectively.",Pharmacokinetics of Levetiracetam in Healthy Hispaniolan Amazon Parrots ( Amazona ventralis ) After Oral Administration of a Single Dose. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25843318/),[l] / [kg],0.807,128763,DB01202,Levetiracetam
,25843318,volumes of distribution,"The concentration-time profiles resembled characteristic absorption, with maximum plasma concentrations of 61.0 μg/mL and 95.1 μg/mL at 60 minutes; terminal half-lives at 2.38 and 2.37 hours; volumes of distribution of 0.807 and 0.773 L/kg, with an area under the curve at 14 100 and 28 820 mg × min/L; and clearance rates of 3.65 and 3.60 mL/min per kg, respectively.",Pharmacokinetics of Levetiracetam in Healthy Hispaniolan Amazon Parrots ( Amazona ventralis ) After Oral Administration of a Single Dose. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25843318/),[l] / [kg],0.773,128764,DB01202,Levetiracetam
,25843318,area under the curve,"The concentration-time profiles resembled characteristic absorption, with maximum plasma concentrations of 61.0 μg/mL and 95.1 μg/mL at 60 minutes; terminal half-lives at 2.38 and 2.37 hours; volumes of distribution of 0.807 and 0.773 L/kg, with an area under the curve at 14 100 and 28 820 mg × min/L; and clearance rates of 3.65 and 3.60 mL/min per kg, respectively.",Pharmacokinetics of Levetiracetam in Healthy Hispaniolan Amazon Parrots ( Amazona ventralis ) After Oral Administration of a Single Dose. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25843318/),[mg·min] / [l],14 100,128765,DB01202,Levetiracetam
,25843318,area under the curve,"The concentration-time profiles resembled characteristic absorption, with maximum plasma concentrations of 61.0 μg/mL and 95.1 μg/mL at 60 minutes; terminal half-lives at 2.38 and 2.37 hours; volumes of distribution of 0.807 and 0.773 L/kg, with an area under the curve at 14 100 and 28 820 mg × min/L; and clearance rates of 3.65 and 3.60 mL/min per kg, respectively.",Pharmacokinetics of Levetiracetam in Healthy Hispaniolan Amazon Parrots ( Amazona ventralis ) After Oral Administration of a Single Dose. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25843318/),[mg·min] / [l],28 820,128766,DB01202,Levetiracetam
,25843318,clearance rates,"The concentration-time profiles resembled characteristic absorption, with maximum plasma concentrations of 61.0 μg/mL and 95.1 μg/mL at 60 minutes; terminal half-lives at 2.38 and 2.37 hours; volumes of distribution of 0.807 and 0.773 L/kg, with an area under the curve at 14 100 and 28 820 mg × min/L; and clearance rates of 3.65 and 3.60 mL/min per kg, respectively.",Pharmacokinetics of Levetiracetam in Healthy Hispaniolan Amazon Parrots ( Amazona ventralis ) After Oral Administration of a Single Dose. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25843318/),[ml] / [kg·min],3.65,128767,DB01202,Levetiracetam
,25843318,clearance rates,"The concentration-time profiles resembled characteristic absorption, with maximum plasma concentrations of 61.0 μg/mL and 95.1 μg/mL at 60 minutes; terminal half-lives at 2.38 and 2.37 hours; volumes of distribution of 0.807 and 0.773 L/kg, with an area under the curve at 14 100 and 28 820 mg × min/L; and clearance rates of 3.65 and 3.60 mL/min per kg, respectively.",Pharmacokinetics of Levetiracetam in Healthy Hispaniolan Amazon Parrots ( Amazona ventralis ) After Oral Administration of a Single Dose. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25843318/),[ml] / [kg·min],3.60,128768,DB01202,Levetiracetam
greater,25843318,Plasma concentrations,"Plasma concentrations were greater than 5.5 mg/L for up to 9.4 and 12 hours, suggesting an 8- and 12-hour oral dosing at 50 and 100 mg/kg, respectively, would be sufficient to maintain targeted values.",Pharmacokinetics of Levetiracetam in Healthy Hispaniolan Amazon Parrots ( Amazona ventralis ) After Oral Administration of a Single Dose. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25843318/),[mg] / [l],5.5,128769,DB01202,Levetiracetam
,28446744,blood flow rate,"The blood flow rate was 250 ml/min, and the predilution replacement therapy fluid flow rate was 2000 ml/h.",Levetiracetam Pharmacokinetics in a Patient with Intracranial Hemorrhage Undergoing Continuous Veno-Venous Hemofiltration. ,Q-Q54,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28446744/),[ml] / [min],250,128926,DB01202,Levetiracetam
,28446744,fluid flow rate,"The blood flow rate was 250 ml/min, and the predilution replacement therapy fluid flow rate was 2000 ml/h.",Levetiracetam Pharmacokinetics in a Patient with Intracranial Hemorrhage Undergoing Continuous Veno-Venous Hemofiltration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28446744/),[ml] / [h],2000,128927,DB01202,Levetiracetam
,28446744,maximum concentration (Cmax),"The levetiracetam maximum concentration (Cmax), minimum concentration (Cmin), half-life, area under the concentration-time curve (AUC0-12), clearance (CL), and volume of distribution (Vd) were 30.7 µg/ml, 16.1 µg/ml, 12.9 h, 272 mg·hr/L, 3.68 L/h, and 0.73 L/kg, respectively.",Levetiracetam Pharmacokinetics in a Patient with Intracranial Hemorrhage Undergoing Continuous Veno-Venous Hemofiltration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28446744/),[μg] / [ml],30.7,128928,DB01202,Levetiracetam
,28446744,volume of distribution (Vd),"The levetiracetam maximum concentration (Cmax), minimum concentration (Cmin), half-life, area under the concentration-time curve (AUC0-12), clearance (CL), and volume of distribution (Vd) were 30.7 µg/ml, 16.1 µg/ml, 12.9 h, 272 mg·hr/L, 3.68 L/h, and 0.73 L/kg, respectively.",Levetiracetam Pharmacokinetics in a Patient with Intracranial Hemorrhage Undergoing Continuous Veno-Venous Hemofiltration. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28446744/),[l] / [kg],0.73,128929,DB01202,Levetiracetam
,28446744,sieving coefficient,The sieving coefficient was 1.03±0.08.,Levetiracetam Pharmacokinetics in a Patient with Intracranial Hemorrhage Undergoing Continuous Veno-Venous Hemofiltration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28446744/),,1.03,128930,DB01202,Levetiracetam
,32048179,peak plasma cannabidiol concentrations,Median peak plasma cannabidiol concentrations was 13.1 ng/mL (interquartile range 6.8-39.3 ng mL); median time to peak of 2.0 h (interquartile range 2.0-4.0 h).,Disposition of Oral Cannabidiol-Rich Cannabis Extracts in Children with Epilepsy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32048179/),[ng] / [ml],13.1,133353,DB01202,Levetiracetam
,32048179,time to peak,Median peak plasma cannabidiol concentrations was 13.1 ng/mL (interquartile range 6.8-39.3 ng mL); median time to peak of 2.0 h (interquartile range 2.0-4.0 h).,Disposition of Oral Cannabidiol-Rich Cannabis Extracts in Children with Epilepsy. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32048179/),h,2.0,133354,DB01202,Levetiracetam
,32048179,acute elimination half-life,Mean acute elimination half-life of oral cannabidiol was 6.2 h (standard deviation 1.8 h).,Disposition of Oral Cannabidiol-Rich Cannabis Extracts in Children with Epilepsy. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/32048179/),h,6.2,133355,DB01202,Levetiracetam
,32048179,half-life of degradation,There was an observed half-life of degradation of 533 days noted for cannabidiol concentrations when stored for 0.6-3.1 years.,Disposition of Oral Cannabidiol-Rich Cannabis Extracts in Children with Epilepsy. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32048179/),d,533,133356,DB01202,Levetiracetam
,29210977,CL/F,"The mean (±SD) of LEV CL/F in group A (n = 180), B (n = 92), and C (n = 58) was 4.41 ± 2.06 L/h, 7.23 ± 3.72 L/h, and 4.87 ± 1.65 L/h, respectively.",Influence of Comedication on Levetiracetam Pharmacokinetics. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29210977/),[l] / [h],4.41,134944,DB01202,Levetiracetam
,29210977,CL/F,"The mean (±SD) of LEV CL/F in group A (n = 180), B (n = 92), and C (n = 58) was 4.41 ± 2.06 L/h, 7.23 ± 3.72 L/h, and 4.87 ± 1.65 L/h, respectively.",Influence of Comedication on Levetiracetam Pharmacokinetics. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29210977/),[l] / [h],7.23,134945,DB01202,Levetiracetam
,29210977,CL/F,"The mean (±SD) of LEV CL/F in group A (n = 180), B (n = 92), and C (n = 58) was 4.41 ± 2.06 L/h, 7.23 ± 3.72 L/h, and 4.87 ± 1.65 L/h, respectively.",Influence of Comedication on Levetiracetam Pharmacokinetics. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29210977/),[l] / [h],4.87,134946,DB01202,Levetiracetam
,29210977,C0,LEV C0 values were significantly lower in the EIAEDs group than in the monotherapy group (17.30 ± 7.77 versus 20.08 ± 9.69 mcg/mL; P = 0.038) or indeed the NEIAEDs group (17.30 ± 7.77 versus 20.49 ± 9.46 mcg/mL; P = 0.027).,Influence of Comedication on Levetiracetam Pharmacokinetics. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29210977/),[mcg] / [ml],17.30,134947,DB01202,Levetiracetam
,29210977,C0,LEV C0 values were significantly lower in the EIAEDs group than in the monotherapy group (17.30 ± 7.77 versus 20.08 ± 9.69 mcg/mL; P = 0.038) or indeed the NEIAEDs group (17.30 ± 7.77 versus 20.49 ± 9.46 mcg/mL; P = 0.027).,Influence of Comedication on Levetiracetam Pharmacokinetics. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29210977/),[mcg] / [ml],20.08,134948,DB01202,Levetiracetam
,29210977,C0,LEV C0 values were significantly lower in the EIAEDs group than in the monotherapy group (17.30 ± 7.77 versus 20.08 ± 9.69 mcg/mL; P = 0.038) or indeed the NEIAEDs group (17.30 ± 7.77 versus 20.49 ± 9.46 mcg/mL; P = 0.027).,Influence of Comedication on Levetiracetam Pharmacokinetics. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29210977/),[mcg] / [ml],20.49,134949,DB01202,Levetiracetam
,26865186,half-life,"The half-life of retigabine in plasma was 2.5 h, with appreciable concentrations reached in the brain within 1 h of administration.",Profile of retigabine-induced neuronal apoptosis in the developing rat brain. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26865186/),h,2.5,135025,DB01202,Levetiracetam
,18641550,CL,"The administration of inducers led to a significant increase in mean LTG CL (values of 0.045-0.070 L/h/kg vs. 0.028 L/h/kg being reached in monotherapy), whereas VPA led to a significant decrease in CL (0.014 L/h/kg).",Population pharmacokinetics of lamotrigine with data from therapeutic drug monitoring in German and Spanish patients with epilepsy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18641550/),[l] / [h·kg],0.045-0.070,137436,DB01202,Levetiracetam
,18641550,CL,"The administration of inducers led to a significant increase in mean LTG CL (values of 0.045-0.070 L/h/kg vs. 0.028 L/h/kg being reached in monotherapy), whereas VPA led to a significant decrease in CL (0.014 L/h/kg).",Population pharmacokinetics of lamotrigine with data from therapeutic drug monitoring in German and Spanish patients with epilepsy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18641550/),[l] / [h·kg],0.028,137437,DB01202,Levetiracetam
,18641550,CL,"The administration of inducers led to a significant increase in mean LTG CL (values of 0.045-0.070 L/h/kg vs. 0.028 L/h/kg being reached in monotherapy), whereas VPA led to a significant decrease in CL (0.014 L/h/kg).",Population pharmacokinetics of lamotrigine with data from therapeutic drug monitoring in German and Spanish patients with epilepsy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18641550/),[l] / [h·kg],0.014,137438,DB01202,Levetiracetam
,32267792,concentrations,Mean plasma LEV concentrations were 14.4 mg/L (1000 mg/day) and 27.7 mg/L (2000 mg/day).,Pharmacokinetics of Subcutaneous Levetiracetam in Palliative Care Patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32267792/),[mg] / [l],14.4,138445,DB01202,Levetiracetam
,32267792,concentrations,Mean plasma LEV concentrations were 14.4 mg/L (1000 mg/day) and 27.7 mg/L (2000 mg/day).,Pharmacokinetics of Subcutaneous Levetiracetam in Palliative Care Patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32267792/),[mg] / [l],27.7,138446,DB01202,Levetiracetam
,32267792,population clearance,The population clearance (2.5 L/h) and the elimination half-life (10.4 hours) were successfully estimated.,Pharmacokinetics of Subcutaneous Levetiracetam in Palliative Care Patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32267792/),[l] / [h],2.5,138447,DB01202,Levetiracetam
,32267792,elimination half-life,The population clearance (2.5 L/h) and the elimination half-life (10.4 hours) were successfully estimated.,Pharmacokinetics of Subcutaneous Levetiracetam in Palliative Care Patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/32267792/),h,10.4,138448,DB01202,Levetiracetam
,33217623,effluent rate,"Seven CRRT patients received continuous venovenous hemodiafiltration (CVVHDF) [median pre-replacement rate 700 mL/h (range 500-1000), post-replacement rate 500 mL/h (range 200-1000), effluent rate 2500 mL/h (range 1700-3650) and delivered CRRT dose 27 mL/kg/h (range 19-54)] and one patient received CVV hemofiltration (CVVH).",Levetiracetam pharmacokinetics in critically ill patients undergoing renal replacement therapy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33217623/),[ml] / [h],2500,141593,DB01202,Levetiracetam
,33217623,CL,"The mm mean levetiracetam CL during CVVHDF was 31.2 ± 8.5 mL/min, and the and the mean t1/2 was 10.4 ± 2.2 h.",Levetiracetam pharmacokinetics in critically ill patients undergoing renal replacement therapy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33217623/),[ml] / [min],31.2,141594,DB01202,Levetiracetam
,33217623,t1/2,"The mm mean levetiracetam CL during CVVHDF was 31.2 ± 8.5 mL/min, and the and the mean t1/2 was 10.4 ± 2.2 h.",Levetiracetam pharmacokinetics in critically ill patients undergoing renal replacement therapy. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33217623/),h,10.4,141595,DB01202,Levetiracetam
,33217623,clearance,"For the patient requiring CVVH, clearance and t1/2 were 22.5 mL/min and 9.5 h, respectively.",Levetiracetam pharmacokinetics in critically ill patients undergoing renal replacement therapy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33217623/),[ml] / [min],22.5,141596,DB01202,Levetiracetam
,33217623,t1/2,"For the patient requiring CVVH, clearance and t1/2 were 22.5 mL/min and 9.5 h, respectively.",Levetiracetam pharmacokinetics in critically ill patients undergoing renal replacement therapy. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33217623/),h,9.5,141597,DB01202,Levetiracetam
,33217623,blood flow rate,Mean levetiracetam CL during SLED performed at a blood flow rate of 250 mL/min and a dialysate flow rate of 100 mL/min was 74.0 ± 25.3 mL/min and t1/2 was 4.8 ± 2.3 h.,Levetiracetam pharmacokinetics in critically ill patients undergoing renal replacement therapy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33217623/),[ml] / [min],250,141598,DB01202,Levetiracetam
,33217623,dial,Mean levetiracetam CL during SLED performed at a blood flow rate of 250 mL/min and a dialysate flow rate of 100 mL/min was 74.0 ± 25.3 mL/min and t1/2 was 4.8 ± 2.3 h.,Levetiracetam pharmacokinetics in critically ill patients undergoing renal replacement therapy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33217623/),[ml] / [min],74.0,141599,DB01202,Levetiracetam
,33217623,t1/2,Mean levetiracetam CL during SLED performed at a blood flow rate of 250 mL/min and a dialysate flow rate of 100 mL/min was 74.0 ± 25.3 mL/min and t1/2 was 4.8 ± 2.3 h.,Levetiracetam pharmacokinetics in critically ill patients undergoing renal replacement therapy. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33217623/),h,4.8,141600,DB01202,Levetiracetam
,15857447,um,"The mean umbilical cord serum/maternal serum ratio was 1.14 (range, 0.97-1.45) (n = 4).",Levetiracetam concentrations in serum and in breast milk at birth and during lactation. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15857447/),,1.14,141903,DB01202,Levetiracetam
,15857447,milk/maternal serum concentration ratio,"The mean milk/maternal serum concentration ratio was 1.00 (range, 0.76-1.33) at 3 to 5 days after delivery (n = 7).",Levetiracetam concentrations in serum and in breast milk at birth and during lactation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15857447/),,1.00,141904,DB01202,Levetiracetam
,12558570,area under the curve (AUC),"Pharmacokinetic parameters of a single dose of LEV (1,500 mg) coadministered with steady-state concentrations of VPA (8 days of 500 mg, b.i.d.) did not differ significantly from the pharmacokinetics of LEV administered alone [area under the curve (AUC) of 397 and 400 microg/h/ml, respectively].","Levetiracetam, a new antiepileptic agent: lack of in vitro and in vivo pharmacokinetic interaction with valproic acid. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12558570/),[μg] / [h·ml],397,142573,DB01202,Levetiracetam
,12558570,area under the curve (AUC),"Pharmacokinetic parameters of a single dose of LEV (1,500 mg) coadministered with steady-state concentrations of VPA (8 days of 500 mg, b.i.d.) did not differ significantly from the pharmacokinetics of LEV administered alone [area under the curve (AUC) of 397 and 400 microg/h/ml, respectively].","Levetiracetam, a new antiepileptic agent: lack of in vitro and in vivo pharmacokinetic interaction with valproic acid. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12558570/),[μg] / [h·ml],400,142574,DB01202,Levetiracetam
,30463865,anti,"Utilizing standard population pharmacokinetic data, the expected antifactor Xa activity without TPE was 0.14 IU/mL.",Effect of plasma exchange on antifactor Xa activity of enoxaparin and serum levetiracetam levels. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30463865/),[iu] / [ml],0.14,142888,DB01202,Levetiracetam
,34114632,AUC0-12,"Range 1 demonstrated AUC0-12 167.0 ± 45.6 h*μg/mL, Cmax 19.19 ± 4.12 μg/mL and Ctrough 9.99 ± 3.86 µg/mL.",The Pharmacokinetics of Crushed Levetiracetam Tablets Administered to Neonates. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34114632/),[h·μg] / [ml],167.0,143683,DB01202,Levetiracetam
,34114632,Cmax,"Range 1 demonstrated AUC0-12 167.0 ± 45.6 h*μg/mL, Cmax 19.19 ± 4.12 μg/mL and Ctrough 9.99 ± 3.86 µg/mL.",The Pharmacokinetics of Crushed Levetiracetam Tablets Administered to Neonates. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34114632/),[μg] / [ml],19.19,143684,DB01202,Levetiracetam
,34114632,Ctrough,"Range 1 demonstrated AUC0-12 167.0 ± 45.6 h*μg/mL, Cmax 19.19 ± 4.12 μg/mL and Ctrough 9.99 ± 3.86 µg/mL.",The Pharmacokinetics of Crushed Levetiracetam Tablets Administered to Neonates. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34114632/),[μg] / [ml],9.99,143685,DB01202,Levetiracetam
,34114632,AUC0-12,"Range 2, AUC0-12 316.5 ± 108.4 h*μg/mL, Cmax 35.12 ± 10.54 µg/mL and Ctrough 19.25 ± 8.48 µg/mL.",The Pharmacokinetics of Crushed Levetiracetam Tablets Administered to Neonates. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34114632/),[h·μg] / [ml],316.5,143686,DB01202,Levetiracetam
,34114632,Cmax,"Range 2, AUC0-12 316.5 ± 108.4 h*μg/mL, Cmax 35.12 ± 10.54 µg/mL and Ctrough 19.25 ± 8.48 µg/mL.",The Pharmacokinetics of Crushed Levetiracetam Tablets Administered to Neonates. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34114632/),[μg] / [ml],35.12,143687,DB01202,Levetiracetam
,34114632,Ctrough,"Range 2, AUC0-12 316.5 ± 108.4 h*μg/mL, Cmax 35.12 ± 10.54 µg/mL and Ctrough 19.25 ± 8.48 µg/mL.",The Pharmacokinetics of Crushed Levetiracetam Tablets Administered to Neonates. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34114632/),[μg] / [ml],19.25,143688,DB01202,Levetiracetam
,34114632,AUC0-12,"Range 3, AUC0-12 290.9 (range 176.14-405.59) h*μg/mL, Cmax 36.11 (range 27.58-44.64) µg/mL and Ctrough 13.03 (2.98-23.07) µg/mL.",The Pharmacokinetics of Crushed Levetiracetam Tablets Administered to Neonates. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34114632/),[h·μg] / [ml],290.9,143689,DB01202,Levetiracetam
,34114632,Cmax,"Range 3, AUC0-12 290.9 (range 176.14-405.59) h*μg/mL, Cmax 36.11 (range 27.58-44.64) µg/mL and Ctrough 13.03 (2.98-23.07) µg/mL.",The Pharmacokinetics of Crushed Levetiracetam Tablets Administered to Neonates. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34114632/),[μg] / [ml],36.11,143690,DB01202,Levetiracetam
,34114632,Ctrough,"Range 3, AUC0-12 290.9 (range 176.14-405.59) h*μg/mL, Cmax 36.11 (range 27.58-44.64) µg/mL and Ctrough 13.03 (2.98-23.07) µg/mL.",The Pharmacokinetics of Crushed Levetiracetam Tablets Administered to Neonates. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34114632/),[μg] / [ml],13.03,143691,DB01202,Levetiracetam
exceeded,7894687,Absolute recovery,Absolute recovery of the drug exceeded 97%.,High-performance liquid chromatographic and megabore gas-liquid chromatographic determination of levetiracetam (ucb L059) in human serum after solid-phase extraction. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7894687/),%,97,143949,DB01202,Levetiracetam
,26795744,elimination half-life,Her levetiracetam concentration was 463 mcg/ml 8 h post ingestion (therapeutic range 10-40 mcg/ml) and her concentration-time data best fitted a one-compartment model with first-order input and an elimination half-life of 10.4 h.,Cardiovascular toxicity with levetiracetam overdose. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/26795744/),h,10.4,145038,DB01202,Levetiracetam
,24311644,Retention rates,"Retention rates were 59% in the LEV group, and 41% in the PGB group.",Levetiracetam and pregabalin for antiepileptic monotherapy in patients with primary brain tumors. A phase II randomized study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24311644/),%,59,146841,DB01202,Levetiracetam
,24311644,Retention rates,"Retention rates were 59% in the LEV group, and 41% in the PGB group.",Levetiracetam and pregabalin for antiepileptic monotherapy in patients with primary brain tumors. A phase II randomized study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24311644/),%,41,146842,DB01202,Levetiracetam
,22771222,T(max),"On day 3, mean T(max) was 2.2h, C(max) was 60.2μg/ml and AUC was 403.7μg/h/ml.",Results of phase II pharmacokinetic study of levetiracetam for prevention of post-traumatic epilepsy. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22771222/),h,2.2,150166,DB01202,Levetiracetam
,22771222,C(max),"On day 3, mean T(max) was 2.2h, C(max) was 60.2μg/ml and AUC was 403.7μg/h/ml.",Results of phase II pharmacokinetic study of levetiracetam for prevention of post-traumatic epilepsy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22771222/),[μg] / [ml],60.2,150167,DB01202,Levetiracetam
,22771222,AUC,"On day 3, mean T(max) was 2.2h, C(max) was 60.2μg/ml and AUC was 403.7μg/h/ml.",Results of phase II pharmacokinetic study of levetiracetam for prevention of post-traumatic epilepsy. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22771222/),[μg] / [h·ml],403.7,150168,DB01202,Levetiracetam
,22771222,T(max),T(max) was longer in the elderly than in children and non-elderly adults (5.96h vs. 1.5h and 1.8h; p=0.0001).,Results of phase II pharmacokinetic study of levetiracetam for prevention of post-traumatic epilepsy. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22771222/),h,5.96,150169,DB01202,Levetiracetam
,22771222,T(max),T(max) was longer in the elderly than in children and non-elderly adults (5.96h vs. 1.5h and 1.8h; p=0.0001).,Results of phase II pharmacokinetic study of levetiracetam for prevention of post-traumatic epilepsy. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22771222/),h,1.5,150170,DB01202,Levetiracetam
,22771222,T(max),T(max) was longer in the elderly than in children and non-elderly adults (5.96h vs. 1.5h and 1.8h; p=0.0001).,Results of phase II pharmacokinetic study of levetiracetam for prevention of post-traumatic epilepsy. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22771222/),h,1.8,150171,DB01202,Levetiracetam
,22771222,AUC,AUC was non-significantly lower in children compared with adults and the elderly (317.4μg/h/ml vs. 461.4μg/h/ml and 450.2μg/h/ml; p=0.08).,Results of phase II pharmacokinetic study of levetiracetam for prevention of post-traumatic epilepsy. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22771222/),[μg] / [h·ml],317.4,150172,DB01202,Levetiracetam
,22771222,AUC,AUC was non-significantly lower in children compared with adults and the elderly (317.4μg/h/ml vs. 461.4μg/h/ml and 450.2μg/h/ml; p=0.08).,Results of phase II pharmacokinetic study of levetiracetam for prevention of post-traumatic epilepsy. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22771222/),[μg] / [h·ml],461.4,150173,DB01202,Levetiracetam
,22771222,AUC,AUC was non-significantly lower in children compared with adults and the elderly (317.4μg/h/ml vs. 461.4μg/h/ml and 450.2μg/h/ml; p=0.08).,Results of phase II pharmacokinetic study of levetiracetam for prevention of post-traumatic epilepsy. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22771222/),[μg] / [h·ml],450.2,150174,DB01202,Levetiracetam
,22771222,C(max),C(max) trended higher in i.v.- versus tablet- or n.g.-treated subjects (78.4μg/ml vs. 59μg/ml and 48.2μg/ml; p=0.07).,Results of phase II pharmacokinetic study of levetiracetam for prevention of post-traumatic epilepsy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22771222/),[μg] / [ml],78.4,150175,DB01202,Levetiracetam
,22771222,C(max),C(max) trended higher in i.v.- versus tablet- or n.g.-treated subjects (78.4μg/ml vs. 59μg/ml and 48.2μg/ml; p=0.07).,Results of phase II pharmacokinetic study of levetiracetam for prevention of post-traumatic epilepsy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22771222/),[μg] / [ml],59,150176,DB01202,Levetiracetam
,22771222,C(max),C(max) trended higher in i.v.- versus tablet- or n.g.-treated subjects (78.4μg/ml vs. 59μg/ml and 48.2μg/ml; p=0.07).,Results of phase II pharmacokinetic study of levetiracetam for prevention of post-traumatic epilepsy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22771222/),[μg] / [ml],48.2,150177,DB01202,Levetiracetam
,29965883,CL/F,Significant differences were observed in LEV CL/F between males and females when LEV CL/F was expressed as L/h [mean (SD): 4.79 (1.84) L/h in males versus 4.13 (1.64) L/h in females; P < 0.001].,"Influence of Sex, Age, and Weight on Levetiracetam Pharmacokinetics. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29965883/),[l] / [h],4.79,152449,DB01202,Levetiracetam
,29965883,CL/F,Significant differences were observed in LEV CL/F between males and females when LEV CL/F was expressed as L/h [mean (SD): 4.79 (1.84) L/h in males versus 4.13 (1.64) L/h in females; P < 0.001].,"Influence of Sex, Age, and Weight on Levetiracetam Pharmacokinetics. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29965883/),[l] / [h],4.13,152450,DB01202,Levetiracetam
,29965883,CL/F,These differences were not significant when LEV CL/F was normalized by weight [mean (SD): 60.64 (24.90) mL/h/kg in males versus 64.10 (28.87) mL/h/kg in females; n.s.].,"Influence of Sex, Age, and Weight on Levetiracetam Pharmacokinetics. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29965883/),[ml] / [h·kg],60.64,152451,DB01202,Levetiracetam
,29965883,CL/F,These differences were not significant when LEV CL/F was normalized by weight [mean (SD): 60.64 (24.90) mL/h/kg in males versus 64.10 (28.87) mL/h/kg in females; n.s.].,"Influence of Sex, Age, and Weight on Levetiracetam Pharmacokinetics. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29965883/),[ml] / [h·kg],64.10,152452,DB01202,Levetiracetam
,29965883,CL/F,"However, when LEV CL/F was expressed in mL/h/kg, a progressive reduction was observed [normal weight: 72.21 (28.97); overweight: 57.84 (25.38); obese: 49.45 (14.50); P < 0.001].","Influence of Sex, Age, and Weight on Levetiracetam Pharmacokinetics. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29965883/),[ml] / [h·kg],72.21,152453,DB01202,Levetiracetam
,29965883,CL/F,"However, when LEV CL/F was expressed in mL/h/kg, a progressive reduction was observed [normal weight: 72.21 (28.97); overweight: 57.84 (25.38); obese: 49.45 (14.50); P < 0.001].","Influence of Sex, Age, and Weight on Levetiracetam Pharmacokinetics. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29965883/),[ml] / [h·kg],57.84,152454,DB01202,Levetiracetam
,29965883,CL/F,"However, when LEV CL/F was expressed in mL/h/kg, a progressive reduction was observed [normal weight: 72.21 (28.97); overweight: 57.84 (25.38); obese: 49.45 (14.50); P < 0.001].","Influence of Sex, Age, and Weight on Levetiracetam Pharmacokinetics. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29965883/),[ml] / [h·kg],49.45,152455,DB01202,Levetiracetam
,30238679,CMAX,"The LP group had lower CMAX (13.38 μg/mL) compared to the L group (33.01 μg/mL) and LZ group (34.13 μg/mL), lower AUC (134.86 versus 352.95 and 452.76 hours·μg/mL, respectively), and higher CL/F (0.17 versus 0.08 and 0.07 L/kg/hr, respectively).","Population pharmacokinetics of extended-release levetiracetam in epileptic dogs when administered alone, with phenobarbital or zonisamide. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30238679/),[μg] / [ml],13.38,152549,DB01202,Levetiracetam
,30238679,CMAX,"The LP group had lower CMAX (13.38 μg/mL) compared to the L group (33.01 μg/mL) and LZ group (34.13 μg/mL), lower AUC (134.86 versus 352.95 and 452.76 hours·μg/mL, respectively), and higher CL/F (0.17 versus 0.08 and 0.07 L/kg/hr, respectively).","Population pharmacokinetics of extended-release levetiracetam in epileptic dogs when administered alone, with phenobarbital or zonisamide. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30238679/),[μg] / [ml],33.01,152550,DB01202,Levetiracetam
,30238679,CMAX,"The LP group had lower CMAX (13.38 μg/mL) compared to the L group (33.01 μg/mL) and LZ group (34.13 μg/mL), lower AUC (134.86 versus 352.95 and 452.76 hours·μg/mL, respectively), and higher CL/F (0.17 versus 0.08 and 0.07 L/kg/hr, respectively).","Population pharmacokinetics of extended-release levetiracetam in epileptic dogs when administered alone, with phenobarbital or zonisamide. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30238679/),[μg] / [ml],34.13,152551,DB01202,Levetiracetam
,30238679,AUC,"The LP group had lower CMAX (13.38 μg/mL) compared to the L group (33.01 μg/mL) and LZ group (34.13 μg/mL), lower AUC (134.86 versus 352.95 and 452.76 hours·μg/mL, respectively), and higher CL/F (0.17 versus 0.08 and 0.07 L/kg/hr, respectively).","Population pharmacokinetics of extended-release levetiracetam in epileptic dogs when administered alone, with phenobarbital or zonisamide. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30238679/),[h·μg] / [ml],134.86,152552,DB01202,Levetiracetam
,30238679,AUC,"The LP group had lower CMAX (13.38 μg/mL) compared to the L group (33.01 μg/mL) and LZ group (34.13 μg/mL), lower AUC (134.86 versus 352.95 and 452.76 hours·μg/mL, respectively), and higher CL/F (0.17 versus 0.08 and 0.07 L/kg/hr, respectively).","Population pharmacokinetics of extended-release levetiracetam in epileptic dogs when administered alone, with phenobarbital or zonisamide. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30238679/),[h·μg] / [ml],352.95,152553,DB01202,Levetiracetam
,30238679,AUC,"The LP group had lower CMAX (13.38 μg/mL) compared to the L group (33.01 μg/mL) and LZ group (34.13 μg/mL), lower AUC (134.86 versus 352.95 and 452.76 hours·μg/mL, respectively), and higher CL/F (0.17 versus 0.08 and 0.07 L/kg/hr, respectively).","Population pharmacokinetics of extended-release levetiracetam in epileptic dogs when administered alone, with phenobarbital or zonisamide. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30238679/),[h·μg] / [ml],452.76,152554,DB01202,Levetiracetam
,30238679,CL/F,"The LP group had lower CMAX (13.38 μg/mL) compared to the L group (33.01 μg/mL) and LZ group (34.13 μg/mL), lower AUC (134.86 versus 352.95 and 452.76 hours·μg/mL, respectively), and higher CL/F (0.17 versus 0.08 and 0.07 L/kg/hr, respectively).","Population pharmacokinetics of extended-release levetiracetam in epileptic dogs when administered alone, with phenobarbital or zonisamide. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30238679/),[l] / [h·kg],0.17,152555,DB01202,Levetiracetam
,30238679,CL/F,"The LP group had lower CMAX (13.38 μg/mL) compared to the L group (33.01 μg/mL) and LZ group (34.13 μg/mL), lower AUC (134.86 versus 352.95 and 452.76 hours·μg/mL, respectively), and higher CL/F (0.17 versus 0.08 and 0.07 L/kg/hr, respectively).","Population pharmacokinetics of extended-release levetiracetam in epileptic dogs when administered alone, with phenobarbital or zonisamide. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30238679/),[l] / [h·kg],0.08,152556,DB01202,Levetiracetam
,30238679,CL/F,"The LP group had lower CMAX (13.38 μg/mL) compared to the L group (33.01 μg/mL) and LZ group (34.13 μg/mL), lower AUC (134.86 versus 352.95 and 452.76 hours·μg/mL, respectively), and higher CL/F (0.17 versus 0.08 and 0.07 L/kg/hr, respectively).","Population pharmacokinetics of extended-release levetiracetam in epileptic dogs when administered alone, with phenobarbital or zonisamide. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30238679/),[l] / [h·kg],0.07,152557,DB01202,Levetiracetam
,30238679,half,The half-life that defined the terminal slope of the plasma concentration versus time curve (~5 hours) was similar to values previously reported for healthy dogs.,"Population pharmacokinetics of extended-release levetiracetam in epileptic dogs when administered alone, with phenobarbital or zonisamide. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30238679/),h,5,152558,DB01202,Levetiracetam
,19264451,t(max),The median t(max) was delayed from 0.9 to 4h.,Pharmacokinetics of levetiracetam XR 500mg tablets. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19264451/),h,0.9,155679,DB01202,Levetiracetam
,19264451,t(max),The median t(max) was delayed from 0.9 to 4h.,Pharmacokinetics of levetiracetam XR 500mg tablets. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19264451/),h,4,155680,DB01202,Levetiracetam
,25283522,"C max,ss","Corresponding values after repeated iv infusions were C max,ss 1.01 (0.91, 1.12) and AUCτ,ss 0.89 (0.83, 0.96).",Pharmacokinetics of the antiepileptic drug levetiracetam in healthy Japanese and Caucasian volunteers following intravenous administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25283522/),,1.01,168237,DB01202,Levetiracetam
,25283522,"AUCτ,ss","Corresponding values after repeated iv infusions were C max,ss 1.01 (0.91, 1.12) and AUCτ,ss 0.89 (0.83, 0.96).",Pharmacokinetics of the antiepileptic drug levetiracetam in healthy Japanese and Caucasian volunteers following intravenous administration. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25283522/),,0.89,168238,DB01202,Levetiracetam
,33447943,apparent clearance,The median value of apparent clearance for children (0.074 L/h/kg [range 0.038-0.079]) was higher than that for adults (0.054 L/h/kg [range 0.039-0.061]).,Population Pharmacokinetics of Levetiracetam: A Systematic Review. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33447943/),[l] / [h·kg],0.074,169024,DB01202,Levetiracetam
,33447943,apparent clearance,The median value of apparent clearance for children (0.074 L/h/kg [range 0.038-0.079]) was higher than that for adults (0.054 L/h/kg [range 0.039-0.061]).,Population Pharmacokinetics of Levetiracetam: A Systematic Review. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33447943/),[l] / [h·kg],0.054,169025,DB01202,Levetiracetam
,28503770,peak concentrations,"Mean ± SD peak concentrations for LEVCIR and LEVCER were 50.72 ± 10.60 and 53.58 ± 15.94 μg/ml, respectively.",Disposition of levetiracetam in healthy adult horses. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28503770/),[μg] / [ml],50.72,169302,DB01202,Levetiracetam
,28503770,peak concentrations,"Mean ± SD peak concentrations for LEVCIR and LEVCER were 50.72 ± 10.60 and 53.58 ± 15.94 μg/ml, respectively.",Disposition of levetiracetam in healthy adult horses. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28503770/),[μg] / [ml],53.58,169303,DB01202,Levetiracetam
,28503770,y-intercept,The y-intercept for IV administration was 64.54 ± 24.99 μg/ml.,Disposition of levetiracetam in healthy adult horses. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28503770/),[μg] / [ml],64.54,169304,DB01202,Levetiracetam
,28503770,terminal half-life,"The terminal half-life was 6.38 ± 1.97, 7.07 ± 1.93 and 6.22 ± 1.35 hr for LEVCIR , LEVCER, and LEVIV , respectively.",Disposition of levetiracetam in healthy adult horses. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/28503770/),h,6.38,169305,DB01202,Levetiracetam
,28503770,terminal half-life,"The terminal half-life was 6.38 ± 1.97, 7.07 ± 1.93 and 6.22 ± 1.35 hr for LEVCIR , LEVCER, and LEVIV , respectively.",Disposition of levetiracetam in healthy adult horses. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/28503770/),h,7.07,169306,DB01202,Levetiracetam
,28503770,terminal half-life,"The terminal half-life was 6.38 ± 1.97, 7.07 ± 1.93 and 6.22 ± 1.35 hr for LEVCIR , LEVCER, and LEVIV , respectively.",Disposition of levetiracetam in healthy adult horses. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/28503770/),h,6.22,169307,DB01202,Levetiracetam
,28503770,Volume of distribution at steady-state,Volume of distribution at steady-state was 630 ± 73.4 ml/kg.,Disposition of levetiracetam in healthy adult horses. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28503770/),[ml] / [kg],630,169308,DB01202,Levetiracetam
,28503770,Total body clearance,Total body clearance after IV administration was 74.40 ± 19.20 ml kg-1 hr-1 .,Disposition of levetiracetam in healthy adult horses. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28503770/),[ml] / [h·kg],74.40,169309,DB01202,Levetiracetam
,28503770,Bioavailability,"Bioavailability was 96 ± 10, and 98 ± 13% for LEVCIR and LEVCER , respectively.",Disposition of levetiracetam in healthy adult horses. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28503770/),%,96,169310,DB01202,Levetiracetam
,28503770,Bioavailability,"Bioavailability was 96 ± 10, and 98 ± 13% for LEVCIR and LEVCER , respectively.",Disposition of levetiracetam in healthy adult horses. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28503770/),%,98,169311,DB01202,Levetiracetam
,16861095,C(max),"After a single dose, the IV infusion and oral tablet were similar in terms of C(max) (50.5 and 47.7 microg/mL, respectively) and AUC (392.4 and 427.9 pg x h/mL).",Single-dose bioavailability of levetiracetam intravenous infusion relative to oral tablets and multiple-dose pharmacokinetics and tolerability of levetiracetam intravenous infusion compared with placebo in healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16861095/),[μg] / [ml],50.5,169919,DB01202,Levetiracetam
,16861095,C(max),"After a single dose, the IV infusion and oral tablet were similar in terms of C(max) (50.5 and 47.7 microg/mL, respectively) and AUC (392.4 and 427.9 pg x h/mL).",Single-dose bioavailability of levetiracetam intravenous infusion relative to oral tablets and multiple-dose pharmacokinetics and tolerability of levetiracetam intravenous infusion compared with placebo in healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16861095/),[μg] / [ml],47.7,169920,DB01202,Levetiracetam
,16861095,AUC,"After a single dose, the IV infusion and oral tablet were similar in terms of C(max) (50.5 and 47.7 microg/mL, respectively) and AUC (392.4 and 427.9 pg x h/mL).",Single-dose bioavailability of levetiracetam intravenous infusion relative to oral tablets and multiple-dose pharmacokinetics and tolerability of levetiracetam intravenous infusion compared with placebo in healthy subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16861095/),[h·pg] / [ml],392.4,169921,DB01202,Levetiracetam
,16861095,AUC,"After a single dose, the IV infusion and oral tablet were similar in terms of C(max) (50.5 and 47.7 microg/mL, respectively) and AUC (392.4 and 427.9 pg x h/mL).",Single-dose bioavailability of levetiracetam intravenous infusion relative to oral tablets and multiple-dose pharmacokinetics and tolerability of levetiracetam intravenous infusion compared with placebo in healthy subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16861095/),[h·pg] / [ml],427.9,169922,DB01202,Levetiracetam
,29114943,maximum concentration (Cmax ),"The median dosage of 86.2 mg/kg, (range, 80-94.3) achieved a mean maximum concentration (Cmax ) of 89.8 ± 25.8 μg/mL at 4.9 ±1.57 hours.",Pharmacokinetics of Single Oral Dose Extended-Release Levetiracetam in Healthy Cats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29114943/),[μg] / [ml],89.8,170742,DB01202,Levetiracetam
,29114943,concentrations,"Mean concentrations were 43.7 ± 18.4 and 4.9 ± 3.4 μg/mL at 12 and 24 hours, respectively.",Pharmacokinetics of Single Oral Dose Extended-Release Levetiracetam in Healthy Cats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29114943/),[μg] / [ml],43.7,170743,DB01202,Levetiracetam
,29114943,concentrations,"Mean concentrations were 43.7 ± 18.4 and 4.9 ± 3.4 μg/mL at 12 and 24 hours, respectively.",Pharmacokinetics of Single Oral Dose Extended-Release Levetiracetam in Healthy Cats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29114943/),[μg] / [ml],4.9,170744,DB01202,Levetiracetam
,29114943,half-life,The half-life was 4.1 ± 1.0 hours.,Pharmacokinetics of Single Oral Dose Extended-Release Levetiracetam in Healthy Cats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29114943/),h,4.1,170745,DB01202,Levetiracetam
,26800696,peak concentration at steady state,"The peak concentration at steady state was 32.2 mcg/mL, and the trough concentration was 16.1 mcg/mL (goal 12-46 mcg/mL).",Levetiracetam Pharmacokinetics During Continuous Venovenous Hemofiltration and Acute Liver Dysfunction. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26800696/),[mcg] / [ml],32.2,173258,DB01202,Levetiracetam
,26800696,trough concentration,"The peak concentration at steady state was 32.2 mcg/mL, and the trough concentration was 16.1 mcg/mL (goal 12-46 mcg/mL).",Levetiracetam Pharmacokinetics During Continuous Venovenous Hemofiltration and Acute Liver Dysfunction. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26800696/),[mcg] / [ml],16.1,173259,DB01202,Levetiracetam
,26800696,volume of distribution,"The volume of distribution was 0.65 L/kg, and the elimination half-life was 11.4 h.",Levetiracetam Pharmacokinetics During Continuous Venovenous Hemofiltration and Acute Liver Dysfunction. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26800696/),[l] / [kg],0.65,173260,DB01202,Levetiracetam
,26800696,elimination half-life,"The volume of distribution was 0.65 L/kg, and the elimination half-life was 11.4 h.",Levetiracetam Pharmacokinetics During Continuous Venovenous Hemofiltration and Acute Liver Dysfunction. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/26800696/),h,11.4,173261,DB01202,Levetiracetam
,28363098,AUC,The mean AUC±SD and Cmax±SD was 288.4±86.3(mg/L)h and 37.8±10.4mg/L respectively for brand LEV and 319.2±104.7(mg/L)h and 41.6±12.3mg/L respectively for the generic LEV.,Brand-to-generic levetiracetam switch in patients with epilepsy in a routine clinical setting. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28363098/),[mg] / [l],288.4,175425,DB01202,Levetiracetam
,28363098,AUC,The mean AUC±SD and Cmax±SD was 288.4±86.3(mg/L)h and 37.8±10.4mg/L respectively for brand LEV and 319.2±104.7(mg/L)h and 41.6±12.3mg/L respectively for the generic LEV.,Brand-to-generic levetiracetam switch in patients with epilepsy in a routine clinical setting. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28363098/),[mg] / [l],319.2,175426,DB01202,Levetiracetam
,28363098,Cmax,The mean AUC±SD and Cmax±SD was 288.4±86.3(mg/L)h and 37.8±10.4mg/L respectively for brand LEV and 319.2±104.7(mg/L)h and 41.6±12.3mg/L respectively for the generic LEV.,Brand-to-generic levetiracetam switch in patients with epilepsy in a routine clinical setting. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28363098/),[mg] / [l],37.8,175427,DB01202,Levetiracetam
,28363098,Cmax,The mean AUC±SD and Cmax±SD was 288.4±86.3(mg/L)h and 37.8±10.4mg/L respectively for brand LEV and 319.2±104.7(mg/L)h and 41.6±12.3mg/L respectively for the generic LEV.,Brand-to-generic levetiracetam switch in patients with epilepsy in a routine clinical setting. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28363098/),[mg] / [l],41.6,175428,DB01202,Levetiracetam
,25312351,total clearance,"In this trial, levetiracetam total clearance decreased proportionally with creatinine clearance: 52, 31, 25, 20 and 11 mL/min/1.73 m(2) in healthy controls and in patients with mild, moderate, severe renal impairment, and ESRD, respectively.",Levetiracetam pharmacokinetics in Japanese subjects with renal impairment. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25312351/),[ml] / [1.73·min],52,185107,DB01202,Levetiracetam
,25312351,total clearance,"In this trial, levetiracetam total clearance decreased proportionally with creatinine clearance: 52, 31, 25, 20 and 11 mL/min/1.73 m(2) in healthy controls and in patients with mild, moderate, severe renal impairment, and ESRD, respectively.",Levetiracetam pharmacokinetics in Japanese subjects with renal impairment. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25312351/),[ml] / [1.73·min],31,185108,DB01202,Levetiracetam
,25312351,total clearance,"In this trial, levetiracetam total clearance decreased proportionally with creatinine clearance: 52, 31, 25, 20 and 11 mL/min/1.73 m(2) in healthy controls and in patients with mild, moderate, severe renal impairment, and ESRD, respectively.",Levetiracetam pharmacokinetics in Japanese subjects with renal impairment. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25312351/),[ml] / [1.73·min],25,185109,DB01202,Levetiracetam
,25312351,total clearance,"In this trial, levetiracetam total clearance decreased proportionally with creatinine clearance: 52, 31, 25, 20 and 11 mL/min/1.73 m(2) in healthy controls and in patients with mild, moderate, severe renal impairment, and ESRD, respectively.",Levetiracetam pharmacokinetics in Japanese subjects with renal impairment. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25312351/),[ml] / [1.73·min],20,185110,DB01202,Levetiracetam
,25312351,total clearance,"In this trial, levetiracetam total clearance decreased proportionally with creatinine clearance: 52, 31, 25, 20 and 11 mL/min/1.73 m(2) in healthy controls and in patients with mild, moderate, severe renal impairment, and ESRD, respectively.",Levetiracetam pharmacokinetics in Japanese subjects with renal impairment. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25312351/),[ml] / [1.73·min],11,185111,DB01202,Levetiracetam
,11879369,half-lives,"In children, the half-lives of levetiracetam and its metabolite ucb L057 were 6.0 +/- 1.1 and 8.1 +/-2.7 hours, respectively.",Pharmacokinetic study of levetiracetam in children. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11879369/),h,6.0,186173,DB01202,Levetiracetam
,11879369,half-lives,"In children, the half-lives of levetiracetam and its metabolite ucb L057 were 6.0 +/- 1.1 and 8.1 +/-2.7 hours, respectively.",Pharmacokinetic study of levetiracetam in children. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11879369/),h,8.1,186174,DB01202,Levetiracetam
,11879369,Cmax,"The Cmax and area under the curve (AUC) of levetiracetam equated for a 1-mg/kg dose were lower in children (Cmax, norm=1.33 plus minus 0.35 microg/ml; AUCnorm=12.4 +/- 3.5 microg/h/ml) than in adults (Cmax, norm=1.38 +/- 0.05 microg/ml; AUCnorm=11.48 +/- 0.63 microg/h/ml), whereas the renal clearance was higher.",Pharmacokinetic study of levetiracetam in children. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11879369/),[μg] / [ml],1.33,186175,DB01202,Levetiracetam
,11879369,AUCnorm,"The Cmax and area under the curve (AUC) of levetiracetam equated for a 1-mg/kg dose were lower in children (Cmax, norm=1.33 plus minus 0.35 microg/ml; AUCnorm=12.4 +/- 3.5 microg/h/ml) than in adults (Cmax, norm=1.38 +/- 0.05 microg/ml; AUCnorm=11.48 +/- 0.63 microg/h/ml), whereas the renal clearance was higher.",Pharmacokinetic study of levetiracetam in children. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11879369/),[μg] / [h·ml],12.4,186176,DB01202,Levetiracetam
,11879369,Cmax,"The Cmax and area under the curve (AUC) of levetiracetam equated for a 1-mg/kg dose were lower in children (Cmax, norm=1.33 plus minus 0.35 microg/ml; AUCnorm=12.4 +/- 3.5 microg/h/ml) than in adults (Cmax, norm=1.38 +/- 0.05 microg/ml; AUCnorm=11.48 +/- 0.63 microg/h/ml), whereas the renal clearance was higher.",Pharmacokinetic study of levetiracetam in children. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11879369/),[μg] / [ml],1.38,186177,DB01202,Levetiracetam
,11879369,AUCnorm,"The Cmax and area under the curve (AUC) of levetiracetam equated for a 1-mg/kg dose were lower in children (Cmax, norm=1.33 plus minus 0.35 microg/ml; AUCnorm=12.4 +/- 3.5 microg/h/ml) than in adults (Cmax, norm=1.38 +/- 0.05 microg/ml; AUCnorm=11.48 +/- 0.63 microg/h/ml), whereas the renal clearance was higher.",Pharmacokinetic study of levetiracetam in children. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11879369/),[μg] / [h·ml],11.48,186178,DB01202,Levetiracetam
,11879369,apparent body clearance,The apparent body clearance (1.43 +/- 0.36 ml/min/kg) was approximately 30-40% higher in children than in adults.,Pharmacokinetic study of levetiracetam in children. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11879369/),[ml] / [kg·min],1.43,186179,DB01202,Levetiracetam
,21879984,peak concentration,Mean ± SD peak concentration was 25.54 ± 7.97 μg/mL.,Pharmacokinetics of levetiracetam after oral and intravenous administration of a single dose to clinically normal cats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21879984/),[μg] / [ml],25.54,186395,DB01202,Levetiracetam
,21879984,y-intercept,The mean y-intercept for i.v. administration was 37.52 ± 6.79 μg/mL.,Pharmacokinetics of levetiracetam after oral and intravenous administration of a single dose to clinically normal cats. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21879984/),[μg] / [ml],37.52,186396,DB01202,Levetiracetam
,21879984,Half-life,"Half-life (harmonic mean ± pseudo-SD) was 2.95 ± 0.95 hours and 2.86 ± 0.65 hours for oral and i.v. administration, respectively.",Pharmacokinetics of levetiracetam after oral and intravenous administration of a single dose to clinically normal cats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21879984/),h,2.95,186397,DB01202,Levetiracetam
,21879984,Half-life,"Half-life (harmonic mean ± pseudo-SD) was 2.95 ± 0.95 hours and 2.86 ± 0.65 hours for oral and i.v. administration, respectively.",Pharmacokinetics of levetiracetam after oral and intravenous administration of a single dose to clinically normal cats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21879984/),h,2.86,186398,DB01202,Levetiracetam
,21879984,volume of distribution at steady state,"Mean volume of distribution at steady state was 0.52 ± 0.09 L/kg, and mean clearance was 2.0 ± 0.60 mL/kg/min.",Pharmacokinetics of levetiracetam after oral and intravenous administration of a single dose to clinically normal cats. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21879984/),[l] / [kg],0.52,186399,DB01202,Levetiracetam
,21879984,clearance,"Mean volume of distribution at steady state was 0.52 ± 0.09 L/kg, and mean clearance was 2.0 ± 0.60 mL/kg/min.",Pharmacokinetics of levetiracetam after oral and intravenous administration of a single dose to clinically normal cats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21879984/),[ml] / [kg·min],2.0,186400,DB01202,Levetiracetam
,21879984,oral bioavailability,Mean oral bioavailability was 102 ± 39%.,Pharmacokinetics of levetiracetam after oral and intravenous administration of a single dose to clinically normal cats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21879984/),%,102,186401,DB01202,Levetiracetam
,20848732,Half-lives,"Half-lives of valproate, phenobarbital, diazepam (and metabolites), phenytoin, and levetiracetam were 2.6, 15.8, 22.3, 16.3, and 3.2 h, respectively, compared to 0.8, 7.5, 7.7, 16.0, and 1.5 h reported for adult mice.",The pharmacokinetics of commonly used antiepileptic drugs in immature CD1 mice. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20848732/),h,2.6,189846,DB01202,Levetiracetam
,20848732,Half-lives,"Half-lives of valproate, phenobarbital, diazepam (and metabolites), phenytoin, and levetiracetam were 2.6, 15.8, 22.3, 16.3, and 3.2 h, respectively, compared to 0.8, 7.5, 7.7, 16.0, and 1.5 h reported for adult mice.",The pharmacokinetics of commonly used antiepileptic drugs in immature CD1 mice. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20848732/),h,15.8,189847,DB01202,Levetiracetam
,20848732,Half-lives,"Half-lives of valproate, phenobarbital, diazepam (and metabolites), phenytoin, and levetiracetam were 2.6, 15.8, 22.3, 16.3, and 3.2 h, respectively, compared to 0.8, 7.5, 7.7, 16.0, and 1.5 h reported for adult mice.",The pharmacokinetics of commonly used antiepileptic drugs in immature CD1 mice. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20848732/),h,22.3,189848,DB01202,Levetiracetam
,20848732,Half-lives,"Half-lives of valproate, phenobarbital, diazepam (and metabolites), phenytoin, and levetiracetam were 2.6, 15.8, 22.3, 16.3, and 3.2 h, respectively, compared to 0.8, 7.5, 7.7, 16.0, and 1.5 h reported for adult mice.",The pharmacokinetics of commonly used antiepileptic drugs in immature CD1 mice. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20848732/),h,16.3,189849,DB01202,Levetiracetam
,20848732,Half-lives,"Half-lives of valproate, phenobarbital, diazepam (and metabolites), phenytoin, and levetiracetam were 2.6, 15.8, 22.3, 16.3, and 3.2 h, respectively, compared to 0.8, 7.5, 7.7, 16.0, and 1.5 h reported for adult mice.",The pharmacokinetics of commonly used antiepileptic drugs in immature CD1 mice. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20848732/),h,3.2,189850,DB01202,Levetiracetam
,20848732,Half-lives,"Half-lives of valproate, phenobarbital, diazepam (and metabolites), phenytoin, and levetiracetam were 2.6, 15.8, 22.3, 16.3, and 3.2 h, respectively, compared to 0.8, 7.5, 7.7, 16.0, and 1.5 h reported for adult mice.",The pharmacokinetics of commonly used antiepileptic drugs in immature CD1 mice. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20848732/),h,0.8,189851,DB01202,Levetiracetam
,20848732,Half-lives,"Half-lives of valproate, phenobarbital, diazepam (and metabolites), phenytoin, and levetiracetam were 2.6, 15.8, 22.3, 16.3, and 3.2 h, respectively, compared to 0.8, 7.5, 7.7, 16.0, and 1.5 h reported for adult mice.",The pharmacokinetics of commonly used antiepileptic drugs in immature CD1 mice. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20848732/),h,7.5,189852,DB01202,Levetiracetam
,20848732,Half-lives,"Half-lives of valproate, phenobarbital, diazepam (and metabolites), phenytoin, and levetiracetam were 2.6, 15.8, 22.3, 16.3, and 3.2 h, respectively, compared to 0.8, 7.5, 7.7, 16.0, and 1.5 h reported for adult mice.",The pharmacokinetics of commonly used antiepileptic drugs in immature CD1 mice. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20848732/),h,7.7,189853,DB01202,Levetiracetam
,20848732,Half-lives,"Half-lives of valproate, phenobarbital, diazepam (and metabolites), phenytoin, and levetiracetam were 2.6, 15.8, 22.3, 16.3, and 3.2 h, respectively, compared to 0.8, 7.5, 7.7, 16.0, and 1.5 h reported for adult mice.",The pharmacokinetics of commonly used antiepileptic drugs in immature CD1 mice. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20848732/),h,16.0,189854,DB01202,Levetiracetam
,20848732,Half-lives,"Half-lives of valproate, phenobarbital, diazepam (and metabolites), phenytoin, and levetiracetam were 2.6, 15.8, 22.3, 16.3, and 3.2 h, respectively, compared to 0.8, 7.5, 7.7, 16.0, and 1.5 h reported for adult mice.",The pharmacokinetics of commonly used antiepileptic drugs in immature CD1 mice. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20848732/),h,1.5,189855,DB01202,Levetiracetam
>,12731458,bioavailability,"Results of these studies indicate that levetiracetam has a very favorable pharmacokinetic profile, characterized by excellent oral absorption and bioavailability (> 95%) and a mean elimination half-life in adults, children and the elderly of 7, 6 and 10.5 h, respectively.",The pharmacokinetic characteristics of levetiracetam. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12731458/),%,95,192152,DB01202,Levetiracetam
,12731458,elimination half-life,"Results of these studies indicate that levetiracetam has a very favorable pharmacokinetic profile, characterized by excellent oral absorption and bioavailability (> 95%) and a mean elimination half-life in adults, children and the elderly of 7, 6 and 10.5 h, respectively.",The pharmacokinetic characteristics of levetiracetam. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12731458/),h,7,192153,DB01202,Levetiracetam
,12731458,elimination half-life,"Results of these studies indicate that levetiracetam has a very favorable pharmacokinetic profile, characterized by excellent oral absorption and bioavailability (> 95%) and a mean elimination half-life in adults, children and the elderly of 7, 6 and 10.5 h, respectively.",The pharmacokinetic characteristics of levetiracetam. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12731458/),h,6,192154,DB01202,Levetiracetam
,12731458,elimination half-life,"Results of these studies indicate that levetiracetam has a very favorable pharmacokinetic profile, characterized by excellent oral absorption and bioavailability (> 95%) and a mean elimination half-life in adults, children and the elderly of 7, 6 and 10.5 h, respectively.",The pharmacokinetic characteristics of levetiracetam. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12731458/),h,10.5,192155,DB01202,Levetiracetam
,16886975,maximum plasma concentration,"Respective geometric means (coefficient of variation) for 4,000 mg administered over 15 min and 2,500 mg infused over 5 min were maximum plasma concentration, 145 (24.6%) and 94.3 (36.2%) mug/ml; area under the plasma concentration-time curve, 1,239 (19.2%) and 585 (9.6%) mug/h/ml; terminal half-life, 8.0 (14.5%) and 7.0 (12.7%) h.","Levetiracetam intravenous infusion: a randomized, placebo-controlled safety and pharmacokinetic study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16886975/),[μg] / [ml],145,192572,DB01202,Levetiracetam
,16886975,maximum plasma concentration,"Respective geometric means (coefficient of variation) for 4,000 mg administered over 15 min and 2,500 mg infused over 5 min were maximum plasma concentration, 145 (24.6%) and 94.3 (36.2%) mug/ml; area under the plasma concentration-time curve, 1,239 (19.2%) and 585 (9.6%) mug/h/ml; terminal half-life, 8.0 (14.5%) and 7.0 (12.7%) h.","Levetiracetam intravenous infusion: a randomized, placebo-controlled safety and pharmacokinetic study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16886975/),[μg] / [ml],94.3,192573,DB01202,Levetiracetam
,16886975,area under the plasma concentration-time curve,"Respective geometric means (coefficient of variation) for 4,000 mg administered over 15 min and 2,500 mg infused over 5 min were maximum plasma concentration, 145 (24.6%) and 94.3 (36.2%) mug/ml; area under the plasma concentration-time curve, 1,239 (19.2%) and 585 (9.6%) mug/h/ml; terminal half-life, 8.0 (14.5%) and 7.0 (12.7%) h.","Levetiracetam intravenous infusion: a randomized, placebo-controlled safety and pharmacokinetic study. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16886975/),[μg] / [h·ml],"1,239",192574,DB01202,Levetiracetam
,16886975,area under the plasma concentration-time curve,"Respective geometric means (coefficient of variation) for 4,000 mg administered over 15 min and 2,500 mg infused over 5 min were maximum plasma concentration, 145 (24.6%) and 94.3 (36.2%) mug/ml; area under the plasma concentration-time curve, 1,239 (19.2%) and 585 (9.6%) mug/h/ml; terminal half-life, 8.0 (14.5%) and 7.0 (12.7%) h.","Levetiracetam intravenous infusion: a randomized, placebo-controlled safety and pharmacokinetic study. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16886975/),[μg] / [h·ml],585,192575,DB01202,Levetiracetam
,16886975,terminal half-life,"Respective geometric means (coefficient of variation) for 4,000 mg administered over 15 min and 2,500 mg infused over 5 min were maximum plasma concentration, 145 (24.6%) and 94.3 (36.2%) mug/ml; area under the plasma concentration-time curve, 1,239 (19.2%) and 585 (9.6%) mug/h/ml; terminal half-life, 8.0 (14.5%) and 7.0 (12.7%) h.","Levetiracetam intravenous infusion: a randomized, placebo-controlled safety and pharmacokinetic study. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16886975/),h,8.0,192576,DB01202,Levetiracetam
,16886975,terminal half-life,"Respective geometric means (coefficient of variation) for 4,000 mg administered over 15 min and 2,500 mg infused over 5 min were maximum plasma concentration, 145 (24.6%) and 94.3 (36.2%) mug/ml; area under the plasma concentration-time curve, 1,239 (19.2%) and 585 (9.6%) mug/h/ml; terminal half-life, 8.0 (14.5%) and 7.0 (12.7%) h.","Levetiracetam intravenous infusion: a randomized, placebo-controlled safety and pharmacokinetic study. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16886975/),h,7.0,192577,DB01202,Levetiracetam
,29194744,elimination half-life,"After i.v. administration to healthy foals, levetiracetam had a mean (±s.d.) elimination half-life of 7.76 ± 0.51 h, a mean systemic clearance of 61.67 ± 10.96 (mL/h/kg) and a mean apparent volume of distribution at steady state of 0.670 ± 0.124 (L/kg).",Pharmacokinetics of the anticonvulsant levetiracetam in neonatal foals. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/29194744/),h,7.76,196254,DB01202,Levetiracetam
,29194744,systemic clearance,"After i.v. administration to healthy foals, levetiracetam had a mean (±s.d.) elimination half-life of 7.76 ± 0.51 h, a mean systemic clearance of 61.67 ± 10.96 (mL/h/kg) and a mean apparent volume of distribution at steady state of 0.670 ± 0.124 (L/kg).",Pharmacokinetics of the anticonvulsant levetiracetam in neonatal foals. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29194744/),[ml] / [h·kg],61.67,196255,DB01202,Levetiracetam
,29194744,apparent volume of distribution at steady state,"After i.v. administration to healthy foals, levetiracetam had a mean (±s.d.) elimination half-life of 7.76 ± 0.51 h, a mean systemic clearance of 61.67 ± 10.96 (mL/h/kg) and a mean apparent volume of distribution at steady state of 0.670 ± 0.124 (L/kg).",Pharmacokinetics of the anticonvulsant levetiracetam in neonatal foals. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29194744/),[l] / [kg],0.670,196256,DB01202,Levetiracetam
,29194744,peak concentration,"Following intragastric administration, levetiracetam had a peak concentration of 38.34 ± 7.42 mg/L and time to achieve peak concentration was 0.875 (0.5-1.5) h.",Pharmacokinetics of the anticonvulsant levetiracetam in neonatal foals. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29194744/),[mg] / [l],38.34,196257,DB01202,Levetiracetam
,29194744,time to achieve peak concentration,"Following intragastric administration, levetiracetam had a peak concentration of 38.34 ± 7.42 mg/L and time to achieve peak concentration was 0.875 (0.5-1.5) h.",Pharmacokinetics of the anticonvulsant levetiracetam in neonatal foals. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29194744/),h,0.875,196258,DB01202,Levetiracetam
,29194744,bioavailability,Mean bioavailability for IG administration was excellent (103.04 ± 14.51%).,Pharmacokinetics of the anticonvulsant levetiracetam in neonatal foals. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29194744/),%,103.04,196259,DB01202,Levetiracetam
,25711374,peak concentration (Cmax ),"Compared to the PB and PB-BR groups, the BR group had significantly higher peak concentration (Cmax ) (73.4 ± 24.0 versus 37.5 ± 13.7 and 26.5 ± 8.96 μg/mL, respectively, P < .001) and AUC (329 ± 114 versus 140 ± 64.7 and 98.7 ± 42.2 h*μg/mL, respectively, P < .001), and significantly lower clearance (CL/F) (71.8 ± 22.1 versus 187 ± 81.9 and 269 ± 127 mL/h/kg, respectively, P = .028).","Effect of chronic administration of phenobarbital, or bromide, on pharmacokinetics of levetiracetam in dogs with epilepsy. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25711374/),[μg] / [ml],73.4,201441,DB01202,Levetiracetam
,25711374,peak concentration (Cmax ),"Compared to the PB and PB-BR groups, the BR group had significantly higher peak concentration (Cmax ) (73.4 ± 24.0 versus 37.5 ± 13.7 and 26.5 ± 8.96 μg/mL, respectively, P < .001) and AUC (329 ± 114 versus 140 ± 64.7 and 98.7 ± 42.2 h*μg/mL, respectively, P < .001), and significantly lower clearance (CL/F) (71.8 ± 22.1 versus 187 ± 81.9 and 269 ± 127 mL/h/kg, respectively, P = .028).","Effect of chronic administration of phenobarbital, or bromide, on pharmacokinetics of levetiracetam in dogs with epilepsy. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25711374/),[μg] / [ml],37.5,201442,DB01202,Levetiracetam
,25711374,peak concentration (Cmax ),"Compared to the PB and PB-BR groups, the BR group had significantly higher peak concentration (Cmax ) (73.4 ± 24.0 versus 37.5 ± 13.7 and 26.5 ± 8.96 μg/mL, respectively, P < .001) and AUC (329 ± 114 versus 140 ± 64.7 and 98.7 ± 42.2 h*μg/mL, respectively, P < .001), and significantly lower clearance (CL/F) (71.8 ± 22.1 versus 187 ± 81.9 and 269 ± 127 mL/h/kg, respectively, P = .028).","Effect of chronic administration of phenobarbital, or bromide, on pharmacokinetics of levetiracetam in dogs with epilepsy. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25711374/),[μg] / [ml],26.5,201443,DB01202,Levetiracetam
,25711374,AUC,"Compared to the PB and PB-BR groups, the BR group had significantly higher peak concentration (Cmax ) (73.4 ± 24.0 versus 37.5 ± 13.7 and 26.5 ± 8.96 μg/mL, respectively, P < .001) and AUC (329 ± 114 versus 140 ± 64.7 and 98.7 ± 42.2 h*μg/mL, respectively, P < .001), and significantly lower clearance (CL/F) (71.8 ± 22.1 versus 187 ± 81.9 and 269 ± 127 mL/h/kg, respectively, P = .028).","Effect of chronic administration of phenobarbital, or bromide, on pharmacokinetics of levetiracetam in dogs with epilepsy. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25711374/),[h·μg] / [ml],329,201444,DB01202,Levetiracetam
,25711374,AUC,"Compared to the PB and PB-BR groups, the BR group had significantly higher peak concentration (Cmax ) (73.4 ± 24.0 versus 37.5 ± 13.7 and 26.5 ± 8.96 μg/mL, respectively, P < .001) and AUC (329 ± 114 versus 140 ± 64.7 and 98.7 ± 42.2 h*μg/mL, respectively, P < .001), and significantly lower clearance (CL/F) (71.8 ± 22.1 versus 187 ± 81.9 and 269 ± 127 mL/h/kg, respectively, P = .028).","Effect of chronic administration of phenobarbital, or bromide, on pharmacokinetics of levetiracetam in dogs with epilepsy. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25711374/),[h·μg] / [ml],140,201445,DB01202,Levetiracetam
,25711374,AUC,"Compared to the PB and PB-BR groups, the BR group had significantly higher peak concentration (Cmax ) (73.4 ± 24.0 versus 37.5 ± 13.7 and 26.5 ± 8.96 μg/mL, respectively, P < .001) and AUC (329 ± 114 versus 140 ± 64.7 and 98.7 ± 42.2 h*μg/mL, respectively, P < .001), and significantly lower clearance (CL/F) (71.8 ± 22.1 versus 187 ± 81.9 and 269 ± 127 mL/h/kg, respectively, P = .028).","Effect of chronic administration of phenobarbital, or bromide, on pharmacokinetics of levetiracetam in dogs with epilepsy. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25711374/),[h·μg] / [ml],98.7,201446,DB01202,Levetiracetam
,25711374,clearance (CL/F),"Compared to the PB and PB-BR groups, the BR group had significantly higher peak concentration (Cmax ) (73.4 ± 24.0 versus 37.5 ± 13.7 and 26.5 ± 8.96 μg/mL, respectively, P < .001) and AUC (329 ± 114 versus 140 ± 64.7 and 98.7 ± 42.2 h*μg/mL, respectively, P < .001), and significantly lower clearance (CL/F) (71.8 ± 22.1 versus 187 ± 81.9 and 269 ± 127 mL/h/kg, respectively, P = .028).","Effect of chronic administration of phenobarbital, or bromide, on pharmacokinetics of levetiracetam in dogs with epilepsy. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25711374/),[ml] / [h·kg],71.8,201447,DB01202,Levetiracetam
,25711374,clearance (CL/F),"Compared to the PB and PB-BR groups, the BR group had significantly higher peak concentration (Cmax ) (73.4 ± 24.0 versus 37.5 ± 13.7 and 26.5 ± 8.96 μg/mL, respectively, P < .001) and AUC (329 ± 114 versus 140 ± 64.7 and 98.7 ± 42.2 h*μg/mL, respectively, P < .001), and significantly lower clearance (CL/F) (71.8 ± 22.1 versus 187 ± 81.9 and 269 ± 127 mL/h/kg, respectively, P = .028).","Effect of chronic administration of phenobarbital, or bromide, on pharmacokinetics of levetiracetam in dogs with epilepsy. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25711374/),[ml] / [h·kg],187,201448,DB01202,Levetiracetam
,25711374,clearance (CL/F),"Compared to the PB and PB-BR groups, the BR group had significantly higher peak concentration (Cmax ) (73.4 ± 24.0 versus 37.5 ± 13.7 and 26.5 ± 8.96 μg/mL, respectively, P < .001) and AUC (329 ± 114 versus 140 ± 64.7 and 98.7 ± 42.2 h*μg/mL, respectively, P < .001), and significantly lower clearance (CL/F) (71.8 ± 22.1 versus 187 ± 81.9 and 269 ± 127 mL/h/kg, respectively, P = .028).","Effect of chronic administration of phenobarbital, or bromide, on pharmacokinetics of levetiracetam in dogs with epilepsy. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25711374/),[ml] / [h·kg],269,201449,DB01202,Levetiracetam
,30336720,volume of distribution,"Noncompartmental modeling of lacosamide pharmacokinetics revealed significant extracorporeal removal, a volume of distribution of 0.69 L/kg, elimination half-life of 13.6 hours, and peak and trough concentrations of 7.4 and 3.7 mg/L, respectively (goal trough, 5-10 mg/L).",Lacosamide Pharmacokinetics in a Critically Ill Patient During Continuous Renal Replacement Therapy. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30336720/),[l] / [kg],0.69,211785,DB01202,Levetiracetam
,30336720,elimination half-life,"Noncompartmental modeling of lacosamide pharmacokinetics revealed significant extracorporeal removal, a volume of distribution of 0.69 L/kg, elimination half-life of 13.6 hours, and peak and trough concentrations of 7.4 and 3.7 mg/L, respectively (goal trough, 5-10 mg/L).",Lacosamide Pharmacokinetics in a Critically Ill Patient During Continuous Renal Replacement Therapy. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/30336720/),h,13.6,211786,DB01202,Levetiracetam
,30336720,peak,"Noncompartmental modeling of lacosamide pharmacokinetics revealed significant extracorporeal removal, a volume of distribution of 0.69 L/kg, elimination half-life of 13.6 hours, and peak and trough concentrations of 7.4 and 3.7 mg/L, respectively (goal trough, 5-10 mg/L).",Lacosamide Pharmacokinetics in a Critically Ill Patient During Continuous Renal Replacement Therapy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30336720/),[mg] / [l],7.4,211787,DB01202,Levetiracetam
,30336720,trough concentrations,"Noncompartmental modeling of lacosamide pharmacokinetics revealed significant extracorporeal removal, a volume of distribution of 0.69 L/kg, elimination half-life of 13.6 hours, and peak and trough concentrations of 7.4 and 3.7 mg/L, respectively (goal trough, 5-10 mg/L).",Lacosamide Pharmacokinetics in a Critically Ill Patient During Continuous Renal Replacement Therapy. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30336720/),[mg] / [l],3.7,211788,DB01202,Levetiracetam
,30336720,trough,"Noncompartmental modeling of lacosamide pharmacokinetics revealed significant extracorporeal removal, a volume of distribution of 0.69 L/kg, elimination half-life of 13.6 hours, and peak and trough concentrations of 7.4 and 3.7 mg/L, respectively (goal trough, 5-10 mg/L).",Lacosamide Pharmacokinetics in a Critically Ill Patient During Continuous Renal Replacement Therapy. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30336720/),[mg] / [l],5-10,211789,DB01202,Levetiracetam
,29626789,flow rate,Chromatography was performed using isocratic elution with mobile phase A: B (10: 90) for 2.0 min with flow rate 0.4 mL/min.,Determination of plasma Levetiracetam level by Liquid Chromatography-Tandem Mass Spectrometry (LC-MS-MS) and its application in pharmacokinetics studies in neonates. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29626789/),[ml] / [min],0.4,216264,DB01202,Levetiracetam
,29626789,injection volume,The injection volume was 1.0 μL and the total run time was 2.0 min.,Determination of plasma Levetiracetam level by Liquid Chromatography-Tandem Mass Spectrometry (LC-MS-MS) and its application in pharmacokinetics studies in neonates. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29626789/),μl,1.0,216265,DB01202,Levetiracetam
,29626789,total run time,The injection volume was 1.0 μL and the total run time was 2.0 min.,Determination of plasma Levetiracetam level by Liquid Chromatography-Tandem Mass Spectrometry (LC-MS-MS) and its application in pharmacokinetics studies in neonates. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29626789/),min,2.0,216266,DB01202,Levetiracetam
,29626789,mass transition,"The mass transition for LEV was 171.2/126.0 and 230.0/112.0 for IS with retention time of 0.73 and 0.72 min, respectively.",Determination of plasma Levetiracetam level by Liquid Chromatography-Tandem Mass Spectrometry (LC-MS-MS) and its application in pharmacokinetics studies in neonates. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29626789/),-1,171.2,216267,DB01202,Levetiracetam
,29626789,mass transition,"The mass transition for LEV was 171.2/126.0 and 230.0/112.0 for IS with retention time of 0.73 and 0.72 min, respectively.",Determination of plasma Levetiracetam level by Liquid Chromatography-Tandem Mass Spectrometry (LC-MS-MS) and its application in pharmacokinetics studies in neonates. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29626789/),-1,126.0,216268,DB01202,Levetiracetam
,29626789,mass transition,"The mass transition for LEV was 171.2/126.0 and 230.0/112.0 for IS with retention time of 0.73 and 0.72 min, respectively.",Determination of plasma Levetiracetam level by Liquid Chromatography-Tandem Mass Spectrometry (LC-MS-MS) and its application in pharmacokinetics studies in neonates. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29626789/),-1,230.0,216269,DB01202,Levetiracetam
,29626789,mass transition,"The mass transition for LEV was 171.2/126.0 and 230.0/112.0 for IS with retention time of 0.73 and 0.72 min, respectively.",Determination of plasma Levetiracetam level by Liquid Chromatography-Tandem Mass Spectrometry (LC-MS-MS) and its application in pharmacokinetics studies in neonates. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29626789/),-1,112.0,216270,DB01202,Levetiracetam
,29626789,retention time,"The mass transition for LEV was 171.2/126.0 and 230.0/112.0 for IS with retention time of 0.73 and 0.72 min, respectively.",Determination of plasma Levetiracetam level by Liquid Chromatography-Tandem Mass Spectrometry (LC-MS-MS) and its application in pharmacokinetics studies in neonates. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29626789/),min,0.73,216271,DB01202,Levetiracetam
,29626789,retention time,"The mass transition for LEV was 171.2/126.0 and 230.0/112.0 for IS with retention time of 0.73 and 0.72 min, respectively.",Determination of plasma Levetiracetam level by Liquid Chromatography-Tandem Mass Spectrometry (LC-MS-MS) and its application in pharmacokinetics studies in neonates. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29626789/),min,0.72,216272,DB01202,Levetiracetam
,24739070,half life,A single dose pharamockinetic after re-exposure showed an increased half life of 18.4 hours (normal half life 7 hours) and levetiracetam content in the peritoneal dialysate.,A missed opportunity - consequences of unknown levetiracepam pharmacokinetics in a peritoneal dialysis patient. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24739070/),h,18.4,221573,DB01202,Levetiracetam
,24739070,half life,A single dose pharamockinetic after re-exposure showed an increased half life of 18.4 hours (normal half life 7 hours) and levetiracetam content in the peritoneal dialysate.,A missed opportunity - consequences of unknown levetiracepam pharmacokinetics in a peritoneal dialysis patient. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24739070/),h,7,221574,DB01202,Levetiracetam
,17324224,t(max),"Following single-dose administration of 500 mg and 1500 mg of levetiracetam, the median t(max) was 0.5 and 0.5 h; t(1/2) was 7.3 +/- 0.8 and 7.3 +/- 0.7 h; C(max) was 13.6 +/- 3.2 and 47.1 +/- 12.1 microg ml(-1); AUC(0-infinity) was 109.3 +/- 14.1 and 340.4 +/- 50.6 microg h(-1) ml(-1); and AUC(0-t) was 105.7 +/- 13.3 and 329.0 +/- 47.9 microg h(-1) ml(-1), respectively.",Single-dose pharmacokinetics of levetiracetam in healthy Chinese male subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17324224/),h,0.5,221614,DB01202,Levetiracetam
,17324224,t(1/2),"Following single-dose administration of 500 mg and 1500 mg of levetiracetam, the median t(max) was 0.5 and 0.5 h; t(1/2) was 7.3 +/- 0.8 and 7.3 +/- 0.7 h; C(max) was 13.6 +/- 3.2 and 47.1 +/- 12.1 microg ml(-1); AUC(0-infinity) was 109.3 +/- 14.1 and 340.4 +/- 50.6 microg h(-1) ml(-1); and AUC(0-t) was 105.7 +/- 13.3 and 329.0 +/- 47.9 microg h(-1) ml(-1), respectively.",Single-dose pharmacokinetics of levetiracetam in healthy Chinese male subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17324224/),h,7.3,221615,DB01202,Levetiracetam
,17324224,t(1/2),"Following single-dose administration of 500 mg and 1500 mg of levetiracetam, the median t(max) was 0.5 and 0.5 h; t(1/2) was 7.3 +/- 0.8 and 7.3 +/- 0.7 h; C(max) was 13.6 +/- 3.2 and 47.1 +/- 12.1 microg ml(-1); AUC(0-infinity) was 109.3 +/- 14.1 and 340.4 +/- 50.6 microg h(-1) ml(-1); and AUC(0-t) was 105.7 +/- 13.3 and 329.0 +/- 47.9 microg h(-1) ml(-1), respectively.",Single-dose pharmacokinetics of levetiracetam in healthy Chinese male subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17324224/),h,7.3,221616,DB01202,Levetiracetam
,17324224,C(max),"Following single-dose administration of 500 mg and 1500 mg of levetiracetam, the median t(max) was 0.5 and 0.5 h; t(1/2) was 7.3 +/- 0.8 and 7.3 +/- 0.7 h; C(max) was 13.6 +/- 3.2 and 47.1 +/- 12.1 microg ml(-1); AUC(0-infinity) was 109.3 +/- 14.1 and 340.4 +/- 50.6 microg h(-1) ml(-1); and AUC(0-t) was 105.7 +/- 13.3 and 329.0 +/- 47.9 microg h(-1) ml(-1), respectively.",Single-dose pharmacokinetics of levetiracetam in healthy Chinese male subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17324224/),[μg] / [ml],13.6,221617,DB01202,Levetiracetam
,17324224,C(max),"Following single-dose administration of 500 mg and 1500 mg of levetiracetam, the median t(max) was 0.5 and 0.5 h; t(1/2) was 7.3 +/- 0.8 and 7.3 +/- 0.7 h; C(max) was 13.6 +/- 3.2 and 47.1 +/- 12.1 microg ml(-1); AUC(0-infinity) was 109.3 +/- 14.1 and 340.4 +/- 50.6 microg h(-1) ml(-1); and AUC(0-t) was 105.7 +/- 13.3 and 329.0 +/- 47.9 microg h(-1) ml(-1), respectively.",Single-dose pharmacokinetics of levetiracetam in healthy Chinese male subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17324224/),[μg] / [ml],47.1,221618,DB01202,Levetiracetam
,17324224,AUC(0-infinity),"Following single-dose administration of 500 mg and 1500 mg of levetiracetam, the median t(max) was 0.5 and 0.5 h; t(1/2) was 7.3 +/- 0.8 and 7.3 +/- 0.7 h; C(max) was 13.6 +/- 3.2 and 47.1 +/- 12.1 microg ml(-1); AUC(0-infinity) was 109.3 +/- 14.1 and 340.4 +/- 50.6 microg h(-1) ml(-1); and AUC(0-t) was 105.7 +/- 13.3 and 329.0 +/- 47.9 microg h(-1) ml(-1), respectively.",Single-dose pharmacokinetics of levetiracetam in healthy Chinese male subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17324224/),[μg] / [h·ml],109.3,221619,DB01202,Levetiracetam
,17324224,AUC(0-infinity),"Following single-dose administration of 500 mg and 1500 mg of levetiracetam, the median t(max) was 0.5 and 0.5 h; t(1/2) was 7.3 +/- 0.8 and 7.3 +/- 0.7 h; C(max) was 13.6 +/- 3.2 and 47.1 +/- 12.1 microg ml(-1); AUC(0-infinity) was 109.3 +/- 14.1 and 340.4 +/- 50.6 microg h(-1) ml(-1); and AUC(0-t) was 105.7 +/- 13.3 and 329.0 +/- 47.9 microg h(-1) ml(-1), respectively.",Single-dose pharmacokinetics of levetiracetam in healthy Chinese male subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17324224/),[μg] / [h·ml],340.4,221620,DB01202,Levetiracetam
,17324224,AUC(0-t),"Following single-dose administration of 500 mg and 1500 mg of levetiracetam, the median t(max) was 0.5 and 0.5 h; t(1/2) was 7.3 +/- 0.8 and 7.3 +/- 0.7 h; C(max) was 13.6 +/- 3.2 and 47.1 +/- 12.1 microg ml(-1); AUC(0-infinity) was 109.3 +/- 14.1 and 340.4 +/- 50.6 microg h(-1) ml(-1); and AUC(0-t) was 105.7 +/- 13.3 and 329.0 +/- 47.9 microg h(-1) ml(-1), respectively.",Single-dose pharmacokinetics of levetiracetam in healthy Chinese male subjects. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17324224/),[μg] / [h·ml],105.7,221621,DB01202,Levetiracetam
,17324224,AUC(0-t),"Following single-dose administration of 500 mg and 1500 mg of levetiracetam, the median t(max) was 0.5 and 0.5 h; t(1/2) was 7.3 +/- 0.8 and 7.3 +/- 0.7 h; C(max) was 13.6 +/- 3.2 and 47.1 +/- 12.1 microg ml(-1); AUC(0-infinity) was 109.3 +/- 14.1 and 340.4 +/- 50.6 microg h(-1) ml(-1); and AUC(0-t) was 105.7 +/- 13.3 and 329.0 +/- 47.9 microg h(-1) ml(-1), respectively.",Single-dose pharmacokinetics of levetiracetam in healthy Chinese male subjects. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17324224/),[μg] / [h·ml],329.0,221622,DB01202,Levetiracetam
,31977751,trough/steady-state serum concentration,"Serum samples were collected after steady-state was reached, with a trough/steady-state serum concentration between 6 and 20 mg/L considered therapeutic.",What Are the Predictors for Achieving Therapeutic Levetiracetam Serum Concentrations in Adult Neurological Patients? ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31977751/),[mg] / [l],6 and 20,228956,DB01202,Levetiracetam
,31977751,serum trough/steady-state concentration (Cmin/ss),The median (interquartile ranges) serum trough/steady-state concentration (Cmin/ss) was 16.2 (9.8-26.1) mg/L.,What Are the Predictors for Achieving Therapeutic Levetiracetam Serum Concentrations in Adult Neurological Patients? ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31977751/),[mg] / [l],16.2,228957,DB01202,Levetiracetam
,31977751,Cmin/ss,The dose-normalized median (interquartile range) Cmin/ss was 11.5 (7.0-16.5) mg/L.,What Are the Predictors for Achieving Therapeutic Levetiracetam Serum Concentrations in Adult Neurological Patients? ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31977751/),[mg] / [l],11.5,228958,DB01202,Levetiracetam
<,33997989,trough concentration,"In our cohort, 57% of patients had a trough concentration <12 mg/L and 12% <5 mg/L.",Predictive Performance of Population Pharmacokinetic Models of Levetiracetam in Children and Evaluation of Dosing Regimen. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33997989/),[mg] / [l],12,229254,DB01202,Levetiracetam
<,33997989,trough concentration,"In our cohort, 57% of patients had a trough concentration <12 mg/L and 12% <5 mg/L.",Predictive Performance of Population Pharmacokinetic Models of Levetiracetam in Children and Evaluation of Dosing Regimen. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33997989/),[mg] / [l],5,229255,DB01202,Levetiracetam
>,33997989,trough concentration,"To reach a trough concentration >5 mg/L, doses ≥30 mg/kg/d for patients ≤50 kg and ≥2000 mg/d for patients >50 kg are required.",Predictive Performance of Population Pharmacokinetic Models of Levetiracetam in Children and Evaluation of Dosing Regimen. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33997989/),[mg] / [l],5,229256,DB01202,Levetiracetam
,28828726,volume of distribution,"The levetiracetam volume of distribution was 0.48 L/kg, and the interdialytic elimination half-life was 31 h.",Levetiracetam Pharmacokinetics in a Critically Ill Anephric Patient on Intermittent Hemodialysis. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28828726/),[l] / [kg],0.48,232261,DB01202,Levetiracetam
,28828726,interdialytic elimination half-life,"The levetiracetam volume of distribution was 0.48 L/kg, and the interdialytic elimination half-life was 31 h.",Levetiracetam Pharmacokinetics in a Critically Ill Anephric Patient on Intermittent Hemodialysis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/28828726/),h,31,232262,DB01202,Levetiracetam
,17381438,um,"The umbilical cord/maternal plasma concentration ratios ranged from 0.56-2.0 (mean 1.15, n=13).","Pharmacokinetics of levetiracetam during pregnancy, delivery, in the neonatal period, and lactation. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17381438/),,1.15,232729,DB01202,Levetiracetam
,17381438,plasma concentration ratios,"The umbilical cord/maternal plasma concentration ratios ranged from 0.56-2.0 (mean 1.15, n=13).","Pharmacokinetics of levetiracetam during pregnancy, delivery, in the neonatal period, and lactation. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17381438/),,1.15,232730,DB01202,Levetiracetam
,17381438,half-life,LEV plasma concentrations in the neonates declined with an estimated half-life of 18 h (n=13).,"Pharmacokinetics of levetiracetam during pregnancy, delivery, in the neonatal period, and lactation. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17381438/),h,18,232731,DB01202,Levetiracetam
,17381438,milk/maternal plasma concentration ratio,"The mean milk/maternal plasma concentration ratio was 1.05 (range, 0.78-1.55, n=11).","Pharmacokinetics of levetiracetam during pregnancy, delivery, in the neonatal period, and lactation. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17381438/),,1.05,232732,DB01202,Levetiracetam
,8827398,half-life,"When used as a monotherapy, topiramate is eliminated primarily in the urine in an unchanged form with a half-life of 20 to 30 hours; elimination is faster in patients receiving concurrent medication with enzyme-inducing anticonvulsants, in whom the extent of biotransformation becomes more prominent.","The clinical pharmacokinetics of the newer antiepileptic drugs. Focus on topiramate, zonisamide and tiagabine. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8827398/),h,20 to 30,232847,DB01202,Levetiracetam
,8827398,half-life,"It is rapidly absorbed, 50% bound to plasma proteins and is eliminated predominantly by biotransformation; zonisamide has a half-life of 50 to 70 hours in monotherapy patients, or 25 to 35 hours in patients comedicated with enzyme-inducing anticonvulsants.","The clinical pharmacokinetics of the newer antiepileptic drugs. Focus on topiramate, zonisamide and tiagabine. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8827398/),h,50 to 70,232848,DB01202,Levetiracetam
,8827398,half-life,"It is rapidly absorbed, 50% bound to plasma proteins and is eliminated predominantly by biotransformation; zonisamide has a half-life of 50 to 70 hours in monotherapy patients, or 25 to 35 hours in patients comedicated with enzyme-inducing anticonvulsants.","The clinical pharmacokinetics of the newer antiepileptic drugs. Focus on topiramate, zonisamide and tiagabine. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8827398/),h,25 to 35,232849,DB01202,Levetiracetam
,8827398,half-life,"It is highly (96%) bound to plasma proteins and it is eliminated primarily by cytochrome P450 3A-mediated oxidation, with a half-life of about 7 hours in healthy volunteers.","The clinical pharmacokinetics of the newer antiepileptic drugs. Focus on topiramate, zonisamide and tiagabine. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8827398/),h,7,232850,DB01202,Levetiracetam
,21219341,peak concentration (C(max) ),"Compared with values determined when LEV was administered alone, concurrent administration of PB resulted in a decrease in LEV peak concentration (C(max) ) from 32.39 ± 6.76 to 18.22 ± 8.97 (P = 0.0071), a decrease in elimination half-life (T(1/2) ) from 3.43 ± 0.47 to 1.73 ± 0.22 (P = 0.0005), and an increase in oral clearance from 124.93 ± 26.93 to 252.99 ± 135.43 ml/h/kg (P < 0.0001).",The pharmacokinetics of levetiracetam in healthy dogs concurrently receiving phenobarbital. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21219341/),,32.39,236411,DB01202,Levetiracetam
,21219341,peak concentration (C(max) ),"Compared with values determined when LEV was administered alone, concurrent administration of PB resulted in a decrease in LEV peak concentration (C(max) ) from 32.39 ± 6.76 to 18.22 ± 8.97 (P = 0.0071), a decrease in elimination half-life (T(1/2) ) from 3.43 ± 0.47 to 1.73 ± 0.22 (P = 0.0005), and an increase in oral clearance from 124.93 ± 26.93 to 252.99 ± 135.43 ml/h/kg (P < 0.0001).",The pharmacokinetics of levetiracetam in healthy dogs concurrently receiving phenobarbital. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21219341/),,18.22,236412,DB01202,Levetiracetam
,21219341,elimination half-life (T(1/2) ),"Compared with values determined when LEV was administered alone, concurrent administration of PB resulted in a decrease in LEV peak concentration (C(max) ) from 32.39 ± 6.76 to 18.22 ± 8.97 (P = 0.0071), a decrease in elimination half-life (T(1/2) ) from 3.43 ± 0.47 to 1.73 ± 0.22 (P = 0.0005), and an increase in oral clearance from 124.93 ± 26.93 to 252.99 ± 135.43 ml/h/kg (P < 0.0001).",The pharmacokinetics of levetiracetam in healthy dogs concurrently receiving phenobarbital. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21219341/),,3.43,236413,DB01202,Levetiracetam
,21219341,elimination half-life (T(1/2) ),"Compared with values determined when LEV was administered alone, concurrent administration of PB resulted in a decrease in LEV peak concentration (C(max) ) from 32.39 ± 6.76 to 18.22 ± 8.97 (P = 0.0071), a decrease in elimination half-life (T(1/2) ) from 3.43 ± 0.47 to 1.73 ± 0.22 (P = 0.0005), and an increase in oral clearance from 124.93 ± 26.93 to 252.99 ± 135.43 ml/h/kg (P < 0.0001).",The pharmacokinetics of levetiracetam in healthy dogs concurrently receiving phenobarbital. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21219341/),,1.73,236414,DB01202,Levetiracetam
,21219341,oral clearance,"Compared with values determined when LEV was administered alone, concurrent administration of PB resulted in a decrease in LEV peak concentration (C(max) ) from 32.39 ± 6.76 to 18.22 ± 8.97 (P = 0.0071), a decrease in elimination half-life (T(1/2) ) from 3.43 ± 0.47 to 1.73 ± 0.22 (P = 0.0005), and an increase in oral clearance from 124.93 ± 26.93 to 252.99 ± 135.43 ml/h/kg (P < 0.0001).",The pharmacokinetics of levetiracetam in healthy dogs concurrently receiving phenobarbital. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21219341/),[ml] / [h·kg],124.93,236415,DB01202,Levetiracetam
,21219341,oral clearance,"Compared with values determined when LEV was administered alone, concurrent administration of PB resulted in a decrease in LEV peak concentration (C(max) ) from 32.39 ± 6.76 to 18.22 ± 8.97 (P = 0.0071), a decrease in elimination half-life (T(1/2) ) from 3.43 ± 0.47 to 1.73 ± 0.22 (P = 0.0005), and an increase in oral clearance from 124.93 ± 26.93 to 252.99 ± 135.43 ml/h/kg (P < 0.0001).",The pharmacokinetics of levetiracetam in healthy dogs concurrently receiving phenobarbital. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21219341/),[ml] / [h·kg],252.99,236416,DB01202,Levetiracetam
,29360159,effective dose,"JNJ-46356479 was active in the 6-Hz model at both 32-mA and 44-mA stimulus intensities (median effective dose = 2.8 and 10.2 mg/kg, respectively).",Potent and selective pharmacodynamic synergy between the metabotropic glutamate receptor subtype 2-positive allosteric modulator JNJ-46356479 and levetiracetam in the mouse 6-Hz (44-mA) model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29360159/),[mg] / [kg],2.8,248859,DB01202,Levetiracetam
,29360159,effective dose,"JNJ-46356479 was active in the 6-Hz model at both 32-mA and 44-mA stimulus intensities (median effective dose = 2.8 and 10.2 mg/kg, respectively).",Potent and selective pharmacodynamic synergy between the metabotropic glutamate receptor subtype 2-positive allosteric modulator JNJ-46356479 and levetiracetam in the mouse 6-Hz (44-mA) model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29360159/),[mg] / [kg],10.2,248860,DB01202,Levetiracetam
,17199019,half-life,Human pharmacology studies have shown that brivaracetam has a half-life of 8 h and nearly complete bioavailability.,Brivaracetam (UCB 34714). ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17199019/),h,8,248873,DB01202,Levetiracetam
,20138814,flow rate,Compounds were separated on a Acquity UPLC BEH C(18) 2.1 mm x 100 mm column using gradient elution with mobile phase solution A and 0.1% formic acid in methanol (mobile phase solution B) with a flow rate of 0.4 ml/min and a total runtime of 4.0 min.,Quantification of levetiracetam in plasma of neonates by ultra performance liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20138814/),[ml] / [min],0.4,249443,DB01202,Levetiracetam
,20138814,total runtime,Compounds were separated on a Acquity UPLC BEH C(18) 2.1 mm x 100 mm column using gradient elution with mobile phase solution A and 0.1% formic acid in methanol (mobile phase solution B) with a flow rate of 0.4 ml/min and a total runtime of 4.0 min.,Quantification of levetiracetam in plasma of neonates by ultra performance liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20138814/),min,4.0,249444,DB01202,Levetiracetam
,20138814,recovery,Matrix effects were minor: the recovery of LEV was between 97.7% and 100%.,Quantification of levetiracetam in plasma of neonates by ultra performance liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20138814/),%,97.7,249445,DB01202,Levetiracetam
,20138814,recovery,Matrix effects were minor: the recovery of LEV was between 97.7% and 100%.,Quantification of levetiracetam in plasma of neonates by ultra performance liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20138814/),%,100,249446,DB01202,Levetiracetam
,21950640,trough concentration,"Monte Carlo simulations were performed for multiple levetiracetam dosing regimens to determine the probability of achieving a target trough concentration of 6 μg/ml or greater, 20 μg/ml or greater, and 6-20 μg/ml.",Steady-state pharmacokinetics of intravenous levetiracetam in neurocritical care patients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21950640/),[μg] / [ml],6,249799,DB01202,Levetiracetam
,21950640,trough concentration,"Monte Carlo simulations were performed for multiple levetiracetam dosing regimens to determine the probability of achieving a target trough concentration of 6 μg/ml or greater, 20 μg/ml or greater, and 6-20 μg/ml.",Steady-state pharmacokinetics of intravenous levetiracetam in neurocritical care patients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21950640/),[μg] / [ml],20,249800,DB01202,Levetiracetam
,21950640,trough concentration,"Monte Carlo simulations were performed for multiple levetiracetam dosing regimens to determine the probability of achieving a target trough concentration of 6 μg/ml or greater, 20 μg/ml or greater, and 6-20 μg/ml.",Steady-state pharmacokinetics of intravenous levetiracetam in neurocritical care patients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21950640/),[μg] / [ml],6-20,249801,DB01202,Levetiracetam
,21950640,maximum serum concentration,"The mean ± SD levetiracetam maximum serum concentration was 28.0 ± 8.0 μg/ml, minimum serum concentration 3.1 ± 1.8 μg/ml, half-life 5.2 ± 1.2 hours, systemic clearance 5.6 ± 1.8 L/hour, and volume of distribution at steady state 36.8 ± 6.3 L.",Steady-state pharmacokinetics of intravenous levetiracetam in neurocritical care patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21950640/),[μg] / [ml],28.0,249802,DB01202,Levetiracetam
,21950640,minimum serum concentration,"The mean ± SD levetiracetam maximum serum concentration was 28.0 ± 8.0 μg/ml, minimum serum concentration 3.1 ± 1.8 μg/ml, half-life 5.2 ± 1.2 hours, systemic clearance 5.6 ± 1.8 L/hour, and volume of distribution at steady state 36.8 ± 6.3 L.",Steady-state pharmacokinetics of intravenous levetiracetam in neurocritical care patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21950640/),[μg] / [ml],3.1,249803,DB01202,Levetiracetam
,21950640,half-life,"The mean ± SD levetiracetam maximum serum concentration was 28.0 ± 8.0 μg/ml, minimum serum concentration 3.1 ± 1.8 μg/ml, half-life 5.2 ± 1.2 hours, systemic clearance 5.6 ± 1.8 L/hour, and volume of distribution at steady state 36.8 ± 6.3 L.",Steady-state pharmacokinetics of intravenous levetiracetam in neurocritical care patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21950640/),h,5.2,249804,DB01202,Levetiracetam
,21950640,systemic clearance,"The mean ± SD levetiracetam maximum serum concentration was 28.0 ± 8.0 μg/ml, minimum serum concentration 3.1 ± 1.8 μg/ml, half-life 5.2 ± 1.2 hours, systemic clearance 5.6 ± 1.8 L/hour, and volume of distribution at steady state 36.8 ± 6.3 L.",Steady-state pharmacokinetics of intravenous levetiracetam in neurocritical care patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21950640/),[l] / [h],5.6,249805,DB01202,Levetiracetam
,21950640,volume of distribution at steady state,"The mean ± SD levetiracetam maximum serum concentration was 28.0 ± 8.0 μg/ml, minimum serum concentration 3.1 ± 1.8 μg/ml, half-life 5.2 ± 1.2 hours, systemic clearance 5.6 ± 1.8 L/hour, and volume of distribution at steady state 36.8 ± 6.3 L.",Steady-state pharmacokinetics of intravenous levetiracetam in neurocritical care patients. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21950640/),l,36.8,249806,DB01202,Levetiracetam
,21950640,trough concentration,Increasing the doses of levetiracetam increased the probability of achieving a target trough concentration of 6 μg/ml or greater but also increased the probability of achieving trough concentrations greater than 20 μg/ml.,Steady-state pharmacokinetics of intravenous levetiracetam in neurocritical care patients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21950640/),[μg] / [ml],6,249807,DB01202,Levetiracetam
greater,21950640,trough concentrations,Increasing the doses of levetiracetam increased the probability of achieving a target trough concentration of 6 μg/ml or greater but also increased the probability of achieving trough concentrations greater than 20 μg/ml.,Steady-state pharmacokinetics of intravenous levetiracetam in neurocritical care patients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21950640/),[μg] / [ml],20,249808,DB01202,Levetiracetam
,21950640,trough concentration,Levetiracetam doses of 1000 mg every 8 hours and 1500-2000 mg every 12 hours provided the highest probability of achieving a target trough concentration between 6 and 20 μg/ml.,Steady-state pharmacokinetics of intravenous levetiracetam in neurocritical care patients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21950640/),[μg] / [ml],6 and 20,249809,DB01202,Levetiracetam
,21950640,trough concentrations,Higher doses or more frequent dosing may be needed to achieve target trough concentrations of 6-20 μg/ml.,Steady-state pharmacokinetics of intravenous levetiracetam in neurocritical care patients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21950640/),[μg] / [ml],6-20,249810,DB01202,Levetiracetam
,30168416,infusion time,"The objective of this study was to evaluate the bioequivalence between single-dose intravenous (IV) infusion injection (the infusion time was 15 minutes and 45 minutes) and tablets of 1,000 mg levetiracetam in healthy Chinese male subjects.","Bioequivalence study of the antiepileptic drug levetiracetam in concentrated solution for injection versus oral tablets in healthy Chinese subjects under fasting conditions: A randomized, open-label, three-way crossover study . ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30168416/),min,15,255890,DB01202,Levetiracetam
,30168416,infusion time,"The objective of this study was to evaluate the bioequivalence between single-dose intravenous (IV) infusion injection (the infusion time was 15 minutes and 45 minutes) and tablets of 1,000 mg levetiracetam in healthy Chinese male subjects.","Bioequivalence study of the antiepileptic drug levetiracetam in concentrated solution for injection versus oral tablets in healthy Chinese subjects under fasting conditions: A randomized, open-label, three-way crossover study . ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30168416/),min,45,255891,DB01202,Levetiracetam
,30168416,tmax,"After a single dose, the AUC, Vd, Cl, and T1/2 were all essentially consistent among the treatment; tmax of 15-minute IV, 45-minute IV, and oral tablets were 0.25 hours, 0.75 hours, and 0.5 hours, respectively.","Bioequivalence study of the antiepileptic drug levetiracetam in concentrated solution for injection versus oral tablets in healthy Chinese subjects under fasting conditions: A randomized, open-label, three-way crossover study . ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30168416/),h,0.25,255892,DB01202,Levetiracetam
,30168416,tmax,"After a single dose, the AUC, Vd, Cl, and T1/2 were all essentially consistent among the treatment; tmax of 15-minute IV, 45-minute IV, and oral tablets were 0.25 hours, 0.75 hours, and 0.5 hours, respectively.","Bioequivalence study of the antiepileptic drug levetiracetam in concentrated solution for injection versus oral tablets in healthy Chinese subjects under fasting conditions: A randomized, open-label, three-way crossover study . ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30168416/),h,0.75,255893,DB01202,Levetiracetam
,30168416,tmax,"After a single dose, the AUC, Vd, Cl, and T1/2 were all essentially consistent among the treatment; tmax of 15-minute IV, 45-minute IV, and oral tablets were 0.25 hours, 0.75 hours, and 0.5 hours, respectively.","Bioequivalence study of the antiepileptic drug levetiracetam in concentrated solution for injection versus oral tablets in healthy Chinese subjects under fasting conditions: A randomized, open-label, three-way crossover study . ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30168416/),h,0.5,255894,DB01202,Levetiracetam
,30168416,tmax,The tmax of the oral tablets was between that of the 15-minute IV and the 45-minute IV.,"Bioequivalence study of the antiepileptic drug levetiracetam in concentrated solution for injection versus oral tablets in healthy Chinese subjects under fasting conditions: A randomized, open-label, three-way crossover study . ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30168416/),min,15,255895,DB01202,Levetiracetam
,30168416,tmax,The tmax of the oral tablets was between that of the 15-minute IV and the 45-minute IV.,"Bioequivalence study of the antiepileptic drug levetiracetam in concentrated solution for injection versus oral tablets in healthy Chinese subjects under fasting conditions: A randomized, open-label, three-way crossover study . ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30168416/),min,45,255896,DB01202,Levetiracetam
,34247386,trough concentrations,"Levetiracetam regimens from available clinical resources were evaluated on the probability of target attainment (PTA) using pharmacodynamics (PD) target of the trough concentrations and area under the time-concentration curve within a range of 6-20 mg/L and 222-666 mg × hour/L for the initial 72 hours of therapy, respectively.",Levetiracetam dosing in patients receiving continuous renal replacement therapy. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34247386/),[mg] / [l],6-20,261075,DB01202,Levetiracetam
,34247386,area under the time-concentration curve,"Levetiracetam regimens from available clinical resources were evaluated on the probability of target attainment (PTA) using pharmacodynamics (PD) target of the trough concentrations and area under the time-concentration curve within a range of 6-20 mg/L and 222-666 mg × hour/L for the initial 72 hours of therapy, respectively.",Levetiracetam dosing in patients receiving continuous renal replacement therapy. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34247386/),[h·mg] / [l],222-666,261076,DB01202,Levetiracetam
,34247386,effluent rates,Our results showed the optimal levetiracetam dosing regimen of 750-1000 mg every 12 hours is recommended for adult patients receiving both CRRT modalities with two different effluent rates of 25 and 35 mL/kg/h.,Levetiracetam dosing in patients receiving continuous renal replacement therapy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34247386/),[ml] / [h·kg],25,261077,DB01202,Levetiracetam
,34247386,effluent rates,Our results showed the optimal levetiracetam dosing regimen of 750-1000 mg every 12 hours is recommended for adult patients receiving both CRRT modalities with two different effluent rates of 25 and 35 mL/kg/h.,Levetiracetam dosing in patients receiving continuous renal replacement therapy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34247386/),[ml] / [h·kg],35,261078,DB01202,Levetiracetam
,33480487,time to reach the maximum plasma concentration (Tmax),The time to reach the maximum plasma concentration (Tmax) was markedly shorter with intra- rectal administration (45±26 min) than with intragastric administration (270±99 min).,Comparison of pharmacokinetics of intragastrically and intrarectally administered levetiracetam tablets in healthy non-epileptic dogs. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33480487/),min,45,262971,DB01202,Levetiracetam
,33480487,time to reach the maximum plasma concentration (Tmax),The time to reach the maximum plasma concentration (Tmax) was markedly shorter with intra- rectal administration (45±26 min) than with intragastric administration (270±99 min).,Comparison of pharmacokinetics of intragastrically and intrarectally administered levetiracetam tablets in healthy non-epileptic dogs. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33480487/),min,270,262972,DB01202,Levetiracetam
,19175400,trough concentration,"Monte Carlo simulations showed that a 10mg/kg twice daily (b.i.d.) regimen provides a plasma concentration similar to that obtained in adults for the recommended 500 mg b.i.d. starting dose, and that a 20 mg/kg b.i.d. regimen would achieve the previously described 6-20 mg/L target range for the trough concentration.",Population pharmacokinetics of levetiracetam and dosing recommendation in children with epilepsy. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19175400/),[mg] / [l],6-20,267459,DB01202,Levetiracetam
,28289434,serum concentration,The mean serum concentration of LEV was 8.7 µg/mL.,Experience and pharmacokinetics of Levetiracetam in Korean neonates with neonatal seizures. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28289434/),μg,8.7,270595,DB01202,Levetiracetam
,28289434,half-life,"In the PPK analysis for Korean neonates, the half-life was 9.6 hours; clearance, 0.357 L/hr; and volume of distribution, 4.947 L, showing differences from those in adults.",Experience and pharmacokinetics of Levetiracetam in Korean neonates with neonatal seizures. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28289434/),h,9.6,270596,DB01202,Levetiracetam
,28289434,clearance,"In the PPK analysis for Korean neonates, the half-life was 9.6 hours; clearance, 0.357 L/hr; and volume of distribution, 4.947 L, showing differences from those in adults.",Experience and pharmacokinetics of Levetiracetam in Korean neonates with neonatal seizures. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28289434/),[l] / [h],0.357,270597,DB01202,Levetiracetam
,28289434,volume of distribution,"In the PPK analysis for Korean neonates, the half-life was 9.6 hours; clearance, 0.357 L/hr; and volume of distribution, 4.947 L, showing differences from those in adults.",Experience and pharmacokinetics of Levetiracetam in Korean neonates with neonatal seizures. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28289434/),l,4.947,270598,DB01202,Levetiracetam
,10210031,time to maximum concentration (Tmax),"After administration, levetiracetam rapidly appeared in both serum (time to maximum concentration (Tmax) mean range 0.25 0.50 h) and CSF (Tmax mean range 1.33-1.92 h), suggesting ready penetration of the blood brain barrier.",Blood and cerebrospinal fluid pharmacokinetics of the novel anticonvulsant levetiracetam (ucb L059) in the rat. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10210031/),h,0.25,271047,DB01202,Levetiracetam
,10210031,Tmax,"After administration, levetiracetam rapidly appeared in both serum (time to maximum concentration (Tmax) mean range 0.25 0.50 h) and CSF (Tmax mean range 1.33-1.92 h), suggesting ready penetration of the blood brain barrier.",Blood and cerebrospinal fluid pharmacokinetics of the novel anticonvulsant levetiracetam (ucb L059) in the rat. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10210031/),h,1.33-1.92,271048,DB01202,Levetiracetam
,10210031,apparent elimination half-life (t1/2),"However, while apparent elimination half-life (t1/2) values for both serum and CSF were dose-independent (mean value range 1.8-2.8 and 4.4-4.9 h, respectively), t1/2 values for CSF were significantly larger.",Blood and cerebrospinal fluid pharmacokinetics of the novel anticonvulsant levetiracetam (ucb L059) in the rat. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10210031/),h,1.8-2.8,271049,DB01202,Levetiracetam
,10210031,apparent elimination half-life (t1/2),"However, while apparent elimination half-life (t1/2) values for both serum and CSF were dose-independent (mean value range 1.8-2.8 and 4.4-4.9 h, respectively), t1/2 values for CSF were significantly larger.",Blood and cerebrospinal fluid pharmacokinetics of the novel anticonvulsant levetiracetam (ucb L059) in the rat. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10210031/),h,4.4-4.9,271050,DB01202,Levetiracetam
,10210031,serum free/total serum levetiracetam,"As the serum free/total serum levetiracetam concentration ratio (free fraction) was 1.01+/-0.02 (mean+/-S.E.M.), it can be concluded that levetiracetam is not protein bound.",Blood and cerebrospinal fluid pharmacokinetics of the novel anticonvulsant levetiracetam (ucb L059) in the rat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10210031/),,1.01,271051,DB01202,Levetiracetam
,10210031,concentration ratio (free fraction),"As the serum free/total serum levetiracetam concentration ratio (free fraction) was 1.01+/-0.02 (mean+/-S.E.M.), it can be concluded that levetiracetam is not protein bound.",Blood and cerebrospinal fluid pharmacokinetics of the novel anticonvulsant levetiracetam (ucb L059) in the rat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10210031/),,1.01,271052,DB01202,Levetiracetam
,12915337,half-life,"Although its half-life is relatively short (6 to 8 hours), its duration of action is longer than anticipated from its pharmacokinetics in plasma, and a twice-daily dosing regimen is adequate to produce the desired response.",The ideal pharmacokinetic properties of an antiepileptic drug: how close does levetiracetam come? ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12915337/),h,6 to 8,271378,DB01202,Levetiracetam
